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Abstract 
Atrial fibrillation (AF) remains as the most prevalent tachyarrhythmia, with a prevalence 
in the U.S., of 1% in the general population. The current therapeutic/treatment paradigm 
for the patient with atrial fibrillation, is to first attempt to restore normal rhythm via anti-
arrhythmic pharmaceuticals. If this does not ameliorate the problem, or the patient does 
not well tolerate the drug side-effects, a transcatheter ablation is usually performed. The 
relatively recent introduction of cryoballoon based ablation has provided the 
electrophysiologist with an easier method of treating AF via pulmonary vein isolation. 
However, despite current clinical use research questions regarding anatomy, dosing, and 
device-tissue interactions have remained unanswered. 
Anatomical studies of the phrenic nerve, coronary sinus, left atria, and pulmonary vein 
anatomy were performed using high-resolution MRI and direct measurements on heart 
specimens. These novel anatomical studies may guide future device iterations and the 
computer based models used for numerical simulation. The amount of cooling required to 
injure and/or kill cardiac tissue, lung tissue, and the phrenic nerve was quantified using 
novel in-vitro models. These data may be used for procedural modeling and dosing 
optimization. Device-tissue interactions were studied using a functional, isolated heart-
lung bloc model and a patent has been filed for this methodology. Using this model 
infrared imaging was performed to quantify the level of cooling being achieved by 
cryoballoon catheters. A separate study was performed using MRI to quantify ice 
dynamics and to our knowledge is the first cardiac cryoablation performed in an MR 
environment. This collection of work will aid the clinical, scientific, and engineering 
communities in further optimization of cardiac cryoablation.  
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Introduction: 
Atrial fibrillation (AF) remains as the most prevalent tachyarrhythmia, with a prevalence 
in the U.S., of 1% in the general population 
1
. However, prevalence is age related and for 
persons over age 40 it increases 2.3% and for those over age 65 to 5.9% 
2
. It is 
characterized by uncoordinated electrical and mechanical myocardial activity, termed 
fibrillation. In its observed appearance, the heart looks as though it is quivering. One of 
the startling findings of this arrhythmia is its self-perpetuating nature. In general, if left 
untreated, paroxysmal AF (self-terminating episodes) eventually turns into persistent AF 
(not self-terminating) and then permanent AF (i.e., a constant state of fibrillation) 
3–5
. In 
other words, the longer an AF patient waits for therapeutic intervention, be it drugs, an 
ablation procedure, or both, the harder it is to restore a normal rhythm. Such difficulties 
in the restoration/treatment are in part due to both structural and biomolecular remodeling 
of the myocardial tissues that provides a sustaining substrate for maintenance of AF. 
Structural remodeling refers to physical changes, such as dilation of the atria and the 
formation of interstitial fibrosis. The biomolecular remodeling of primary concern in such 
patients is electrophysiologic in nature: this results the shortening of the atrial effective 
refractory periods, thus aiding perpetuation and also preventing natural termination of 
fibrillation. This self-perpetuation becomes especially disturbing when a given patient’s 
prognosis is taken into account: mortality rates double and stroke occurrences increase by 
5% per year in such patients with AF (i.e., 2 to 7 times the rate of people without AF) 
5
.  
The current therapeutic/treatment paradigm for the patient with atrial fibrillation, is to 
first attempt to restore normal rhythm via anti-arrhythmic pharmaceuticals. If this does 
not ameliorate the problem, or the patient does not well tolerate the drug side-effects, a 
transcatheter ablation is usually performed. However more recently, this treatment 
paradigm is beginning to shift, due to promising research showing that patients have 
better outcomes with ablative treatments or a combination of drugs and ablation, versus 
drugs alone 
6
 . Although transcatheter ablation therapy generally requires more than one 
procedure, it offers the unique benefit of being a potentially “curative” treatment for 
cardiac dysfunction. 
   2 
  
  
Atrial fibrillation requires both a substrate and a trigger for maintenance and initiation, 
respectively. Through non-contact or contact mapping of the atria, the electrophysiologist 
in the catheterization laboratory can electrically and/or anatomically map a patient’s 
heart. This type of mapping helps not only to better identify the potential sources of 
triggers and provides a visual reconstruction for intravascular navigation of therapeutic 
catheters, but aids the physician to efficiently performing such procedures. From here, the 
physician can attempt to ablate and destroy focal triggers or create linear lesions that will 
electrically isolate given areas of the heart; i.e., due to creation of non-conductive scar 
tissue. The linear lesions are typically used to help create a modified Cox-Maze lesion 
set, that serves to guide electrical activity, as if it were traveling through a maze and the 
lesions are the walls of the maze (hence part of the name). Since Haissaguerre’s7 seminal 
paper, published in 1998, established that the pulmonary veins (PV) were a substantial 
source of AF triggers, electrically isolating the PVs has become a cornerstone of the 
typical patient ablative procedure. Other common atrial triggers also exist, that lead to 
better outcomes when ablated, such as the neuronal autonomic ganglia plexus found 
epicardially near the pulmonary vein ostia
8
. It should be noted, that often pulmonary vein 
isolations may directly or indirectly modify these plexus triggers. 
The modern cardiac electrophysiologist has a wide range of energy sources to select from 
for creating transcatheter ablation lesions, including: radiofrequency (RF; irrigated and 
non-irrigated), cryothermal (cryo), chemical, and/or laser. Further, high-intensity focused 
ultrasound, electroporation (IRE), and microwave are currently under development, but 
not yet in clinical use
9
. All of these later modalities, except electroporation, have benefits 
and drawbacks related to functioning on a thermal basis; they either increase or decrease 
temperature to destroy tissue and create an isolating lesion of fibrosis. Today, RF ablation 
remains as the current gold standard being used most frequently. It offers the benefit of 
faster procedural times due to faster thermal treatment and also better catheter 
manipulation. Yet, cyoablation has the unique ability to adhere to the tissue upon energy 
application, ensuring the catheter does not change position during the therapy delivery. 
Therefore, the physician does not need to apply constant pressure, possibly reducing the 
risk of perforations, which may lead to cardiac tamponade (fluid in the space around the 
heart that prevents complete filling and can lead to death). Cryoablation also offers the 
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option of cryomapping which involves a short application of energy (focal cooling), so to 
test a lesion location before making it permanent. Cryomapping aids in avoiding damage 
to the native conduction system because when problems present, the treatment is stopped 
and the tissue can typically recover. Further, when comparing heating (RF) versus 
cooling (cryo): 2) cryo has been found to better preserve the structure of associated 
tissues, by not causing hyperthermal fixation of proteins
10
, 2) cryo has a lower incidence 
of thrombus
11,12
, 3) cryo does not create charring or popping of tissue, and 4) until 
recently cryo has not been reported to cause pulmonary vein stenosis
13
. Interestingly, 
although RF is the current clinical “gold standard”, both cryo and RF have been shown to 
be relatively equal in therapeutic efficacies
14
.  
More recently, the utilization of new cryoballoons, devices that go into the pulmonary 
veins, are inflated, and then simultaneously cools the whole vein annulus, have the 
potential for creating circumferential lesions. In other words, this approach isolates the 
whole vein at once and thus has shown promise in helping to reduce procedure times for 
therapeutic cryoablation
15–17
. Nevertheless, cardiac cryothermal cellular and tissue effects 
remain relatively unstudied compared to hyperthermal treatments.  
To date, transcatheter ablation has proven to be effective therapy, resulting in AF 
elimination rates as high as 90% for some centers, while being relatively safe with a 
procedural mortality rate of 2 to 3% 
5
. However, transcatheter ablation is not without 
potential complications and these have been highly related to spatial anatomical 
orientations of tissue adjacent to the atria. For examples, two such tissues, the phrenic 
nerve and esophagus, have been found using 3D reconstruction to be 2.1+/-0.4 mm and 
10+/-6 mm from the atria, respectively
18,19
. Currently, with the available technologies, the 
highest complications in such procedures is phrenic nerve palsy (PNP), with reported 
rates as high as 11.2%
16
: this may even result in hemi paralysis of the diaphragm. It has 
been generally reported that PNP will generally resolve within a year, but occasionally it 
is permanent
16
. Further, patients have reported varying degrees of decreased quality of 
life, with diaphragm hemiparalysis in some severe cases mechanical ventilation has been 
required. Atrioesophageal fistula is another potential AF procedural complication, 
described as the formation of a hole from the atria to the esophagus, resulting in much 
graver consequences, with associated mortalities higher than 75%. Yet, it is reported to 
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only occur in <.1% of cases, but appears to be more prone to occur with RF 
treatment
20,21
. Nevertheless, esophageal damage is probably much higher than reported 
because patients are not screened for this postoperatively
20
. In addition, pulmonary vein 
stenosis has only been recently reported in the literature to be caused from cryoballoon 
treatment and surprisingly the first rate reported was 3% 
16
. Furthermore, lung injury and 
esophageal hypomotility have also been reported, but fortunately, most of such patients 
are generally asymptomatic.  
It has been suggested that the tolerances of tissues to cryoenergy can vary widely
22
 and 
there is virtually no data on the tolerances for cardiac and/or surrounding tissues. Despite 
this fact, cryoablation is being performed clinically: in other words, there is little 
information regarding the relative sensitivities of tissues involved. On the other hand, 
numerous cell viability studies have been performed extensively in the field of oncology 
so to determine the biophysical response to freezing and have found large differences 
between tissue and cell types
23,24
. There are a wide range of techniques available to 
investigate thermal effects, such as: cryomicroscopy, differential scanning calorimetery, 
histology, and viability assays. Yet to date, there have been virtually no published data on 
the thermal tolerances of cardiomyocytes themselves, and much less on the adjacent 
tissue types. Many of the related studies found in literature focus on the feasibility of 
creating a lesion, not the physical processes that are actually happening to the tissues and 
cells
22
. 
Importantly, there has been an increased interest in clinically monitoring the previously 
discussed adjacent tissues during ablative procedures, but due to temperature monitoring 
limitations, high variability in anatomy, and variability of cryoenergy applications; it has 
not been possible to draw conclusions about individual tissue thermal tolerances. One of 
the greatest limits of the currently available clinical research is the lack of associated 
temperature monitoring during the delivery of therapy. Thus, without understanding what 
is actually happening to these tissues, in terms of a thermal dose, it is very difficult to 
predict the outcomes, or qualitative tissue tolerances. For example, recent studies on the 
properties of the esophagus have shown that performing luminal temperature monitoring, 
and power monitoring for RF ablation, does not correlate with the ultimate formation of a 
fistula
20,25
. These studies used a single thermal sensor while it has been shown that using 
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multiple sensors better results can be attained
26
. However, this does not remedy the fact 
that the endoluminal temperature is lower than the intramural temperatures, and the 
operator needs to use caution when making decisions based on such measurements
27
. 
Interestingly, it has also been suggested that the clinical use of temperature probes may 
actually interact with applied RF energies and actually increase the risks for esophagus 
damage
28
.  
If a better overall knowledge of thermal injury thresholds for the heart and it’s 
surrounding tissues can be obtained, it will not only be immediately useful for both 
clinician and medical device designers, but will become increasingly valuable when MRI 
and ultrasound thermography gain greater use. It has been shown that thermometry using 
both of these modalities is possible for use during ablation procedures, thereby 
eliminating the need of primitive thermal sensors and providing the whole picture 
“thermal dose” that the tissues are receiving 29–31. It should be considered that with the 
ever increasing uses and availability of MRI, it is only a matter of time until clinical 
ablation procedures will utilize MRI or 3D ultrasound rather than fluoroscopy. In fact, 
MRI compatible RF ablation catheters have already been developed by various groups 
32
 
as well as by our laboratory. Such novel monitoring techniques will provide physicians 
with the benefits of: limited radiation exposure, loss of the requirement to wear lead, 
and/or high resolution temperature monitoring. Additionally, it can easily be envisioned 
that software packages could be designed to have temperature thresholds and thermal 
dose limits as presets, so to help prevent procedural complications. Nevertheless, to 
accomplish such goals, a thorough understanding of what these doses and thresholds 
should be, still need to be attained. 
For the preceding reasons the focus of the studies in my thesis falls into three main 
categories: anatomy, thermal injury thresholds, and device-tissue interactions. As 
mentioned previously the collateral injury that occurs due to ablation procedures can be 
in a large part considered as anatomical interactions (i.e., close proximities of adjacent 
tissues causes them to experience energy meant for the myocardium). For this reason, 
studies were undertaken to fill the field of cardiac ablations’ gaps of knowledge on the 
relative thoracic anatomy in the atrial fibrillation patient. For example, the data obtained 
in the phrenic nerve anatomical project can also be used for future computer modeling to 
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treatments. In the second section of my thesis, on thermal injury thresholds, the primary 
aims were to determine to what degree of cooling is necessary to achieve complete 
cardiac lesions. These studies not only fill another gap in basic knowledge, but may be 
subsequently used to titrate dosing and therefore reduce collateral injury. Further, the 
output from these studies could potentially be used for future predictive computer 
modeling of cryo ablative therapies applied not only in the heart. The third section of my 
thesis focuses on the system level interactions between the ablation devices and tissues. 
To date, it is unknown to what degree ice, and accompanying injury, extends outside the 
myocardium. Using MRI and infrared thermometry novel insights were gained as to how 
far the cooling extends outside the desired treatment area and at what rates. To create the 
most anatomically appropriate environment a novel heart-lung preparation has been 
developed. The preceding chapters will also include respective introductions to 
familiarize the reader with their exact context and purpose. 
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I- Section 1 Anatomical Aspects of Ablation: 
The focus of this section of my thesis is anatomical aspects of cardiac ablation for the 
treatment of atrial fibrillation: it consists of three published or in submission manuscripts 
on anatomy related to AF. The three specific anatomical topics include: the phrenic 
nerves, anatomy of the coronary sinus, and general cardiac anatomy of AF versus non-AF 
patients.  
The importance of thorough understanding of cardiac anatomy cannot be understated in 
the context of ablation for both the practicing clinician and the medical device design 
engineer. Originally, in the clinical setting a mental representation of the anatomy was 
absolutely critical for proper catheter navigation. Today, with the introduction of the 
latest technologies, such as three dimensional electroanatomical mapping and merging of 
realtime catheter navigation systems with pre-procedural imaging, this intimate 
knowledge of anatomy takes on differing utilities. Nonetheless, understanding a given 
patient’s thoracic anatomy remains a requisite knowledge for the electrophysiologist so to 
optimize therapeutic results. For the medical device designer, the environment and use 
conditions of such systems of interest, will ultimately guide the design of components 
from start to finish. Further, precise anatomical geometry in a computational design 
environment can cut developmental times and prototype generations to yield a more 
efficient product development cycle.  It is for these reasons that the first chapter of this 
thesis seeks to expand the current thoracic anatomical knowledge found in the literature. 
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I.I-  Chapter 1: Phrenic Nerve Anatomy 
The topic of phrenic nerve anatomy was chosen for investigation because there is very 
little published data available in this area, despite phrenic nerve injury being the most 
common procedural complication of cryoballoon ablation 
17
. In general, the right phrenic 
nerve in general follows the posterior or posterolateral aspect of the superior vena cava 
and the left phrenic nerve passes over the marginal veins of the left ventricle (Figure 1). 
The right and left phrenic nerves travel within or encapsulated by the pericardium. 
 
 
Figure 1: General anatomical course of the phrenic nerve. (Image from Gray’s Anatomy33, 
public domain). 
A primary goal of the phrenic nerve anatomical MRI studies was to determine with 
relation of cryoballoon ablation positioning relative to where exactly the phrenic nerves 
were located. As described in the subsequent article there are only a handful of 
previously reported anatomical studies on phrenic nerve anatomy related to ablation. 
Here I describe how using the perfusion fixed heart/lung blocs allowed for high 
resolution MRI to identify where the actual nerves are located relative to the potential 
locations of cryoballoon placements. I believe that this is the first such anatomical study 
to utilize such an approach.  
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I.I.I- High-Resolution MRI Reconstructions of Human Phrenic Nerve 
Anatomy in Relation to the Pulmonary Veins and Computational 
Modeling of Cryoballoon Ablative Therapy 
Ryan P. Goff BS
1,2,3
, Julianne H. Spencer PhD 
1,2,3
, Paul A. Iaizzo PhD 
1,2
 
 
Introduction 
Today, phrenic nerve injury is the highest non-access site related complication of 
cryoballoon ablation for the treatment of drug refractory atrial fibrillation (AF): this was 
recently reported in the pivotal US trial STOP-AF
17
 as well as other multi center trials34. 
This form of injury is not unique to cryoballoon ablation, but a recent systematic 
literature review suggests it may occur more frequently in cryoballoon ablations than in 
radiofrequency ablations35.  
The right phrenic nerve in general follows the posterior or posterolateral aspect of the 
superior vena cava and the left phrenic nerve typically passes over the marginal veins of 
the left ventricle (Figure 2). The right and left phrenic nerves (PN) terminate on the 
superior surface of the diaphragm. Injury to a phrenic nerve may result in diaphragmatic 
hemi-paralysis or palsy36,37.  Usually, only the right phrenic nerve has been reported to be 
injured  during cryoballoon ablation and most frequently during ablation of the right 
superior PV38,39. However, recent case reports have been published on left PN injury 36,40 
and this occurrence may rise with increased cryoballoon adoption. 
Reported rates of phrenic nerve injury due to cryoballoon ablation vary in the literature, 
in the range of 2% 41 to 24%42. The reported time course of phrenic nerve functional 
recovery may be highly variable for each patient43. However, with the use intraprocedural 
phrenic nerve pacing, many times these complications are being reported as only 
transient, implying recovery even before procedure end 44. Yet, the noted shortest 
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recovery time periods reported are on the order of hours38 and the longest on the order of 
months45.  
Previous anatomical studies of the phrenic nerves have been performed using multi-slice 
CT46,47 and human cadavers18.  Studies by Sanchez-Quintana and colleagues determined 
that the distance between the right superior (RSPV) and inferior pulmonary veins to the 
right PN is 2.1±0.4 and 7.8±1.2 mm, respectively.  However, it was noted that studies on 
whole body preserved cadavers may have slightly distorted anatomy due to the deflation 
of the lungs and heart. Thus, it would also be unclear what size vessel the measurement 
was being made and whether or not these measurements were being correlated to 
positions where ablation catheters would actually be placed (i.e., measurements may be 
made to the distal vein and not the antral or ostial areas where ablations are typically 
applied. Further, a study carried out by Horton et al., reported that the RSPV was 
15.2±8.3 mm from the pericardiacophrenic artery using CT angiography.  Yet, one needs 
to consider that the aforementioned points may account for the discrepancy in 
measurements between the two studies. 
The proximity of the phrenic nerves to the pulmonary veins, and therefore the placement 
of a cryoballoon during a clinical ablation procedure, is largely thought to be the 
determinant of whether or not injury will likely occur. Further, deep seated balloon 
catheters have also been suggested to distort the cardiac and PV anatomy and thereby 
further reducing the distances these catheters are from a given nerve48. Interestingly, the 
use of smaller balloons has been suggested to be more likely to cause injuries, due to the 
fact that it may be inserted further into the PVs 34,49 . It has been recently noted that the 
proximity of the left phrenic nerve to the left pulmonary veins is largely unstudied in 
comparison to the anatomy of the right 18,38,47.  
The aim of the current study was to employ high-resolution MRI to further quantify the 
anatomic relationships between the human pulmonary veins and phrenic nerves. To date, 
the authors believe this is the first such quantitative study of the left phrenic relationship 
to the PVs in the context of ablation. 
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Figure 2: Anatomical course of the phrenic nerve. 
Methods 
Anatomical Specimen Preparation and Scanning 
Human heart-lung blocs were obtained through the University of Minnesota Bequest 
Program. Specimens were dissected from unpreserved donors. These donor bodies were 
stored at 4°C until the heart-lung blocs were procured and the procurement was typically 
performed within 24 hours of death. The aorta, trachea superior vena cava, and the 
inferior vena cava (when possible on a given specimen) were cannulated and attached to 
a perfusion fixation chamber as described previously 50,51. This approach preserved each 
heart in a modified end-diastolic state (fully expanded atria and ventricles) and also 
dilated the lungs. The pericardium and phrenic nerves were left intact. These hearts were 
fixed with 10% formalin in PBS solution for at least 24 hours, under 40-50 mmHg 
pressure and then stored in formalin.  
In order to increase visibility the phrenic nerves on MRI scans, samples were prepared by 
gluing a thin gauge polymer tube to each phrenic nerve. In order to ensure anatomically 
accurate scans, small incisions were made in the atria and cotton gauze was stuffed into 
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the atria and pulmonary veins to maintain dilated shapes: all incisions were closed by use 
of sutures. To maintain the close approximation of the lung to the heart during 
preparation, specimens were wrapped in polymer film (Seran Wrap, Johnson Co., Racine, 
WI). Samples were then imbedded in 7% agar gel to stabilize the samples during 
scanning and decrease artifact as described previously52. Scans were performed in a 3T 
machine (Seimens TRIO) using an mprage (T1 weighted) protocol and base resolution of 
512. 
Anatomical Reconstructions and measurements 
Datasets (N=10) were analyzed using Mimics (Materialise, Leuven Belgium) to derive 
anatomical measurements.  To do so, each cardiac image set was imported using the 
native DICOM data files generated from the MRI scan and then converted into three 
dimensional renditions (i.e., each 2D DICOM image was layered together to create a 3D 
model). The left atria and pulmonary veins were segmented from the 2D data and then 
volumes were created. To analyze the phrenic nerve locations, a spline was created at the 
tissue/fiducial marker interface (i.e., on the nerve).  
 
 
Figure 3: Computer models of ArticFront 23 mm (left) and 28 mm (right) geometry during 
an ablation. The 23 mm balloon is transparent so that the three measurement splines at the 
tip, middle, and equator can be seen. 
To determine the PN distance from the PV in the context of balloon PV isolation, 23 and 
28 mm ArticFront cryoballoon computer models were obtained from Medtronic, Inc. 
(Minneapolis, MN). These models were then mated with the reconstructed PV ostias by 
alignment in the software package 3-Matic (Materialise). This was done by aligning the 
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tip of a given balloon so that it was coaxial with the pulmonary vein in multiple viewing 
planes. Each balloon reconstruction was then advanced such that a small portion was 
showing through the shell of the pulmonary vein (Figure 4) at more than one point. This 
was done because the veins are not perfectly round, like the model balloon, and therefore 
when back pressure would be applied to the balloon to wedge it in place, as is done 
clinically, they would conform to the balloon. The model balloons had three 
measurement splines at the tip, equator, and midway between the two (Figure 3). The 
minimal distance between the splines on the balloon and the nerve were then measured. 
This was done by comparing the spline distances using the Part Comparison feature 3-
Matic . 
To analyze significant effects on the measurement of distance a general linear model 
(α=.05) was created using Minitab 16 (Minitab Inc., State College, PA) with the factors: 
balloon size, balloon measurement spline, pulmonary vein, and heart specimen as a 
random variable. Pairwise comparisons of the factors were performed using the Tukey 
method with a 95% confidence interval.  
 
Figure 4: An example 3D reconstruction of heart 226 showing the right phrenic nerve (A) in 
relation to a 23 mm cryoballoon in the RSPV (B) and 28 mm cryoballoon in the RIPV (C). 
The left phrenic nerve is shown as well (D).  
Results 
Using the described technique, ten heart-lung blocs were scanned, modeled and then 
assessed. The study population characteristics are detailed in Table 1.  Note, in specimen 
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five the right phrenic nerve could not be clearly identified due to the nerve being heavily 
encapsulated in fat and was therefore not used. Specimen two was of a particularly small 
stature donor and would not accommodate the 28mm balloon in its left common PV and 
thus was not used for this measurement.  Specimens two and three demonstrated right 
common PVs, defined as a right common trunk, that accommodated bath balloons, which 
branched to distinct superior and inferior branches distal that accommodated neither 
balloon.  
Interestingly, the difference in placement of the 23 and 28 mm cryoballoons was quite 
small. The difference between the mid spline distance to the phenic nerve between the 
two cryoballoon sizes was 1.7 ± 1.2 mm. This can be attributed to the fact the distal 
portion of the balloon generally came into contact with the antrum before the waist of the 
balloon. This caused the 23 mm size balloon usually only be slightly positioned deeper 
within a given vein. 
 
Table 1: Donor specimen profiles.  
Specimen Sex Age 
Weight 
(kg) 
Height 
(cm) History 
1 M 77 86.2 152 Myocardial infarction, hypertension 
2 F 74 24.9 152 No cardiac history 
3 F 65 68 163 No cardiac history 
4 M 81 74.8 165 Arrhythmia, leaky heart valve 
5 F 70 63.5 165 
Congestive heart failure, coronary artery 
disease 
6 F 94 49.8 160 Atrial fibrillation, congestive heart failure 
7 F 96 70 155 
Atrial fibrillation, coronary artery disease, 
hypertension  
8 M 97 72.7 178 
Atrial fibrillation, hypertension, heart 
failure 
9 M 79 95 188 Atrial fibrillation 
10 F 81 104.3 168 
Atrial fibrillation, hypertension, congestive 
heart failure 
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Figure 5: Average distance with standard deviation from ipsilateral PN to indicated 
measurement spline of the 23 mm cryoballoon. The  number of measurements averaged 
appears above the bars.  (LSPV=left superior pulmonary vein, LIPV= left inferior 
pulmonary vein, LCPV=left common pulmonary vein, RSPV=right superior pulmonary 
vein, RIPV= right inferior pulmonary vein, RCPV=right common pulmonary vein) 
 
Figure 6: Average distance with standard deviation from ipsilateral PN to indicated 
measurement spline of the 28 mm cryoballoon. The  number of measurements averaged 
appears above the bars.   
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Figure 7: Distribution of distances between ipsilateral PN to mid measurement spline of the 
23 mm cryoballoon. 
 
Figure 8: Distribution of distances between ipsilateral PN to mid measurement spline of the 
23 mm cryoballoon. 
The general linear model yielded a good fit to the data with an adjusted R-squared of 
81.48. It was determined that the factors balloon spline, pulmonary vein, and heart would 
significantly affect the distance to the phrenic nerve (p<0.0005 for all cases, see Figure 
9). The factor balloon size was found to be non-significant (p=0.965). The Tukey 
pairwise comparison results are shown in Table 2. 
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Table 2: Results of Tukey pairwise comparisons. Results shown graphically in Figure 9. 
  N Mean  Grouping 
Balloon 
AF23  103 26.8 A 
AF28 104 26.8 A 
Pulmonary Vein 
LIPV 54 40.2 A 
LSPV 54 38.5 A 
LCPV 3 36.2 A 
RIPV 42 18.3 B 
RSPV 42 14.1 C 
RCPV 12 13.5 B,C 
Balloon Measurement Spline 
Tip 69 30.5 A 
Mid 69 25.1 B 
Equator 69 24.7 B 
 
 
Figure 9: The results from the general linear model demonstrating the min effects on the 
distance to the phrenic nerve. 
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Discussion 
To the author’s knowledge, this is first such study to examine the anatomical relation of 
the phrenic nerves to the projected locations of cryoballoon therapy application in the 
pulmonary vein antrum. Due to the complexity of this study and the desire to utilize fresh 
human heart/lung bloc specimens, our sample size was modest.  Further, because this 
being a human anatomical study, we note that there existed a high degree of variatiability 
within this dataset. Yet, our approach of employing a static imaging of the heart-lung 
blocs, provided very high resolution images for analysis without motion artifact. 
In general, the right phrenic nerves in these human specimens were in significantly closer 
approximations to projected zones of cryoablation versus the left phrenic nerves. These 
computational results fit with reported clinical data that phrenic nerve palsy more 
frequently occurs following ablative therapy on the right side of the left atrium and also 
has only been reported on the left side rarely. This may imply that improper balloon 
placement is the root cause of the left nerve palsies reported or possibly unique patient 
anatomy not encountered in the current anatomical investigation. Regardless, proper 
balloon placement should be strived for therapeutic applications, so to avoid phenic nerve 
or other collateral tissue injury. Interestingly, the proximity of balloon tip, middle, and 
equatorial interfaces with the atrium differed little, yet the tip was significantly closer, as 
somewhat expected, from the projected distances to a given phrenic nerve.  This suggests 
that the changing of the cooling profile of the balloon from the first to second generation 
may not have a drastic effect on the rate of phrenic nerve injury. This is not to say that a 
change in cooling power may not effect injury rates. 
We note here that the current study is not without potential experimental limitations. 
First, the placements of the cryoballoon model within the reconstructed pulmonary veins 
was accomplished by having multiple, small portions of the balloon breaching the shell of 
the reconstructed PV. Yet, it was considered here that this in turn would lead to the best 
approximation of the true balloon placement in compliant anatomy. In the future, it may 
be of value to consider developing a morphing algorithm that could possibly reduce 
subjectivity and optimize placement. The sample size is relatively small given the 
complex nature of the data acquisition and analysis performed. As expected, the random 
factor of heart specimen was found to have a significant effect on distance to the phrenic 
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nerves. This also speaks to the general anatomical variation that may exist between 
patients, suggesting that individual, patient specific imaging may be necessary to asses 
risk of phrenic nerve injury.  It is somewhat unknown to what extent imaging a dynamic 
structure, such as the one investigated here, in a static approach may alter the 
measurements being made (i.e., one must also consider both respiratory and cardiac cycle 
movements). Finally, the computational models developed here were derived from 
anatomical measurements made here from MRI diacom data set that were obtained in a 
diastolic-like state and therefore may be somewhat overestimating these distances. 
Conclusion 
The purpose of this computational modeling study was to better quantify the distances of 
the phrenic nerves to areas where cryoballoon ablations may be applied. This study has 
found that the right phrenic nerves are closer to the pulmonary veins than left, the tip of 
the balloon is closer to the nerves as expected, and balloon size does not alter distance to 
the nerves. A better understanding of human anatomical phrenic nerve proximities to the 
endocardial surfaces in the context of ablation may lead to the optimization of therapeutic 
treatments. The model anatomy created and described here may also be used for future 
experimental studies of associated therapies and hence may aid both clinician and 
medical device designers.  
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I.II- Chapter 2: Coronary Sinus Anatomy 
The coronary sinus has been well noted to be the main venous return of the coronary 
circulation. Importantly, ablation catheters are commonly placed in the coronary sinus 
and navigated to the section of this vein that lie in close proximity to the mitral annulus, 
as well as to the left inferior pulmonary vein. At such locations, ablations may be 
performed to create transmural mitral isthmus lesions. The thought being that performing 
these ablations endocardially and within the coronary sinus, will help to ensure clincial 
transmurality.  
The purpose of following manuscript was to quantify the unique anatomy of the coronary 
sinus and associated structures with respect to transcatheter ablation. Parameters that may 
ultimately influence lesion creation and a comparison of AF to non-AF hearts were 
examined. It should be noted, that other investigators have examined the coronary sinus 
anatomy in the context of ablation 53,54, but to our knowledge this is the first such study 
that was performed using high-resolution MRI scans of perfusion fixed human hearts.  
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Executive Summary  
Objective: To identify morphologic characteristics of the mitral isthmus and coronary 
sinus that may influence how focal ablation catheters are operated and how lesions are 
generated within the atrial tissues at or near the mitral isthmus and coronary sinus. 
Background: Ablations within the coronary sinus (CS) are conducted to treat atrial 
fibrillation (AF). This study investigates the anatomy around the CS in a set of isolated 
human hearts with specific implications for coronary sinus and mitral isthmus ablation 
techniques.  
Methods: The coronary sinus of thirty perfusion-fixed human hearts were assessed at the 
CS ostium and at the mitral isthmus. Specifically, the CS diameter, circumference, 
length, and shape; distance to the left atrial space; and the amount of fat around the CS 
were measured. Human hearts were classified as patients without a history of atrial 
fibrillation (non-AF) or with AF. 
Results: On average, the distance along the coronary sinus to the mitral isthmus was 
50.4±14.1mm in non-AF specimens and 66.8±14.6mm in AF specimens (p<0.01). The 
CS was 3.4±1.3mm away from the left atrial space in non-AF hearts and 5.6±2.0mm 
away in AF hearts (p<0.01). The ostial circumference of the coronary sinus was 
31.2±10.7mm in non-AF hearts and 35.2±15.3mm in AF specimens (p=0.63). The 
coronary sinus circumference at the mitral isthmus was 21.3±7.8mm in non-AF hearts 
and 18.1±4.1mm in AF hearts (p=0.09).  
Conclusions: A detailed understanding of coronary sinus anatomy and how it differs for 
patients with AF is valuable for those who design or use catheter ablation devices. 
Significant differences in the anatomy of AF and non-AF hearts. Further, the cardiac 
features assessed in this study are critical to consider for both optimal catheter placement 
and the selection of proper ablation parameters to achieve successful transmural lesions.  
Keywords: Atrial fibrillation, catheter ablation, magnetic resonance imaging, mitral 
isthmus, coronary sinus 
Abbreviation List 
AF = atrial fibrillation  
CS = coronary sinus 
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LA = left atrium 
MI = mitral isthmus 
Introduction 
Catheter based ablation of atrial fibrillation is a well-established approach for treatment 
and the devises and techniques used to treat the disease continue to evolve. 55,56  More 
specifically, the application of ablative therapies within the coronary sinus and the left 
atrial mitral isthmus, have been shown to effectively treat many patient’s eliciting atrial 
fibrillation57,58 . Today, the creation of a linear lesion at the mitral isthmus is both a 
common practice and a challenge to complete: i.e., while attempting to achieve electrical 
isolation54,59–61. For example, ineffective ablation applications within this region have 
been reported to be subsequently pro-arrhythmic 60,62–64. Thus, new approaches/techniques 
are continually being explored to decrease such occurrences. When properly performed, 
ablations of the coronary sinus and mitral isthmus are able to create a linear set of lesions 
that can terminate conduction pathways for these atrial fibrillation (AF) patients65–69. 
 
In order to carry out effective ablative therapies within the coronary sinus and mitral 
isthmus, physicians must be able to navigate through a highly variable region of cardiac 
anatomy 58,70,71. Thus, a detailed understanding of all associated anatomical structures and 
their relationships to adjoining structure is critical (i.e., the circumflex artery, atrial 
myocardial tissue, and/or the endocardial ridgeline between the left pulmonary vein and 
the mitral annulus) 59,60. Previous studies have used CT or fluoroscopy images to attempt 
to characterize the morphologies and anatomy in this area: i.e., during the course of 
ablation procedures 58,60,72. Additionally, several other reports studied the endocardial 
surface shape of the mitral isthmus. However, they did not identify changes associated 
with cardiac remodeling due to AF 52,59,60.  
 
The purpose of this study was to further characterize the anatomy that may impact 
ablative therapies delivered at the mitral isthmus. To do so, we utilized a unique set of 
MRI anatomical reconstructions of perfusion-fixed human hearts, including both with 
and without a known history of atrial fibrillation. Controls had no known history of 
   24 
  
  
cardiac disease. The high spatial resolution we could obtain via static MR imaging of 
these specimens allowed for precise analyses of coronary sinus and left atrial anatomy. 
As noted above, it is clinically important to investigate the potential variations in this 
regional cardiac anatomy attributed to the consequences of atrial fibrillation, so to 
perform more effective ablation therapies.  
 
Figure 10: Images of a perfusion-fixed human heart specimen.  The image on the left shows 
the anterior surface and the one on the right shows the posterior view.  
Methods 
Study Population 
Data were gathered from 30 human hearts that were considered non-viable for 
transplantation via LifeSource (St. Paul, MN) or from the Bequest donation program at 
the University of Minnesota: these specimens were obtained fresh, with all chambers 
intact and with the great vessels attached. Each heart specimen was then perfusion-fixed 
to elicit an end-diastolic state (see below): i.e., including those from both patients 
diagnosed with AF (n=15) as well as those from individuals with no known cardiac 
clinical diagnoses (n=15). These specimens and the individuals from which they came 
were characterized in Table 3: i.e., genders, ages, clinical histories, body weights and 
heart sizes. A Wilcoxon rank sum test was performed to determine significant (p < 0.05) 
differences between the histories of the AF and non-AF specimens (Table 3). It is 
important to note that the AF population was older and had a larger male to female ratio, 
but had similar body weights relative to the control group. 
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Table 3: Study population demographics for 30 perfusion-fixed human hearts presented as 
the mean ± standard deviation. 
  
Control  
(n=15) 
Atrial Fibrillation 
(n=15) P-Value 
Age (years) 52.8±18.9 71.8±11.1 0.01* 
Gender (male/female) 4/11 9/6 N/A 
Patient Weight (kgs) 76.8±21.8 81.2±24.8 0.65 
 indicates significant difference (p<0.05) 
 
Specimen Preparation and Imaging 
Heart specimens were carefully prepared by cannulating the great vessels, positioning 
them in a specialized chamber and then perfusion-fixing them with a head pressure of 
approximately 50mmHg with 10% formalin, as previously described [21]. This allowed 
the hearts to maintain a pseudo end-diastolic shape and thus elicit a realistic anatomical 
form, so to allow us to obtain these morphometric measurements (Figure 10). Subsequent 
to fixation each heart was embedded with and positioned in a 7% agar solution: this 
allows one to decrease motion artifacts during magnetic resonance scanning52. Scans of 
these 30 human hearts were performed with a 3T scanner (Magnetom TRIO 3T MRI 
scanner, Siemens Corp., Munich, Germany) using an mprage (T1 weighted) protocol with a 
base resolution of 512.   
Anatomical Reconstructions and Measurements 
The dicom datasets obtained from the magnetic resonance imaging (MRI) were then 
imported into Mimics Software (Materialise, Leuven, Belgium) to create 3D models and 
then subsequently make digital measurements. Each cardiac image set was imported and 
segmented into three-dimensional reconstructions of the left atrium and the coronary 
sinus (Figure 11). The left atrial reconstruction was used to define the mitral isthmus area 
that would be accessed via a catheter through the coronary sinus by using the mitral 
annulus and left inferior pulmonary vein as references. A centerline was generated for the 
coronary sinus. Anatomical measurements relevant to ablation in the coronary sinus 
(CS) or a mitral isthmus ablation line were assessed. These measurements included: 
 CS ostial diameters and circumference 
 Distance along the CS from its ostium to the mitral isthmus  
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 CS diameters, circumference, and cross-sectional shape at the mitral isthmus   
 Distance to the left atrium from the CS at the mitral isthmus 
 The presence of fat around the coronary sinus 
 
 
Figure 11: An anatomical reconstruction of the left atrium (LA), coronary sinus (CS), and 
the left inferior pulmonary vein (LIPV) derived from one of the perfusion-fixed human 
hearts. The light blue line depicts the centerline of the CS and the yellow line depicts the 
area of the mitral isthmus (MI). 
 
The 3D models were then re-sliced into 2D data sets to make the CS ostium visible in 
plane. The CS ostial diameters and circumference were measured on this plane. The CS 
centerline was used to determine the distance a catheter would have to travel within the 
CS to reach the mitral isthmus. Next, the 3D models were again re-sliced so that the cross 
section of the CS at the mitral isthmus was in plane. The diameters, circumference, and 
shape of the CS were assessed in this plane as well as the distance to the left atrium and 
presence of fat around the vessel. 
 
The presence of fat and the distance to the left atrial space was also investigated at 
different positions around the coronary sinus at the mitral isthmus. To do so, a line was 
drawn across the mitral annulus as a reference. Next, a line parallel to the mitral annulus 
was drawn across the center of the CS cross-section and defined as 0. Finally, three 
additional lines were created through the center of the CS cross-sections at 45, 90, and 
135 to the 0 line (Figure 12). The presence of fat between the intersection of these lines 
with the boundary of the CS and the left atrium (LA) was assessed as a binary parameter. 
Then the distance from the coronary sinus to the left atrial space was measured at each 
location around the CS. 
   27 
  
  
 
 
Figure 12: Shown in this image is the method used to analyze the relative amounts of fat 
present adjacent to the coronary sinus at the mitral isthmus. The 0 to 180 degree line was 
drawn parallel to the mitral annulus. Using the center of the coronary sinus, 45, 90, and 135 
degree lines were created using 0 degrees as the starting point and rotating 
counterclockwise.  The left atrium (LA) and left ventricle (LV) were labeled for reference. 
 
The location of fat was identified by the variation in contrast seen within the MRIs. This 
was subsequently verified by physically sectioning a heart into 3-5mm thick sections 
following fixation (Figure 13). Finally, these fixed tissue slices were re-scanned by MRI 
to verify that the grayscale of the fat around the CS considered to be present in the scans 
did well correlate to the fat seen on the physical inspection. 
 
Figure 13: Images obtained for one of the human heart specimens: on the left is an MRI 
image and on the right is a photograph of the same human heart specimen sectioned to 
represent the same physical plane. The left atrial endocardial space is labeled. One can 
observed that the specimen section includes the coronary sinus and immediately inferior to 
it is a deposit of fat that is visible on both the MRI and photograph. 
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Statistical Analysis 
Data were presented as the means ± standard deviations. Nonparametric Wilcoxon rank 
sum tests (=0.05) were performed to determine if there were statistical differences 
between the AF and non-AF hearts for the various parameters of interest. 
Results 
Table 4 summarizes many of the observed anatomical differences between the AF and 
non-AF patient hearts (n=30). In terms of diameters and circumferences, the coronary 
sinuses were on average larger at the ostium and smaller at the mitral isthmus for AF 
specimens relative to non-AF specimens. Significant differences between the AF and 
non-AF hearts were identified for: 1) the distances along the coronary sinus to the mitral 
isthmus (p < 0.01), 2) the CS long axis diameters at the mitral isthmus (p = 0.03), and 3) 
the shortest distance from the CS to the left atrium at the mitral isthmus (p < 0.01) (see 
Table 4 ).  
Table 4: Coronary Sinus Anatomical Parameters (n=30) 
  
Non-AF 
Hearts 
(n=15) 
AF Hearts 
(n=15) 
p-
values 
( = 
0.05) 
    
CS Ostial Plane Measurements:    
CS circumference 31.2±10.7mm 35.2±15.3mm 0.63 
CS long axis 11.2±4.1 12.3±6.9 0.92 
CS short axis 6.8±2.6 7.3±3.0 0.69 
Distance from Ostium to Isthmus 
along CS 50.4±14.1 66.8±14.6 <0.01* 
CS at the Mitral Isthmus Plane:    
CS circumference 21.3±7.8 18.1±4.1 0.09 
CS long axis 8.1±3.1 6.4±1.7 0.03* 
CS short axis 4.7±2.0 4.5±1.4 0.97 
      CS to LA distances at Isthmus 3.4±1.3mm 5.6±2.0mm <0.01* 
      General CS shapes:    
     Round 4 6 NA 
     Oval 8 7 NA 
     Slit 3 2 NA 
 
AF=atrial fibrillation; CS=coronary sinus; LA=left atrium 
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Figure 5 summarizes the measurements taken at locations around the CS. The overall 
presence of fat was higher at every position around the CS for the AF specimens with the 
exception of the 270 position. In addition, the 90 and 315 locations were found to be 
significantly different (p=0.03 and p =0.01 respectively).  The smallest percentage of fat 
for the AF patients was observed to be at the 0 location. Altogether, fat was observed in 
79 out of 135 locations (59%) in non-AF hearts and 109 out of 135 locations (81%) in 
hearts with a history of AF. The average distances from the CS to the left atrial space was 
also larger for the AF specimens at every location assessed around the CS. The 0 and 
315 locations were significantly different (p<0.01 and p=0.02 respectively). The shortest 
distances to the left atrium were the smallest at the 0 and 45 locations. 
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Figure 14: (A) Shown here is a bar graph indicating the relative presence of fat around the 
perimeter of the coronary sinus. The graph compares the percentage of non-AF (n=15, blue) 
and AF hearts (n=15, red) where fat was present at different locations around the perimeter 
of the coronary sinus (CS). (B) Distances between different points around to the coronary 
sinus and the left atrial space for non-AF (blue) and AF (red) hearts were provided. An 
asterisk* indicates a significant difference (p < 0.05) between these non-AF and AF 
specimens. 
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Discussion   
The present study was performed so to identify morphologic characteristics of the mitral 
isthmus and coronary sinus that may influence how focal ablation catheters are operated 
and how lesions are generated within the atrial tissues at or near the mitral isthmus and 
coronary sinus.  Currently, ablations within the regional anatomy of the coronary sinus 
(CS) are commonly performed to treat atrial fibrillation (AF). Our novel study 
investigated this important cardiac anatomy in a set of isolated human hearts.  These 
intact human heart specimens were obtain fresh and the carefully prepared (perfusion-
fixed) to allow us to obtain high resolution MRI datasets which were then analyzed.  
Finally, we sectioned these specimens visually studied them as well as re-scanned them.  
In general, we observed notable anatomical differences between the hearts with obtained 
with individuals diagnosed with AF relative to those from the individuals with no know 
cardiac histories.  We consider here that these detailed analyses will provide important 
insights not only to the practicing cardiac electophysiologist and medical device 
designers as well.  
Major Findings   
The average dimensions of the CS at its ostium were larger in AF patients than in the 
hearts with no clinical presentation of AF, but smaller at the plane of the mitral isthmus.  
The average distance a catheter would have to travel to the mitral isthmus via the 
coronary sinus in AF specimens was 5.6±2.0mm, which was significantly (p < 0.01) 
longer than non-AF specimens (3.4±1.3mm).  The perfusion-fixed hearts that were 
obtained from AF patients had a higher rate of fat present around the CS compared to 
hearts with no history of AF.  The distance between the CS and the left atrial space was 
larger in AF hearts than the non-AF group at every location around the CS.  Interestingly, 
the short axis diameter of the CS in the region of the mitral isthmus (4.7±2.0mm) was 
larger than the commonly available 7 Fr (2.3mm) ablation catheter tip. 
Clinical Implications 
The use of traditional anatomical landmarks around the mitral isthmus commonly aids the 
cardiac electrophysiologist in the location of an ablation catheter tip within the coronary 
sinus. However, they may be an insufficient approach to ultimately achieve an effective 
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lesion necessary for electrical isolation59. Thus the clinical implications of the present 
anatomical study are quite relevant to such ablation procedures. We presented anatomical 
information regarding CS size, CS length, the presence of fat around the CS, and distance 
relative to the endocardial surface of the mitral isthmus. Each of these parameters can 
affect the ablation catheter placements, the tip orientations, and/or resultant energy 
delivered. The data presented in this study also suggest that the ability to create a lesion 
for AF patients could be impacted by an increased presence of fat and a larger distance 
between the CS and the endocardial wall. Consistent with such a notion, Wong et al. 
previously reported that when diameters of the CS at the mitral isthmus are larger than 
the catheter tip, the catheter tip will need to be manipulated many times in order to 
achieve tissue contact. The relatively large average diameter found in this study (short 
axis: 4.7±2.0mm for AF specimens) suggests that it will be challenging to place the 
catheter tip on the desired tissue to achieve a successful ablation therapy. 
 
The human heart data provided here also indicated that placement of the catheter tip 
aimed towards the LA in a parallel direction to the mitral valve annulus may increase the 
potential for delivery of a successful transmural lesion. More specifically, the 0 position 
around the CS resulted in the lowest percentage of fat presence (60%) and the second 
shortest distance to the left atrium at 6.0±2.0mm (after the 45 position at 5.8±2.0mm). It 
is well recognized, that the ability to generate an effective lesion requires that catheters 
be placed on viable tissue. We suggest here that better understanding of these parameters 
will allow for planned manipulations of catheters to ensure contact with the desired 
tissue. In other words, this CS-to-device relationship and the knowledge that there are 
regions around the CS more susceptible to the presence of fat suggest that catheter 
placement within CS makes a difference in the creation of an effective lesion set. 
 
It should be noted that the focus of this study did not include lesion characterizations. 
However, previous work by Yokokawa et al. demonstrated that changes in the ablation 
settings may be required to achieve a transmural lesion. The results of our study showed 
that there is an increase in the tissue thickness between the CS and the left atrium in the 
area of the mitral isthmus for specimens with a history of AF (3.4±1.31mm for non-AF 
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hearts versus 5.6±1.97mm for AF hearts). This, in turn, supports the notion that changes 
to ablation durations and settings may be required to result in lesion transmurality.  
Limitations 
It may be considered that a  potential limitation of our present study is that we did not 
specifically investigate the device-tissue interface. Hence, we acknowledge that 
additional work is needed to further understand how to optimize catheter placement 
and/or designs, along with the corresponding ablation settings, to generate transmural 
lesions in these anatomical locations most effectively and thus improve single procedure 
success. Another potential limitation of this study is that the findings may have been 
affected by the average age of the AF patients, i.e., being significantly higher than our 
non-AF population. Additionally, it is not fully understood what effects long-term 
formalin storage of tissues has on the morphology when such high resolution 
measurements are being made. Ideally, a subset of hearts would undergo fresh analysis 
followed by preserved analysis to determine the effects. Finally, although we would like 
to note that it was a major undertaking to obtain this sample of specimens and perform all 
scans and model generation, it may have not been large enough to achieve statistical 
power for some parameters due to the inherent high anatomical variability found in 
humans. Yet, one also has to consider that no difference may typically exist.   
Conclusions 
Ablation procedures performed within the CS with an aim to alter the function within the 
left atrium can be very important to the overall efficacy and completeness of overall 
arrhythmia therapy. Thus, a better understanding this specific regional cardiac anatomy 
and how it may be altered within the AF patient population can help the physician better 
utilize (as well as the device designer to optimize) the next generation of ablation 
systems. The outcomes from this study suggest that additional consideration is required 
to create lesions in these anatomy which are affected by disease states. Specifically, the 
slightly longer lengths of the CS in the hearts obtained from AF patients may suggest that 
the volumes of the left atrium are predicatively larger 59,62.
 
In addition, there are clear 
differences in the thicknesses of the myocardial tissues in the regions of the isthmus in 
the AF hearts. Finally, the circumferences of the CS indicate that the ability to affix a 
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catheter in the distal areas of the CS may require specific manipulations to ensure the 
catheter tip is in contact with atrial tissue. 
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I.III- Chapter 3: Anatomy of the Human Heart of AF Versus Non-AF 
Patients 
The Visible Heart® laboratory here at the University of Minneosta has created a unique 
collection of perfusion fixed human hearts. These hearts are being received through a 
research collaboration with LifeSource (St. Paul, MN), the regional organ procurement 
organization. Hearts that are deemed not viable for transplant are acquired at the time of 
acquisition of other organs that are being used for transplant. All such specimens are 
delivered to the lab within 24 hours, usually within 4 hours of organ cross-clamp time. 
The hearts are then fixed in formalin in an end diastolic shape. This overall process 
described in more detail in the article that follows, which was published in the Journal of 
Geriatric Cardiology. 
Briefly, using this unique human heart library the we sought to quantify differences 
between the hearts of donors with and without AF. Parameters relevant to AF were 
measured, such as: PV sizes, chamber sizes, tissue thickness, and fossa ovalis 
dimensions. 
Specifically, I contributed to all aspects of this publication, including data collection, data 
analysis, manuscript preparation and submission. I also have aided in the preservation of 
specimens in the human heart library throughout my stay in the laboratory: when I began 
my graduate work we had ~150 perfusion dilated heart specimens and at the time of 
writing there are 300+.  
The following is a copy of the published manuscript. 
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I.III.I- Cardiac remodeling as a consequence of atrial fibrillation: An 
anatomical study of perfusion-fixed human heart specimens 
Christopher D. Rolfes, PhD
7,8,9
; Stephen A. Howard, PhD
8,9,10
; Ryan P. Goff, BS 
8,9
; Paul 
A. Iaizzo PhD
 8,9
 
 
Executive Summary  
Background Atrial fibrillation (AF) causes a continuum of atrial anatomical remodeling. 
Methods Using a library of perfusion fixed human hearts, specimens with atrial 
fibrillation were compared to controls. During this preliminary assessment study, direct 
measurements were taken of atrial volume, pulmonary vein (PV) circumference, and left 
atrial wall thicknesses.  
Results Hearts with AF typically had larger atrial volumes, as well as a much larger 
variation in volume compared to controls (range of 59.6-227.1mL in the AF hearts 
compared to 65.1-115.9mL in control). For all hearts, right PVs were larger than left 
(mean 171.4 ± 84.6 for right and 118.2 ± 50.1 for left, p < 0.005). Left atrial wall 
thicknesses ranged 0.7-3.1mm thick for both AF and control hearts.  
Conclusions Hearts with AF had a large range of sizes which is consistent with the 
progression of atrial remodeling during AF. The large range of thicknesses will influence 
the amount of energy needed to create transmural lesions during ablation procedures.  
Keywords: Left atrial dimensions, volumes, pulmonary vein ostia, atrial fibrillation 
Introduction  
Atrial fibrillation (AF) is the most prevalent tachyarrhythmia, with a prevalence of 1% in 
the general population1. One of the particular clinical features of this arrhythmia is its 
self-perpetuating nature. Paroxysmal AF (self-terminating episodes) may eventually turns 
into persistent (> 7 days) and then even permanent AF 3–5. This progression is considered 
in part, due to both structural and electrophysiological remodeling of the tissue that 
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provide substrates for maintenance of such arrhythmias. Structural remodeling associated 
with AF refers to physical changes, such as dilation of the atria and interstitial fibrosis. 
The electrophysiologic remodeling results the shortening of the atrial effective refractory 
periods, thus aiding the perpetuation of an arrhythmia and/or limiting the ability to 
terminate fibrillations. More specifically, the self-perpetuation is especially disturbing 
symptom when patient long-term prognosis is taken into account: mortality rate doubles 
and stroke occurrence averages up to 5% per year in patients with AF, which is 2 to 7 
times the rate of individuals of similar ages whom are uninflected with AF 5.  
The prevalence of atrial fibrillation in relation to age and associated risks  
The clinical treatment of AF is an especially relevant topic in geriatric cardiology due to 
the well documented increasing prevalence with age. When considering an overall 
general population, the relative prevalence of AF is 1%, yet in persons over 40 years of 
age the prevalence reaches 2.3% and then climbs to 5.9% for individuals over 652. The 
geriatric population, defined by the WHO as persons with age greater than 65, contains 
over 75% of people suffering from AF 1. It should also be noted that AF has also been 
found to be more common in men than women (1.1% versus .8%) 1. 
Atrial fibrillation is well known to be associated with decreases in quality of life: as 
reported by as many as 68% of patients with paroxysmal AF73. Interestingly the 
psychological, not physical, quality of life may be impacted more74. In addition to stroke 
5, AF has also been associated with many other health problems that would cause 
decreases in quality of life such as depression, professional and sex life complications75, 
etc. However, it is debated whether or not AF is or is not associated with cognitive 
decline76–78 . It is highly probable that because AF causes an increased risk of stroke and 
emboli, that cognitive decline in part be linked to the potential for multiple small and 
transient cerebral infarcts, yet this will also be dependent on the given patient and their 
anticoagulation management 79.  
In addition to the above detrimental effects of AF, anatomical remodeling of the atria can 
occur within the heart. Patients who have AF tend to have larger left atria and larger 
pulmonary veins which could potentially lead to the further propagation of AF80. 
Alternatively, the reverse has also been shown: upon return to sinus rhythm after 
radiofrequency ablation, there is a measureable reduction in left atrial size81,82. Depending 
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on the length of AF and the stage of remodeling, patients with the arrhythmia may have 
large variation in their anatomy.  
Left Atrial volume measurements  
Heart left atrial (LA) volumes have been selected here to be measured in this sample of 
perfusion fixed human hearts, due to reported AF related atrial remodeling (dilations). 
For example, the work by Leung et al. found that increases in LA volumes could be 
usedto independently predict the increased risks of cardiovascular death, heart failure, 
AF, stroke, or MI83. Further, subsequent reductions in LA volumes (reverse remodeling) 
has been found to be a strong predictor of the successful treatment of AF using either 
catheter based84 or surgical85 ablations. Relative LA volumes for a given patient have also 
been found to predict the potential for recurrence of AF after cardioversion86 and 
conversion of atrial flutter to AF after successful ablation87. More specifically, the 
probability of relapse after catheter ablation was found to be significantly higher for LA 
volumes greater than 145 ml84. LA volume index greater than 135 ml/m2 was found to 
have 100% specificity and LA diameter greater than 60mm was found to have 100% 
sensitivity for prediction of surgical Maze failure85. Not surprisingly, normal LA volumes 
have been found to be associated with absence of thrombus88 and relative LAA 
dimensions have been found to be a positive predictor for stroke/TIAs in patients with 
AF89.  
Pulmonary vein sizes  
Since the clinical discovery that the pulmonary veins (PVs) can be substantial site-
sources of ectopic beats7, PV anatomy has attracted increasing attention. A patient’s 
pulmonary vein sizes are useful measurements when planning for an ablation since some 
procedures, such as cryoballoon ablation, offer multiple sized devices to optimize PV 
isolation. The PV circumference was chosen because even though the PVs (especially the 
left PVs) are typically oval in shape90, they are also considered as compliant and a 
balloon pushed against the ostium will slightly change its shape. In other words, using 
simply the long or short axis for planning may lead to the decision to use a balloon that is 
too big or small, respectively. 
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Left Atrial Wall Thicknesses  
Left atrial wall thicknesses are also commonly assessed and were done so here as well. 
The area on the posterior wall near each of the PVs was measured as well as the center of 
the posterior wall. These locations were selected not only because they are smooth in 
comparison to the left atrial appendage, but they are often areas of therapeutic focus 
during AF ablation procedures. Variation in LA wall thicknesses is also important to 
consider during radiofrequency ablation procedures, since it should influence the amount 
of energy to be applied91.  
One of the primary goals of this preliminary assessment study is to present our ongoing 
investigations as to human cardiac anatomy. Our Visible Heart® Laboratory has a current 
library of over 200 human heart perfusion fixed specimens that we can uniquely employ 
for such investigations. In addition, many of our obtained images are and videos of 
functional cardiac anatomy are available to the general public, via our free-access web 
site, “The Atlas of Human Cardiac Anatomy” (http://www.vhlab.umn.edu/atlas). 
Methods  
Human hearts deemed not viable for transplantation were donated for educational and 
research purposes. Following similar guidelines for transplantation, the hearts were 
stopped, cooled and transported to our lab. Within 24 hours of being excised, these 
specimens were weighed and the aorta, superior vena cava, pulmonary artery, pulmonary 
veins and the inferior vena cava (when possible on a given specimen) were cannulated 
and attached to a perfusion fixation chamber as described previously 50. This approach 
will preserve the hearts in a modified end-diastolic state (fully expanded atria and 
ventricles). These hearts were fixed with 10% formalin in PBS solution for at least 24 
hours under normal physiologic pressure and then stored in formalin.  
Heart specimens have been collected and added to our library since 1997 and to date the 
library has grown to over 200 in the collection. Anatomical studies can be performed on 
this large collection so to better understand the variation in anatomy between different 
hearts. For most of such specimens, pertinent clinical histories are also available, thus 
allowing us to assess the variation in anatomy with respect to the relative disease state of 
the heart. In the present study, we identified and used hearts that had a clinical diagnosis 
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of AF and compared them to hearts with no indication of AF or mitral/tricuspid 
regurgitation (normal anatomy). The AF hearts were sex, age, weight, and height 
matched to control hearts. For all but 2 of this sample of 10 AF hearts, acceptable control 
hearts were found and/or were measureable (Table 5). 
 
 
Table 5:  Patient information from atrial fibrillation and their corresponding control 
hearts. For all but two AF hearts suitable matches were found as controls based on subject 
genders, ages, weights and heights for these collected specimens.  
 
To measure the volumes of the atria, the hearts were oriented such that the annulus of the 
atrioventricular valves would be parallel to the ground while measuring their respective 
side. To measure the volume of the left atrium (LA), the aorta and all but one PV were 
clamped off and the LA and left ventricle were filled with deionized water. After the LA 
was completely filled the water was drawn out and collected until the water level reached 
the level of the annulus of the mitral valve, which was determined by visualization using 
a fiberscope. The weight of the water was taken and this process was repeated a 
minimum of three times. The right atrium (RA) was measured the same way; however 
the pulmonary artery, inferior vena cava, coronary sinus and posterior interventricular 
vein were closed up and the water was drawn out to the level of the tricuspid valve. The 
siphoned water was weighed and repeated three times. Note, that since deionized water 
was used, the weight of the fluid is equivalent to the volume of the chamber. 
All of the other anatomical measurements that were recorded were obtained using 
standard calipers or a C-clamp micrometer. The thicknesses of the LA were determined 
using the C-clamp at five distinct locations: the center of the posterior LA wall and the 
junction of the right superior, right inferior, left inferior and left superior PVs. The 
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junction of a PV was defined as the location in which the vein transitioned into the wall 
of the left atrium. To determine the relative areas of the PVs, the opening of each vessel 
was pinched together to measure half of the circumference (Figure 15) and obtain an area 
assuming the vessel is circular. Although it has been found in the literature that the PVs 
are generally oval in shape, it was decided that comparing the vessels as circular would 
alleviate the problem of re-approximating the oval shape of the pulmonary veins. 
Furthermore, in some of these cases, the PV can be slightly distorted due to the nature of 
the fixation process. 
 
 
 
Figure 15: Illustration of the half circumference measurements taken to obtain diameters 
and area measurements of the various PVs.  
 
The size of the fossa ovalis (FO) in each specimen was also measured; it should be noted 
that since the FOs were not collapsed during the fixation process, we were able to obtain 
accurate assessment of these structures. These areas were determined by measuring the 
diameters along the superior/inferior and the anterior/posterior direction of each FO.  
Values presented are mean with standard error unless otherwise noted. For comparisons 
of continuous variables between two groups a Student’s t test was used.  
Results  
Within these investigated hearts, as expected the AF hearts had larger LA, RA and total 
atrial volumes compared to the controls hearts (Figure 16). However when we compared 
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individual AF heart to their specific sex, age, weight and height matched control, there 
was no clear correlation as to which types of heart had larger atrial chamber sizes. Yet, 
the data did suggest that there was a higher variability within the hearts from the AF 
patients compared to the controls: with a range of 59.6ml to 227.1ml in the AF hearts 
compared to 65.1ml to 115.9 ml in the control hearts. Note that the differences in ranges 
for both atria are over 3 times larger in the AF group than in the control group. 
 
Table 6: The mean and median values of the pulmonary vein ostia between AF and control 
heart specimens. 
 
 
Figure 16: Comparisons of the paired left, right and total atrial volumes between the 
matched AF and control hearts. Note that the AF hearts had greater variability of volumes 
compared to the controls. 
As noted above, the sizes of the pulmonary veins were assessed by assuming all as 
circular openings (Figure 17). Between the two groups, the control hearts had smaller PV 
ostia for both the left and right veins. One can observe two different peaks on these 
histograms; with the higher peak associated with the data from the AF hearts. This 
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finding was consistent also when the right and left PVs were compared separately (Figure 
17). Interestingly, there was also the observed trend that the left PVs were smaller than 
the right PVs in both the control and AF specimens (Table 6). Further, when trying to 
determine that the right PVs were larger than the left, while looking at the whole 
population of hearts, there was a significant difference seen between the two (mean 171.4 
± 84.6 for right and 118.2 ± 50.1 for left, p < 0.005). 
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Figure 17: The relative variation in pulmonary vein ostia sizes between the two groups of 
heart specimens. The histograms provide the corresponding areas of these ostia. Top: the 
relative distributions of pulmonary vein sizes of the right pulmonary veins; with means of 
24.2mm2 and 21.6 mm2 and medians of 23.1 mm2 and 19.9 mm2 respectively. Bottom: the 
left pulmonary vein areas, means of 18.7 mm2 and 19.0 mm2 and medians of 18.4 mm2 and 
17.7 mm2 respectively. The trend lines depict the two point moving averages of the 
distributions and illustrate the relative differences between these two heart populations. 
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Although there were observed trends between the relative areas of the PV ostia of these 
two groups, in contrast there were minimal differences in the thicknesses of the LA walls 
within our samples: the means and medians were 1.19mm and 1.24mm for the AF 
population and 1.26mm and 1.21mm for the control population, respectively. The 
histograms and population spreads between the AF and control groups appear to elicit a 
fair amount of overlap; in other words, they appeared similar between the groups and 
were not dependent upon the diagnoses of AF (Figure 18). Similar findings were also 
observed when examining the relative sizes of the FO in these hearts. The FO dimensions 
only had slightly larger sizes in the anterior-posterior (AP) vectors, whereas they elicited 
minimal or no differences in the superior-inferior vectors (SI) (Figure 19). 
 
 
Figure 18: Relative distribution of thicknesses of the left atrium between the AF and control 
hearts. These thicknesses values were determined by taking measurements from each of the 
four pulmonary vein junctions in each heart, as well as the center of the posterior walls of 
the left atria. The trend lines depict the two point moving averages of the population 
distributions. 
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Figure 19: Average widths and heights of the fossa ovalis sizes between the two populations 
of hearts. The relative widths of the fossa ovalis were designated as the fossa ovalis anterior-
posterior (FOAP) measurements and the heights were designated as the fossa ovalis 
superior-inferior (FOSI) measurements (error bars represent the SEs). It was observed that 
there were no significant differences between the calculated averages of the measurements 
taken of and the distributions of the sizes showed similar trends between the AF and control 
hearts (data not shown).  
Discussion  
In the present study we describe novel measurements of relevant cardiac anatomy 
obtained from our unique library of perfusion fixed human hearts. In this preliminary 
assessment study, we describe approaches to allow for the detailed quantifications of 
specific atrial anatomy. The presented information provides useful insight as to the 
changes in structure that may occur when the human heart remodels following the 
development of AF, and we plan to continue these studies as our relevant library of 
specimens grows.  
Current imaging modalities, including MRI, ultrasound, and CT scans, allow for relative 
approximations of the volumes and sizes of the LA and RA using algorithms available in 
various software packages or by simply estimating diameters. Yet, it is considered that 
measurements of LA volumes are more accurate than diameter data, especially as a given 
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heart dilates, i.e., small increases in diameter will provide for larger increases in derived 
LA volumes 50,92. Our volume measurements take into account the variability of chamber 
anatomies from heart to heart, and thus resulted in a more accurate representation of the 
total chamber sizes. Therefore, these chamber volumes, along with thickness 
measurements of the LA, were considered to better point to variations in anatomy due to 
a given pathological state. However based on our data on this somewhat small sample 
size, we could not make correlations as to the clinical state based solely on these 
measurements. Yet, it should be noted that even in the absence of AF, large atria are 
often indicative of other cardiovascular issues93, thus in these hearts we studied from this 
elderly population of subjects it was likely that the non-AF hearts, or so-called controls, 
may have been not truly normal.  
Our initial characterization of these AF hearts confirmed various trends that have been 
reported within current literature, such as the increased sizes of right PVs compared to 
the left PVs80. However, as with most anatomical studies a large sample set is required so 
to potentially produce statistically significant results. With our growing library of these 
perfusion-fixed human hearts, we will be able to perform ongoing anatomical studies so 
to better assess the differences within various populations of heart disease states or 
demographics. Our collection of specimens to date has allowed us to obtain useful 
insights as to the common anatomical features of the atria from patients with AF with a 
high degree of accuracy. The variety of physical specimens also allows for physician 
education and therapeutic device feedback as any number of devices can be placed within 
the hearts. The continued study of the details of human cardiac anatomywill provide 
further insights as to the changes in structure that may occur when the human heart 
remodels or reverse remodels due the presence of disease or following treatment, 
respectively. Though above study shows that PV measurements are not sufficient to 
diagnose AF, it illuminates the variety of anatomies that accompany the arrhythmia 
within the population. This large variation observed in the diseased patients is important 
for the physicians who treat AF, the educators, and engineers who must design medical 
devices to fit the whole range of anatomies. Using the fixed hearts we plan to continue to 
employ the study methods described here to further build an anatomical database, which 
we hope to compare to MRI, CT and 3-D models derived from each.  
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Conclusion  
Atrial fibrillation comes with a great deal of anatomical and physiological changes. 
Anatomically, the size of the atria can vary greatly, but the pulmonary veins and vena 
cavae do not remodel significantly. The variation in anatomy has great importance and 
should be considered when treating and designing devices for AF.  
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I.IV- Chapter 4: Imaging of balloon based catheters using Visible 
Heart methodologies 
One of the unique opportunities available for our lab’s use is the imaging capabilities of 
the Visible Heart® methodologies. In other words, the isolated heart system described in 
detail previously 94–96 allows for a simultaneous multimodal imaging. This is especially 
useful for the medical device designer and physician for the testing of prototypes, 
education, practice, and mental visualization of various clinical procedures/techniques. 
With the end goal of producing educational publications on cryoballoon ablation I began 
by partnering with a colleague, Dr. Oliver Bandschapp, on imaging of a pulmonary artery 
catheter. Commonly referred to as the Swan-Ganz catheter, this device is a balloon tipped 
catheter, similar to the ArticFront (Medronic, Inc.) cryoballoon catheter. A shortened 
version work was published in the American Journal of Respiratory and Critical Care 
Medicine (impact factor 11.04) in 2012. This video begins with footage filmed in the 
clinic of placement of a pulmonary artery catheter and ends with endocardial journey into 
the distal pulmonary artery wedge position. 
After working with Medtronic and Professor Iaizzo, I was able to procure a Cryo Console 
for permanent use in the laboratory and from there I produced an imaging piece detailing 
the visualized cryoballoon ablation procedure.  In brief, this work demonstrates the 
commonly employed endocardial procedure, with accompanying fluoroscopic views that 
the electrophysiologist would normally see. A similar piece of work which compared the 
new generation cryoballoon to the previous was selected for a poster presentation at the 
2013 Transcatheter Therapeutics conference. The accepted abstract can be found in the 
appendix. Videos are also included on the Atlas of Human Cardiac Anatomy website.  
This preliminary work was followed up with more advanced imaging and quantitative 
work utilizing reanimated heart-lung blocs, see section 3. These novel, intial studies 
allowed us to optimize imaging of balloon catheters and also brought to light 
shortcomings that were later improved upon (i.e., including the lung in the preparation for 
imaging of pulmonary vein isolation). 
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I.IV.I- The Path of a Swan Ganz Catheter Visualized through a Beating 
Human Heart 
Oliver Bandschapp, MD
10,11
, Ryan Goff
11
, George Mallin
11 
, Michael Loushin, MD
12
, and 
Paul A. Iaizzo, PhD
11,12
  
 
Reprinted with permission of the American Thoracic Society. Copyright © 2014 
American Thoracic Society. Am J Respir Crit Care Med. 2012;186(4):385 
 
In 1967 cardiologist Dr. Jeremy Swan envisioned placing a catheter into the pulmonary 
circulation via the right heart by using a catheter with an inflatable balloon at its tip to 
assist navigation without the use of fluoroscopy, which was standard practice at the time. 
His concept predicted that the movement of the balloon would be assisted by the blood 
flow, to direct the catheter through the right atrium, past the tricuspid valve, through the 
right ventricle, past the pulmonary valve, and into the pulmonary circulation. The story 
has been told that Dr. Swan observed sailboats off-shore on a sunny day in Santa Monica; 
all boats were becalmed, except for one, a sailboat with a large spinnaker that made 
reasonable speed, despite only calm winds. This observation stimulated the idea of a 
balloon-tipped catheter.97 Together with Dr. William Ganz, Swan planned to measure the 
intracardiac pressures at the distal lumen of this balloon catheter. By doing so, they 
reasoned that even without visualization, they would know where the tip of the catheter 
was located at any given moment. In essence, they would be able to ‘monitor’ the whole 
procedure and deliver their special catheter safely through the heart.  
Swan and Ganz were right.98 Their procedure proved feasible and reasonably safe to be 
performed at the bedside, with only conventional monitoring in place (i.e., ECG, blood 
pressure, SpO2 and intracardiac pressure readings through the distal lumen). The relative 
ease of performance and the substantial amount of information gathered (i.e., assessment 
of cardiac output, wedge pressure) quickly made their flexible balloon catheter an 
essential diagnostic tool in intensive care units worldwide.99 However, a wealth of new 
data now show that the use of these catheters in critically ill patients has not always been 
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associated with improved clinical outcome.100–103  So, there is substantial controversy 
about the use and indications of Swan Ganz catheters at the moment, and the discussion 
is ongoing.104–106  It is not the intention of this video publication to add to the discussion, 
but rather to give a reprise of Dr. Swan’s vision of ‘sails in the wind’. Here we employed 
Visible Heart® methodologies to reanimate a human heart (male, 45 years) with a clear 
perfusate and make such stunning catheter placement images possible.94 Although this 
heart was not deemed viable for transplant, we were able to elicit viable function of the 
heart in vitro; it sustained a normal sinus rhythm and cardiac outputs over 4 L/min. Thus, 
what started in Dr. Swan’s mind and what we all are imagining ourselves, while staring at 
the pressure curves during Swan Ganz catheter placement, is visible in this actual video 
footage – a balloon catheter traveling through the valves and chambers of a right human 
heart into a wedge position in the pulmonary circulation, in synchrony with typical 
pressure readings from the distal lumen and a timed computer animation. 
 
Figure 20: A representative screen shot of the video as the Swan Ganz catheter is passing 
through the tricuspid valve.  On the top left a fluoroscopic image is presented with a 
computer animation found below to aid the viewer in navigation. On the right, using 
endoscopy and Visible Heart® methodologies11, direct visualization of the balloon is shown 
with the beginning of the characteristic transition in pressure waveform found bottom 
right.  
Advancing the Swan Ganz catheter through the heart into wedge position 
The following is a synopsis of a typical catheter deployment: after central venous (i.e., 
internal jugular vein or subclavian vein) cannulation, the flexible balloon catheter is 
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placed intravascularly through an introducer. Before placing the catheter through this 
port, the operator confirms correct pressure readings from the distal lumen, by gently 
swinging the catheter tip. The movement of the catheter should appear on the monitor as 
a swinging pressure curve. Additionally, the balloon is inflated to make sure no leak is 
present and then deflated prior to placement. Of note, the balloon should be inflated prior 
to advancing the catheter forward and should be fully deflated prior to withdrawing or 
pulling back on the catheter. Patients should be monitored with ECG, blood pressure, and 
SpO2 at all times, as severe arrhythmias can occur during placement of the catheter and/or 
even later on.107,108 Then, the catheter is advanced 10-15cm into the vessel and the balloon 
is inflated. By connecting the distal lumen with a pressure transducer, one can observe 
the actual pressure present at the tip of the catheter during the whole procedure. As the 
catheter is advanced further into the right atrium, the measured pressure remains constant 
at low levels and the waveform stays flat, consistent with the components of a central 
venous pressure waveform. As soon as the tip of the catheter enters the right ventricular 
chamber, ventricular pressure readings appear, indicating the intraventricular position of 
the catheter tip. The typical pressure reading of high systolic pressures together with near 
zero diastolic pressures is present, as long as the tip of the catheter is located in the blood 
pool within the ventricle. If, despite further advancement of the catheter, the pressure 
curve does not change this characteristic, the catheter needs to be redrawn. This could 
signify that the catheter is looping inside the ventricle; catheter knots have been 
described.109  However, once the balloon passes the pulmonary valve, the pressure curve 
shows an abrupt increase of the diastolic pressure together with a stable systolic pressure. 
This increase of diastolic pressure signals that the balloon has just passed the pulmonary 
valve. The catheter is now advanced further into one of the pulmonary arteries. As soon 
as the balloon arrives in the wedge position – the balloon obstructs the entire lumen of the 
vessel – a characteristic decline of the pressure waveform occurs and the pulsatile 
pressure waveform ceases. The obtained pressure readings (‘wedge pressure’) can now be 
used to assess the fluid status of the patient and give indirect information about the filling 
pressures of the left heart chambers.110,111 Importantly, as soon as the actual wedge 
pressure readings are taken, the balloon should be deflated, as lung infarction could occur 
if it is left inflated and wedged for a duration of time. If the balloon is deflated, there 
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should always be a pulsatile waveform in the distal pressure reading on the screen. If not, 
the catheter has migrated too far into the pulmonary circulation and needs to be redrawn 
immediately; fatal vessel rupture or lung infarction could occur otherwise.112,113 
Additionally, the Swan Ganz catheters can be used for cardiac output assessments, either 
by thermodilutionary methods with cold saline or, as presented in the actual video 
footage, with a balloon catheter capable of continuous cardiac output monitoring.  
 
Figure 21: A screen shot similar in description to Fig. 1, but of the pulmonary valve. Note 
characteristic change in diastolic pressure as the balloon passed through the valve found on 
the bottom right. 
 
The insertion and application of Swan Ganz catheters requires meticulous care and 
attention to detail. The intervention is, by its nature, invasive; grave complications during 
such action can and do occur.114 To bring the best care to patients, the anatomy and 
physiology of events need to be thoroughly understood. This video provides a novel 
visual perspective of the critical events that occur while inserting a Swan Ganz catheter 
and shows the resistant yet fragile intracardiac structures. We also refer readers to the 
‘Pulmonary Artery Catheter Education Project’, which can be found at www.pacep.org 
for additional theoretical and educational coverage.  
Financial support: This research was supported in part by the Department of Surgery at 
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I.IV.II- Multimodal imaging of a cryoballoon ablation within a 
reanimated hearts. 
Background:  
Cryoballoon ablation is a relatively new ‘single-shot’ treatment modality for 
pulmonary vein (PV) isolation in patients with drug refractory recurrent symptomatic 
paroxysmal atrial fibrillation (AF).  
Treatment using the cryoballoon for pulmonary vein isolation has been reported in the 
literature to have comparable efficacies and safeties to the widely practiced 
radiofrequency ablation 35.   
Despite the ease of a ‘single-shot’ approach, there can remain technically difficult 
maneuvers needed to successfully access the right inferior pulmonary vein: e.g., the 
hockey stick, C-loop, inversed  
C-loop, and pull-down techniques16. This, along with the suspicion that undersizing 
balloons increases risk of procedural complications35, warrants further study of the 
device-tissue interaction. To date, these interactions and procedural workflow has yet to 
be reported on using isolated large mammalian hearts that allow direct visualization of 
the procedure.  
Methods and Results:  
Human hearts and 75-85 kg Yorkshire cross swine hearts were procured using 
anesthetic and surgical procedures of cardiac transplant95,115.  The hearts were then 
reanimated using Visible Heart® methodologies described previously 115. Following 
catheter placement in the right atrium, via the inferior vena cava, a transseptal puncture 
was performed using a Brockenbough needle (Medtronic, Inc., Minneapolis, MN) to 
catheterize the left atria. The ArticFront® cryoballoon and a FlexCath® steerable sheath 
(Medtronic , Inc.) were introduced to the left atria using an over the wire method. 
Subsequently, the cryoballoon was positioned in the left pulmonary vein ostium and 
inflated. Fluoroscopic contrast mixed with blue or green dye, for videoscope 
visualization, was injected into the PV to verify proper placement. Leakage of the 
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contrast around the balloon indicates poor initial placement.  After repositioning and 
confirming occlusion, a four minute ablation was performed. 
 Images obtained from human heart 271 are shown below right (B) and images 
from swine below left (A). Human heart specimen 271 is from a 68 year old female with 
BMI of 23.8 who died of anoxia and had no relayed relevant cardiac history. 
 
A                                                                                             B 
       
Figure 22:  (A) Dilator and FlexCath advancement through the swine fossa ovalis visualized 
from the right atria (top left), under fluoroscopy (top right), and from the left atria (bottom 
right). Note, a guidewire has already been exchanged for the Brockenbough needle shown in 
bottom left of B. A view from the right atrium (top left) is also shown in B with a view of left 
pulmonary veins (top right), fluoroscopic position (bottom right), and fossa ovalis with right 
pulmonary veins in view (bottom left). 
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A                                                                                             B 
   
Figure 23: Position of the ArticFront as seen from within the left pulmonary vein (top left 
A, top right B), fluoroscopy (top right A, bottom right B), and within the left atria (bottom 
right A, bottom left B). The Cryo Console screen is shown top left in B. These images are 
during the beginning of an injection of fluoroscopic contrast, with blue or green dye for 
direct visualization. Darkening of the vein distal to the balloon on fluoroscopy demonstrates 
good occlusion of the vein. 
 
A                                                                                             B 
  
Figure 24: Near the end of a four minute ablation ice can be seen within the left pulmonary 
vein (top left A, top right B). The temperature profile on the console screen is displayed 
(bottom left A, top left B). An endocardial view of the balloon and ice formation in the tissue 
can be seen as well (bottom right A, bottom left B). The fluoroscopic position is displayed 
top right in A and bottom right in B.  
 
The images yielded from this study demonstrate the procedural workflow using a 
28mm cryoballoon visualized from within the heart using videoscopy and fluoroscopy. 
The degree of ice formation was inspected at both the endocardial surface and from 
within the PV.  
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Conclusions:  
To date, six human specimens and over 30 swine specimens have been animated 
and had balloon cryoablations performed and imaged within them. Direct visualization of 
cryoballoon ablation has led to the creation of novel videos showing the endocardial view 
of this treatment. These videos can be used to inform and educate physicians and patients 
on the use of cryoballoon ablation. This model can be further used by device designers to 
improve current products or test next generation devices.  
Several limitations of the swine animal model do exist. Swine generally have only 
two pulmonary veins and smaller left atria. Yet, this may prove of value when trying to 
simulate difficult human patient anatomies: e.g., those with common left or right 
pulmonary veins or small patient stature. Being this footage was captured utilizing an 
isolated heart, the heat transfer situation is very different from that found clinically. This, 
coupled with the fact that part of the cryoballoon was within the pulmonary vein cannula, 
leads to the authors’ opinion that ice formation and duration after the ablation has been 
stopped may differ significantly from the clinical situation. Our laboratory also has the 
capability to reanimate human, non-viable organ donor hearts, and similar studies are 
underway using these specimens. A video publication is in preparation of these works. 
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I.V- Concluding Remarks 
To summarize the findings of the various studies presented in this section of my thesis, I 
have: 
 Further elucidated the remodeling that occurs in the AF patient versus non-AF patient. 
 Quantified phrenic nerve anatomy using a novel, high resolution technique that may 
also be used for further computer modeling. 
 Quantified coronary sinus anatomy in the context of isthmus lesion creation and 
catheter navigation. 
 Developed preliminary methodologies of imaging balloon based catheters that were 
later expanded and improved upon in my graduate studies. (see Chapter 3, Heart-lung 
bloc reanimation)  
 
I consider here that these studies not only fill in gaps in knowledge in the literature, but 
provide novel experimental approaches that can be built upon in the future. For example, 
the medical device developer may use these findings to: 1) design application specific 
ablation tools for the coronary sinus, 2) make recommendations on therapy dosing and/or 
3) use such information for future product designs by using computer models that can be 
constructed.  Additionally, from these presented studies, I believe that the clinician has 
been provided with new and confirmatory information on anatomy and remodeling 
related to ablation and AF, respectively, that may help guide clinical practice. For 
example, knowledge of the true distances of the phrenic nerves from sites of ablation 
application have yet to be studied in the context of cryoballoon ablation, but are now 
better understood. 
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II- Section 2 Assessment of Cryothermal Injury 
Upon familiarization with the literature in cardiac cryothermal ablation it became 
apparent that there existed a critical knowledge gap or at least not thoroughly investigated 
as it enhances therapeutic delivery. For example, very few, if any, reported studies 
examined the tolerances of the tissues that may be impacted by such aforementioned 
procedures. Nevertheless, in order to eventually predict therapeutic outcomes it is 
necessary to understand what will lead to those outcomes. Therefore, the following 
portion of my thesis will describe experiments I performed to elucidate the viability 
and/or physiologic responses of tissues that may be impacted during cardiac cryothermal 
ablation.  
In this section of my thesis I detail the work of three individual studies. In the first I will 
describe, an in-vitro system that can be feasibly used with any muscular tissue and I 
developed using rectus abdominis and myocardium. The developed experimental 
approach is currently being extensively by other graduate students in the lab to examine 
esophagus and other tissues response to various ablation modalities. Secondly, I sought to 
further understand phrenic nerve cryothermal tolerances, because this is highest reported 
procedural complication of cardiac cryoballoon ablation. This also involved developing a 
unique system to monitor nerve function and record nerve temperature changes during 
therapeutic applications. Lastly, understanding myocardium and lung viability response 
to cryoablation was pursued. These two tissues for study were selected because the 
myocardium is the tissue of target and therefore, understanding how much cooling is 
necessary to obtain a complete lesion is highly valuable for potential predictive modeling 
of therapy. Finally, the methods used for assessing myocardium thermal tolerances were 
determined to work with lung tissue as well and thus I performed a secondary study on 
lung tissue: note that plural tissues have been reported to be collaterally injured as well 
during such clinical procedures.  
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II.I- Chapter 5: Determination of Cryothermal Injury Thresholds in 
Tissues Impacted by Cardiac Cryoablation 
Ryan P. Goff, BS 
13,14,15
; Steve Quallich BS 
13,14,15
; Robert Buechler MS
13,14,15
; 
Jeunghwan Choi PhD 
16
; 
 John Bischof PhD 
13,16
; Paul A. Iaizzo PhD
13,14,15
 
 
Background 
Cardiac balloon cryoablation for the treatment of atrial fibrillation has been gaining 
attention as an approach for isolation of the pulmonary veins (PV) since its first reported 
use in 2003
15
 and in the current clinical form in 2005
116
. Focal cryoablation has been 
used surgically for many years
117
 with transcatheter devices becoming available in more 
recent decades. An advantage of cryoballoon ablation is that it is a ‘single-shot’ 
approach, which aids in accelerating the slow nature of freezing compared to RF energy 
(i.e., not point-by-point ablation). The currently available ArticFront (Medtronic, 
Minneapolis, MN) cryoballoon has been shown to have comparable success rates to RF 
ablation with low adverse events
34,118
. The recent STOP-AF trial concluded similar 
findings to the observational European studies, that being an acceptable safety profile and 
superiority to antiarrhythmic drugs in those who have failed to respond to them
17
.  
Despite widespread and growing clinical use there are still questions regarding dosing 
and treatment times for cryoablation, which may affect both efficacy and collateral 
injury
119,120
.  Parameters affecting RF ablation lesions are thoroughly characterized, and 
temperatures of 50°C or higher are required for the creation of myocardial scars
121
. For 
instance, the effects of power, ablation durations, catheter orientations, catheter sizes, 
usage of irrigation, and contact forces on lesion size have been thoroughly studied for 
RF
122–125
. This is particularly relevant given the release of a second generation 
cryoablation device with a different cooling profile that may affect operation
126
. The 
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highest regularly detected clinical complication is phrenic nerve palsy at rates of 4-8% 
17,118
. The esophagus may be incurring even higher rates of injury, but this is not normally 
detectable unless specifically searched for using endoscopy
44,127
. Given that the phrenic 
nerve and esophagus are in intimate contact with the right PVs and posterior wall of the 
LA, respectively, one can see how adjusting dosing may lead to better outcomes. It is 
recommended by the manufacturer that two separate four minute ablations are applied per 
PV.   
The literature is largely lacking on data of hypothermal injury to the myocardium and 
surrounding tissues that may be impacted. This is the first study to the authors’ 
knowledge to report myocardium tolerance limits for cryo ablation. These data are 
particularly useful for numerical modeling of therapies that may influence decisions 
regarding optimal treatment times or even patient specific recommended treatments. 
Optimization of treatment time may potentially lead to shorter treatments, which still lead 
to transmural lesions, and reduce collateral injury. 
Conversely, in the hyperthermal (i.e., RF, laser, etc.) treatment area there are data 
regarding injury to the myocardium. Work by Pearce and colleagues
128,129
 exploited 
cardiac tissue’s unique, native birefringence to detect protein denaturation after thermal 
ablation. Protein denaturing is thought to be the main mechanism leading to necrosis 
from hyperthermal treatments
130
. However, this same approach cannot be used to 
determine completely necrotic zones caused by freezing because birefringence changes 
potentially prior to actual cell death occurring when cooling. Intracellular ice crystal 
formation and dehydration are the main mechanisms of injury to cells during 
freezing
24,131
. Cooling below the actual freezing point of tissue is necessary for complete 
necrosis, as shown in studies of the kidney
117,132
 and liver
133
 where cooling to -15°C was 
required for necrosis.  
It is therefore the goal of this series of experiments to determine what cooling regimes 
lead to necrosis, injury, or have no detectable effect on myocardium. Infrared (IR) 
thermography was selected because of the large amount of data produced (i.e., every 
pixel produces a thermal profile). Additionally, it is a non-contact measurement 
technique, which is particularly beneficial given the large thermal gradients produced 
during cryoablation (i.e., 100 C/cm), and has been used previously for hypothermal
134
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and hyperthermal
135
 studies in the cancer arena (bischof ref?). The drawback of IR 
thermography is that the accuracy of the measurement is not that of other techniques (i.e., 
+/- 2C or 2%) and that the system used was limited to detection down to -20C. The 
authors hypothesize that injury to tissue will begin to occur when tissue is cooled to the 
phase change temperature (~0 or -.5 C for most tissues). The authors also hypothesize 
that in order to obtain complete necrosis more substantial cooling to the levels found to 
be necessary in other tissues, such as the aforementioned temperatures for liver and 
kidney, will be required. 
Methods 
To first benchmark this novel approach a small sample of swine kidney (n=6, two 
animals) were evaluated and compared to the literature. Kidney cortex is homogenous 
with a smooth, flat surface making it easier to work with. Once it was determined the 
approach was technically sound myocardium and a smaller set of lung samples were 
evaluated. 
Sample preparation 
Human heart(n=3)  and lung(n=3)  specimens were obtained from non-viable cardiac 
transplant organ donors through the regional organ procurement organization, LifeSource 
(St. Paul, MN) within 6 hours of cross-clamp time. Female Yorkshire Cross swine hearts 
(n=15), lungs (2 animals, n=5),  and kidneys,  were chilled and stored in modified Krebs-
Henseleit buffer within 30 minutes post-mortem from the University of Minnesota Meat 
Sciences Laboratory. Swine hearts were then transported to our laboratory within an 
hour. Human and swine samples were dissected from the atria and ventricles to nominal 
thicknesses of five millimeters. Locations were selected that were relatively ‘flat’ with 
low degree of invaginations to provide a uniform surface for infrared (IR) imaging as to 
avoid out of focus effects and non-symmetrical ablation lesions. Samples were placed in 
individual petri dishes with room temperature phosphate buffered saline. 
Dissected samples were placed in an infrared imaging apparatus shown in Figure 25, 
consisting of a plastic petri dish with central ablation probe and 2 millimeters of Sylgard 
(Dow Corning, Midland, MI) polymer formed to the bottom. The system was designed to 
accommodate two cryoablation probes with different cooling powers. One being the Galil 
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Medical (St. Paul, MN) SeedNet system designed for prostate cryoablation using an 
argon refrigerant with cooling rates and end temperatures approximately 400 °C /minute 
and -120 °C. The second system is the Medtronic Cryocath (Minneapolis, MN) system 
using the FreezorMAX catheter with cooling rate and end temperatures approximately 
300 °C /minute and – 84°C. The samples ablated using the Galil system were impaled on 
the needle like catheter and the samples ablated using the Medtronic system had a two 
millimeter biopsy punch hole placed in the center of the sample and then advanced onto 
the catheter. Using this technique approximates a situation that is easy to model 
numerically, removes the variability of catheter contact pressure, and creates uniform, 
axis-symmetric lesions (i.e., round. Figure 25, right). 
 
 
Figure 25: Infrared imaging apparatus shown left and resultant isotherms shown left. The 
samples are impaled onto the cryoprobe and imaged from the top down. A resultant 
isotherm from an ablation performed with the Galil system is shown right with white 
indicating temperatures less than -20°C, blue -20°C to -10°C, green between -10°C to 0°C, 
and red greater than 0°C. 
Infrared imaging and viability assessment 
Prior to sample placement in the sample dish ~5 milliliters of ultrasound gel was 
distributed uniformly about the bottom of the dish. After placement of the sample another 
volume of ultrasound gel was added to surround the sample. Ultrasound gel has been 
shown to have very similar thermal properties as myocardium(
136
 and unpublished data) 
and by surrounding the sample with ultrasound gel we seek to minimize the thermal 
effects that variation in sample size, inherent with biological samples, may have.  
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After sample placement the emissivity and appropriate environmental parameters were 
input to the infrared software (ThermaCAM Researcher Pro 2.9, FLIR Systems, Inc., 
Boston, MA). Emissivity was determined by comparison of IR temperature to a 0.040” T-
type thermocouple temperature (5SRTC, Omega Engineering) being read by a Fluke 51II 
thermometer (Everett, WA). A T-type thermocouple with data logging was affixed to the 
active cooling metal portion of the cryoprobe with Kapton (3M, St. Paul) tape for later 
computer modeling. Ablations of desired durations were subsequently performed. 
After the ablation samples were washed with phosphate buffered saline, incubated with 
60 milliliters of cell culture media (DMEM/F12, 10% fetal bovine serum, and 1% 
penicillin/streptomycin), and placed in a cell culture incubator. Myocardium samples 
were incubated for 22-24 hours to allow full cryo injury to manifest. Incubation of 4 
hours were necessary for lung and kidney samples. Samples were then stained with 1% 
triphenyltetrazolium chloride (TTC) in Trizma buffer (7.4 pH) at 37°C for 1 hour. TTC 
functions by reduction of the compound (i.e., electron donation from NADH oxidation 
from metabolism) and forms a red formazan derivative when in contact with viable 
tissue
137
 . Non-viable tissue turns pale or white after incubation as shown in Figure 26. 
This stain has been validated and widely used previously for identification of infarct 
regions in artery occlusion models
138,139
. The discrepancy in incubation time between 
tissues is believed to be due to the higher mitochondrial content (i.e., more metabolic 
enzymes remaining active for longer periods) of cardiac tissues. 
   
Figure 26: Examples of TTC stained myocardium (left),  kidney (center), and lung (right) 
with central ablation lesions.  
 
The first 6 samples for this study had a .040” gauge T-type thermocouple placed in a 1 
mm superficial slit on the surface of the sample just under the endocardium. The IR 
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thermographic data and thermal profiles were compared to ensure environmental and 
sample parameters were being appropriately set in the IR software. It was found that the 
IR thermography and thermocouple data differed by less than the manufacturer published 
resolution (i.e., less than +/- 2°C or 2% of measurement).  
Data analysis 
After incubation the samples were photographed in a photo booth with ruler for image 
size calibration. The photographs were then analyzed using Matlab (MathWorks, Natick, 
MA) to determine the radial distance from cryoprobe to where the lesion ended and a 
zone of injured and live tissue began. This was done by plotting the gray values from the 
cryo probe edge outward radially and normalizing these values to clearly live and dead 
tissue areas. This yields a sigmoid like curve from 0 to 1 (i.e., dead to live, Figure 27). A 
single operator then selected two critical points on the curve where the transition from 
dead, injured, and live tissue occurs as determined by TTC intensity. Samples that did not 
yield clear sigmoid curves, indicating non-axis symmetric lesions, were removed from 
analysis. 
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Figure 27: Shown left is a plot of the normalized gray values of a TTC stained image plotted 
radially outward from the cryoprobe. Shown right is how the data is classified after picking 
the two critical points (blue stars) on the sigmoid curve. 
The raw IR data was analyzed with a Matlab program that could extract the temperature 
data of a region of interest using user specified radial distances as determined by the 
sigmoidal staining intensity curves (Figure 27). These were then categorized into a 
database of thermal profiles that lead to completely dead tissue, injured tissue, and live 
tissue. Cooling rates and nadir temperatures were extracted from the thermal profiles. 
Results 
The resultant categorical tissue response (i.e., live, injured or transition zone, dead) to the 
thermal ablation was plotted against the cooling rate and minimum temperature reached. 
The kidney results shown in Figure 28 were found to agree with previously published 
data on thermal injury. Comparing Figure 29 to Figure 30 one can see that similar 
patterns arise in both the atria and the ventricle. To look at the effect of which cryoprobe 
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was used, Figure 31 versus Figure 32 displays the data for atrium and ventricular samples 
pooled. Human myocardium and lung responses are shown in Figure 33 and Figure 35, 
respectively.  
 
Figure 28: Swine kidney tissue viability response to ablation with Galil Seednet probe.  
(n=6) 
 
   69 
  
  
 
Figure 29:  Swine atrium tissue viability response to ablation with Medtronic FreezorMax.  
(n=8) 
 
Figure 30: Swine ventricle tissue viability response to ablation with Medtronic FreezorMax. 
(n=14) 
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Figure 31: Swine myocardium tissue viability response to ablation with Medtronic 
FreezorMax. (n=22) 
 
Figure 32: Swine myocardium tissue viability response to ablation with Galil Seednet. 
(n=17) 
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Figure 33: Human myocardium tissue viability response to ablation with Medtronic and 
Galil cryoprobes. (n=6) 
 
Figure 34: Swine lung tissue viability response to ablation with Medtronic and Galil 
cryoprobes. (n=5) 
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Figure 35: Human lung tissue viability response to ablation with Medtronic and Galil 
cryoprobes. (n=6) 
Discussion 
Reported here is the first study on cardiac tissue cryothermal tolerance to the author’s 
knowledge. This novel approach may be adapted to many tissues types, as demonstrated 
here in small sample studies. This methodology may also be used to study the effects of 
multiple freeze-thaw cycles or complex cooling regimes. Data presented here suggest that 
myocardium needs to be cooled to -22.0 ± 3.4 °C for the atria and -22.1 ± 4.1 °C for 
ventricular tissue to obtain complete thermal lesions. The cooling regime is more 
complex than just these two parameters so the authors suggest caution and conservative 
use of these numbers. 
Data presented here suggest that kidney tissues need to be cooled to -19.4 ± 3.6 °C at 
cooling rates of -82  °C/min to obtain complete lesions. This data agrees with previously 
published data on kidney cryothermal tolerance
132
.  Benchmarking the system against 
previous literature data on kidney tissue demonstrates the ability of the system to 
determine injury thresholds accurately.  
Interestingly, the lung data suggests that there may be significant differences between 
swine and human cryothermal tolerance. The human data suggests that cooling to -14.8 
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±7.9 °C at cooling rates of -76.9 °C/min may be required for complete lesions (Figure 
34). The data presented here also suggest that the temperature necessary to destroy 
healthy swine lung tissue are lower than human tissue. Temperatures of -26.0 ±5.1 °C at -
103°C/min (Figure 34) were required for complete lung lesions which are approaching 
the limit of the current infrared camera (i.e., -30°C). The discrepancy may be due to age, 
disease state, species variation, and/or pre-procurement sample treatment (e.g., human 
samples were transported at near zero temperatures for up to several hours before 
experiments). Nevertheless, these rare human specimens provide unique and translational 
insight to cryothermal injury thresholds of the lung. 
This work is not without limitations, as is the case with any in-vitro, animal tissue based 
model. The effect of the tissue being perfused is not fully understood. However, work by 
other groups in the kidney
132
 have found similar temperatures necessary for complete 
necrosis in experimental groups that were perfused or non-perfused. The effect of 
shrinkage or swelling was examined on a subset of ten samples by measurement of the 
distance between two distinct points pre-incubation and post-incubation. The average 
change and standard deviation was found to be an increase of 0.2±1.1 mm. The TTC stain 
is an indicator of metabolic activity and therefore not truly a direct indicator of live 
versus dead tissue. It was considered in this experiment as an acceptable surrogate for 
viability based upon the wealth of previously published literature using it as such in 
cardiac tissues.  
Conclusions 
We report here the first tissue level experiments to elucidate the myocardial tolerance of 
cryothermal treatments. The data presented here suggest there not significant differences 
between swine and human myocardial response, but that there may be differences 
between swine and human lung cryothermal tolerance. The novel system may be used in 
future experiments on multiple tissue types to study the viability response to simple or 
complex cooling regimes. 
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II.II- Chapter 6: Development of a high-throughput, in-vitro model to 
assess ablation parameters and modalities. 
Ryan P. Goff, BS 
17,18,19
; Charles L. Soule MS
18
, Mark A. Benscoter MS
17,18,19 
; Paul A. 
Iaizzo PhD
 17,18 
Introduction 
The field of cardiac ablation is highly complex due to the vast array of products, 
modalities, and treatment techniques available to the electrophysiologist. In the past 
decade, medical device designers have flooded the market with a glut of new products, all 
aimed to better treat the disease, primarily targeting atrial fibrillation due to the fact that it 
is the most prevalent arrhythmia, as stated previously. On the most basic level, the 
duration and “power” (i.e., wattage, depth of cooling, ultrasonic amplitude, etc.) applied 
during an ablation application may be modulated and cause significantly varied 
outcomes140. Further, differing modalities may cause lesion formation by completely 
different biophysical mechanisms141,142and the physiological environment may have 
contrasting effects143. Therefore, objective experimental methods are necessary to 
compare existing and new modalities and devices for the proper evaluation of their 
safeties and efficacies. 
The ablation parameters that may be varied during an applied therapy are numerous and 
the full design space is most likely rarely explored due to the number of variables. For 
example, parameters of radiofrequency ablation modality may include: frequency, 
phasing between electrodes, grounding, wattage, duration of application, device 
geometry, irrigation of device, size of electrodes, electrode surface treatment and 
modification144, contact force, contact angle, etc.  Yet to date, to this point, there are 
virtually no high-throughput experimental test methods to allow one to evaluate ablation 
parameters and their resultant injuries and/or physiological effects. Currently, the gold 
standard for testing of cardiac devices is an in-situ irrigated thigh model140. It should be 
noted that this model requires a dedicated animal for these investigations and this 
                                               
17 Department of Biomedical Engineering, University of Minnesota (Minneapolis, MN) 
18 Department of Surgery, University of Minnesota (Minneapolis, MN) 
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approach is also limited by the number of ablation areas dictated by the given animal 
size. 
The desire for a higher-throughput technique to evaluate multiple parameters is clearly of 
value to the device designer and scientist. A method is presented here which is derived 
from techniques that have been used previously for the study of skeletal145 and cardiac146 
muscle physiology and the response of vascular tissues to cryoablation147. The method 
was also used to assess how adjuvants may enhance cryoablation. Specifically, high salt 
concentrations have been shown to modify ice formation dynamics148 and a high salt 
concentration buffer was compared to normal buffers. This work was accepted for 
presentation at the 2011 European Cardiac Arrhythmia Society congress149. 
Methods 
Fresh rectus abdominis skeletal muscle biopsies and whole excised hearts were obtained 
from Yorkshire-Cross male castrated swine of approximately 75-90 kg as described in 
detail previously 145,146. Specimens were placed on cold Krebs-Ringer buffer for skeletal 
muscle or modified Krebs-Henseleit buffer for cardiac tissues. Samples were dissected to 
be between 3-5 mm in cross-sectional area. A silk suture was attached to each end of the 
sample and then placed within the experimental chamber shown in Figure 36. The 
apparatus consists of a water jacketed glass chamber with oxygenator, platinum electric 
field stimulation panels, and a force transducer by which the bundle is suspended and 
developed force measured. Specimens were stimulated at a rate of 0.1 Hz and allowed to 
recover until contraction force had plateaued.  
Length-tension and voltage stimulation optimizations were performed for each study 
sample. Briefly, the tension was increased until resting tension was stable approximately 
between 1-3 grams of baseline force and developed twitch forces were maximal. 
Voltages were increased until the developed twitch forces were no longer increased by 
voltage steps. The study voltage was then set supra-maximal so to ensure maximal 
stimulations of a given muscle bundle. 
Ablations were performed for varying durations using a clinically available FreezorMax 
® (Medtronic, Inc., Minneapolis, MN) catheter. The catheter was placed in contact with 
the tissue in the mid-section of each bundle: electrical stimulus was turned off during the 
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ablation application. Bundle physiological performances were measured post-ablation for 
a minimum of four hours. After which, each bundle was weighed and as desired stained 
with a viability dye, triphenyltetrazolium chloride (TTC). A 1% solution of TTC in 
phosphate buffered saline (PBS) was used and bundles were incubated at 37°C for one 
hour to demonstrate the area of ablated tissue. 
To investigate this experimental approach’s ability to detect changes in ablation 
parameters, high salt concentration buffers were also tested. As stated previously, higher 
salt concentrations modulate ice formation characteristics and thereby increase injury. 
Thus, the salt concentration of the buffer was increased to 5% sodium chloride versus the 
standard 0.69%. The high salt buffer was only in used during the ablation and 
immediately after thawing it was replaced with normal buffer. A control group for the 
high sodium chloride group was utilized that consisted of replacing the normal buffer 
with the high salt buffer for 5 minutes. 
 
Figure 36: Shown left an illustrated schematic of experimental apparatus consisting of a 
water jacketed chamber, force transducer, platinum field stimulation panels, and gassing 
chamber. Shown right is a photograph of the actual system while a muscle bundle (A) is 
held in place by the force transducer and lower ring (B) during an ablation (C). The field 
stimulation panels (D) are used to elicit contraction. 
Results 
The physical characteristics of the muscle bundles size and length are detailed in Table 7. 
For the study on ablation duration effects (groups 1-5) there were no statistical 
differences between any of these parameters as discerned by a one-way ANOVA. The 
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same is true for the high sodium chloride study groups (groups 6 and 7): although note 
that these groups were quite was small. 
The effect of differing ablation durations on the peak force developed is shown in Figure 
37.  Figure 38 details the effect of extracelluar or buffer salt concentration on ablation 
performance and thus peak twitch force developed. Preliminary data comparing the 
physiological response to ablation of cardiac tissues versus skeletal tissue is shown in 
Figure 39. Data are presented as averages with error bars displayed as standard error. An 
example of pre- and post-TTC stained control and treated samples is shown in Figure 40. 
Table 7: Muscle bundle length and mass characteristics between treatment groups. 
Group Number  Treatment Group Length (mm) Mass (mg) 
Group 1: n = 12 Control 30.9±5.9 209±93 
Group 2: n= 17 1/2 Minute 23.9±3.3 226.6±61 
Group 3: n = 12 1 Minute 30.9±6.6 233±64 
Group 4: n = 12 2 Minute 29.5±3.9 231±71 
Group 5: n = 12 3 Minute 30.9±6.9 228±70 
Group 6: n = 5 NaCl Control 25.4±1.4 174±79 
Group 7: n = 5 1 Minute + 5% NaCl 26.1±3.4 192±40 
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Figure 37: Effect of varying duration cryoablation treatments on normalize maximum force 
generated. 
 
Figure 38: Effect of high NaCl buffer during ablation application as a proposed adjuvant 
therapy. 
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Figure 39: Performance of cardiac tissue compared to skeletal muscle tissue. 
 
 
 
       
A 
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Figure 40: Example of pre- (Left) and post-TTC stained (Right) control (Top) and ablated 
tissues (Bottom). Samples 5, 6,7, and 8 were ablated for 2, 1.5, 1, and 0.5 minutes 
respectively. 
Discussion 
The experimental paradigm presented here provides a controlled environment for testing 
of cryo-ablation parameters in a systematic approach. Further, it is feasible to use with 
multiple modalities and preliminary data was presented on different tissues and 
adjuvants. As expected, with increasing ablation durations the degree of peak twitch force 
generated decreases as demonstrated in Figure 37. It is supposed that the degree of injury 
was well correlated to the reduction in peak twitch force.  
As one means to test the methodological sensitivity of this approach, a high NaCl buffer 
that will act as an adjuvant, was piloted. This effect has been mechanistically explained 
previously and was employed only during the ablation period.  The results in Figure 38 
indicate the effects of the high NaCl buffer: note that during a sham procedure, the effects 
of the buffer changes alone were temporary. When applying the cryoablation therapy 
(freezing) in this high NaCl buffer, the resultant injuries appeared to be significantly 
increased, as judged by the reduction in peak twitch force. More specifically, when 
comparing Figure 37 to Figure 38 it can be observed that the effects of high salt buffer 
application during a 1 minute ablation reduces the developed force below that of even a 3 
minute ablation. These data may suggest that significantly higher injuries were elicited 
due to the additions of the high salt concentration: thus clinically treatment times may be 
reduced or the zones of injury made larger if ablations are performed in high salt 
environments. 
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For the primary development of this experimental methodologies rectus abdominis tissue 
was utilized: it is quite easy to isolate uniform bundles of this muscle and these tissues 
are readily available in our laboratory. Nevertheless, experiments to ultimately 
characterize cardiac ablation catheters should be performed on these respective tissues, 
both from animal models and humans. Therefore, in a preliminary small pilot study, we 
employed cardiac tissue and these results were shown in Figure 39. Interestingly, the 
reduction in force between tissue types for the same duration ablation is quite large. We 
suspect that this is due to differing tissue structures. In cardiac tissue the cells have a 
more network structure (smaller cells making up a syncytium of tissue), whereas in the 
rectus abdominus muscle bundles, the fibers spanned the entire length of the bundle 
(tendon to tendon). Therefore, when an ablation is performed on cardiac tissue, the injury 
is local, but when performed on skeletal muscle, if the lesion encompasses the entire 
cross-section, potentially all fibers in the entire bundle could be injured. In other words, 
this is due to the fact that membrane integrity will have been lost throughout the bundle 
in the central region, lesion area thereby damaging virtually every cell. This highlights 
the importance of using the proper tissue for experimentation.   
The experimental approach described here is not without limitations, as is the case with 
all in-vitro systems. Firstly, it is important to note that the studied tissues were not 
perfused, but oxygen was being supplied through superstation of the buffer (diffusion). 
Thus, depending on muscle bundle diameters, there may be differences in tissue necrosis 
at the core of a given bundle: i.e., where oxygen levels would be lowest. Yet, all attempts 
were being made in the present study to have samples dissected to consistent sizes, in an 
attempt to control for this.  Secondly, ablation catheter contact forces were not controlled 
for: yet, because these muscle bundles were suspend from a moving cantilevered beam 
(force transducer) it was predicted that there should not have be a significant difference in 
the catheter forces applied (i.e., compared to applying the ablation on a hard surface the 
force applied can vary significantly). It should also be noted that an attempt was made to 
place the ablation catheter tip in contact with the tissue in an “end on” fashion, such that 
the catheter tip was perpendicular to the tissue, but in most cases the catheter experienced 
a slight incidence angle.  
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To conclude, the work described here details preliminary development of a novel system 
for evaluation of ablation parameters. As mentioned previously this work has been 
presented to a peer group, the European Cardiac Arrhythmia Society and has been 
accepted for publication in Heart Rhythm pending revisions. At this presentation there 
was much interest in further work with cardiac tissues to better understand how nuances 
in ablation applications may influence lesion formation and muscle physiology.  
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Executive Summary: 
Background: Phrenic nerve injury, both left and right, is considered a significant 
complication of cryoballoon ablation for treatment of drug refractory atrial fibrillation, 
and functional recovery of the phrenic nerve can take anywhere from hours to months.  
Objective: This study focused on short periods of cooling to determine the least extreme 
temperatures that may terminate nerve function related to cryoballoon ablation.  
Methods: Left and/or right phrenic nerves were dissected from the pericardium and 
connective tissue of swine (n=35 preparations). Nerves were placed in a recording 
chamber modified with a thermocouple array; this apparatus was placed in a digital water 
bath to maintain an internal chamber temperature of 37°C. Nerves were stimulated 
proximally with a 1V, 0.1 mS square wave. Bipolar compound action potentials were 
recorded proximal and distal to the site of ablation both before and after ablation, then 
analyzed to determine changes in latency, amplitude, and duration. Temperatures were 
recorded at a rate of 5 hertz, and maximum cooling rates were calculated. 
Results: Phrenic nerves were found to elicit compound action potentials upon stimulation 
for periods up to four hours minimum. Average conduction velocity was 56.7±14.7 m/S 
pre-ablation and 49.8±16.6 m/S post- ablation (p=0.17). Cooling to mild subzero 
temperatures ceased production of action potentials for greater than one hour 
Conclusion: Taking into account data presented here, previous publications, and a 
conservative stance: during cryotherapy applications cooling of the nerve to below 4 °C 
should be avoided whenever possible. 
 
Key words (5-10): Phrenic nerve injury; atrial fibrillation; cryoballoon ablation; phrenic 
thermal tolerance; compound action potential 
List of abbreviations: 
AF=atrial fibrillation 
CAP=compound action potential 
Introduction 
Recently shown in the pivotal US trial STOP-AF17 and other multi center trials34, phrenic 
nerve injury  was noted as the highest non-access site related complication of cryoballoon 
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ablation for the treatment of drug refractory atrial fibrillation (AF).  Further, this form of 
injury is not unique to cryoballoon ablation, yet a recent systematic literature review 
suggests it may occur more frequently in cryoballon ablation than in radiofrequency 
ablation35.  
The right phrenic nerve (PN) in general follows the posterior or posterolateral aspect of 
the vena cava and the left phrenic nerve passes over the marginal veins of the left 
ventricle (Figure 1). Both the right and left phrenic nerves (PN) terminate on the superior 
surface of the diaphragm, thus injury to either phrenic nerve may result in diaphragmatic 
hemi-paralysis or palsy36,37.  Usually, only the right phrenic nerve has been reported to be 
injured  during cryoballoon ablation and most frequently during ablation of the right 
superior PV38,39. However, recent case reports have also been published on left PN injury 
36,40 and such occurrences may only rise with increased cryoballoon adoption. 
Reported rates of phrenic nerve injury varies in the literature: in the range of 4% to 17% 
(see Table 1). The reported time course of phrenic nerve functional recovery also varied 
considerably in the literature. The shortest recovery time periods reported are on the order 
of hours38 and the longest on the order of months.  
 
Figure 41: General anatomical course of the phrenic nerve. (Image from Gray’s 
Anatomy33, public domain). 
Injury of the phrenic nerve by hypterthermal methods (i.e., radiofrequency) has been 
investigated previously in the context of cardiac ablation150.  The effect of hypothermal 
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treatments has also been investigated in the context of topical cooling during open 
surgical procedures. However, these studies were performed on longer time scales 
relevant to surgery. In contrast, Dureuil and colleagues applied topical cooling to canine 
phrenic nerves to 0°C for either 5 or 30 minutes151.  At this level of cooling they found 
recovery of all nerves, but the thirty minute treatment group experienced initial 
reductions in diaphragmatic electrical activity and transdiaphragmatic pressure. It is 
important to that note that most tissues undergo phase change at temperatures slightly 
below zero due to salts and other solutes being present. It is thought that the majority of 
injury during cryo treatments occurs at such a phase change which leads to both 
extracellular and intracellular ice formations142.  It is therefore not surprising that all 
nerves recovered from these treatments. Further, Robicsek and colleagues also have 
investigated cooling PNs for a period of thirty minutes152 they observed: 1) in mixed 
breed canines they found that conduction terminated by cooling to 10-12°C; 2) cooling to 
temperatures between 10-4°C the PNs recovered within an hour; and 3) cooling below 
4°C caused the majority of nerves to not recover within the 4 hour monitoring period. 
These authors noted that the “cold resistant” preparations had a high degree of fatty 
tissue. Therefore, it may be the case that the nerves were not actually experiencing the 
temperatures produced by the probe.  Nevertheless, the authors of these studies should be 
commended for their efforts in elucidation of PN thermal tolerance; however, again two 
sources of error may have influenced the studies. One potential error is that the cooling 
device temperatures were monitored and not the nerve temperatures themselves. 
Therefore, the exact temperatures that the nerves reached were unknown, but more than 
likely close to the probe temperatures. The second to consider is that in many 
experimental apparatuses thermal contact resistances (i.e., microscopic air pockets from 
surface roughness etc.) can significantly alter the degree of heat actually exchanged 
between two objects and may play a role.    
From a clinical perspective, due to the fact that a phrenic nerve is typically not in direct 
contact with an intracardiac ablation catheter and there is a large degree of convective 
warming from blood flow occurring, these nerves are most likely experiencing cooling 
excursions to damaging temperatures for short durations. Yet, one has to consider the 
following clinical aspects, the treatments are generally for 3-4 minutes and there is lag 
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time associated with conduction of the cooling to the nerve, indicating the nerve will only 
be cooled for a fraction of the treatment time.  Therefore, the study we performed and 
presented here was focused on short periods of cooling in an attempt to determine the 
least extreme temperatures that may terminate nerve function.  
 
Table 8: Published incidences of PN injury occurring clinically. Studies are ordered from 
greatest number of patients to least. Entries left blank were not specified in the journal 
publication.  
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Cryoballoon Studies 
Incidence 
of PNP per 
procedure 
Phrenic 
Pacing Resolution  Vein 
Vogt, et al. 41 
2%(12 of 
605)  3 to 9 months   
Neumann, et al. 34 
8% (26 of 
346) Yes 
Less than one year, two before 
procedure end   
Packer, et al. 17 
11% (29 of 
259)  25 of 28 within 144 ± 27 days   
Jackson, et al. 153 
8% (15 of 
200) Yes, SVC 
2 hours to 12 months. 9 before 
procedure end   
Dorwarth, et al. 154 
9% (13 of 
141) Yes, SVC One persistent at discharge 
12 RSPV, 1 
RIPV 
Kuck, et al. 16 
4% (6 of 
136) Yes, SVC 
5 within 12 months, 1 present 
after 10 months 
5 RSPV, 1 
RIPV 
Ghosh, et al. 155 
17% (22 of 
130) 
Yes, Right 
Innominate 
Vein Before procedure end  
Casado-Arroyo, et al.156 
11% (13 of 
121) Yes, SVC No resolution in one case 
RIPV of 3, 
RSPV of 10 
   -Artic Front 
6% (5 of 
80)  Resolution before discharge  
   -Artic Front Advance 
20% (8 of 
41)  
Resolution by 7 months, except 
one  
Defaye, et al. 157 
3% (4 of 
117) Yes Within a few minutes RSPV 
Bitter, et al. 
158
 
3%  (2 of 
82)  Within 3 months   
Guiot, et al. 44 
8% (5 of 
66) Yes, SVC 
"A few days". 1 patient longer 
than procedure duration. Normal 
chest x-ray at 2 weeks.  
Kuhne, et al. 
38
 
6% (4 of 
65) Yes, SVC 
30 seconds in 3 cases, 24 hours 
in the fourth.   
Mandell, et al. 159 
2% (1 of 
62) Yes, SVC Before procedure end RSPV 
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Furnkranz, et al. 160 
3% (2 of 
60) Yes, SVC   
   -Artic Front 
3% (1 of 
30)  By 3 month follow-up  Right sided 
   -Artic Front Advance 
3% (1 of 
30)  
1 day post procedure, not 
related to ablation Left sided 
Peyrol, et al. 
161
 
5% (3 of 
55) Yes, SVC By 1 month  follow-up 
RSPV and 
RIPV 
Chun, et al. (2012) 43 
6% (3 of 
51) Yes, SVC Days 1, 172, 212 post ablation RSPV 
Rao, et al.  39 
6% (3 of 
51) Yes, SVC Before procedure end   
Malmborg, et al. 162 
5% (2 of 
40) Yes, SVC 
1 within the hour, 1 over 6 
months   
Pokushalov, et al. 163 8% (3of 40) Yes, SVC 
2 within 1 week, 1 after cessation 
of cryoablation RSPV 
Schmidt, et al. 164 
3% (1 of 
33) Yes, SVC Within 2 minutes post freeze RSPV 
Chun, et al.  119 
3% (1 of 
32) Yes, SVC By 3 month  follow-up  RSPV 
Catanzariti, et al. 165 
0% (0 of 
30) Yes, SVC     
Chun, et al. (2009) 166 
 11% (3 of 
27) Yes, SVC Before procedure end 
2 RSPV, 
RIPV 
Tang, et al. 167 
4% (1 of 
23) Yes, SVC 1 month post ablation RSPV 
Klein, et al. 45 
14% (3 of 
21) Yes, SVC 
6 and 9 months. One persistent 
at 2 months RSPV 
Linhart, et al. 168 
15% (3 of 
20) Yes, SVC Before procedure end RSPV 
Van Belle, et al. 118 
0% (0 of 
18) Yes, SVC 
 
  
Namdar, et al. 169 
6% (1 of 
18) Yes, SVC 20 minutes 
"large 
RSPV" 
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Methods 
Castrated male Yorkshire Cross swine being used for IACUC approved studies, weighing 
approximately 85±10kg, were used for this study.  Anesthesia was induced with telazol 
and thiopental, animals were then intubated and mechanically ventilated, maintaining a 
PaCO2 of 40 ± 2 mmHg, with a surgical level of anesthesia maintained with isoflurane 
(>1.2 MAC). Access to the thoracic cavity was achieved via a medial sternotomy. The 
left and/or right phrenic nerves were carefully dissected from the pericardium and 
connective tissue and placed in modified Krebs-Henseleit buffer at room temperature. 
The fatty sheaths and remaining connective tissues were dissected from the nerves using 
a stereomicroscope. Nerves were then placed in a nerve-recording chamber (MLT016, 
Kuhne, et al. 170 
 
0% (0 of 
14) Yes, SVC     
Multi Balloon Studies 
Bordignon, et al.171  
(Total) 
5% (7 of 
140) Yes, SVC Recovered by 6 month follow up RSPV 
   -Cryo 
6% (4 of 
70)       
   -Laser 
4% (3 of 
70)       
Horton, et al. 
47
 (Total) 
19% (7 of 
37)  Yes, SVC  RSPV 
   -Cryo 
16% (1 of 
6)       
   -HiFU 
22% (4 of 
18)       
   -Laser 
15% (2 of 
13)       
Sohara, et al. 172 (Hot 
Balloon) 
1% (1 out 
of 100) 
Not in this 
patient, 
otherwise 
yes. Within 3 months.   
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ADInstruments, Dunedin, New Zealand) that was modified by the addition of a 
thermocouple array: the array consisted of a Styrofoam block with four, 40 gauge T-type 
thermocouples (#5SRTC, Omega Engineering, Stamford, CT) embedded 2.5 mm apart. 
The apparatus was placed in a digital water bath set to maintain an internal chamber 
temperature of 37°C (See Figure 1).  
 
Figure 42: Nerve recording chamber displaying recording and stimulating electrode 
configuration. The white Styrofoam thermocouple array can be seen in the middle of the 
chamber. The nerve is stimulated at the left of the picture and evoked CAPs are recorded 
along the length of the nerve as they travel towards the right. 
Nerves were stimulated proximally (i.e., cranially) with a 1V, 0.1 mS square wave 
(S48,Grass Technologies, Middleton, WI). Bipolar compound action potentials (CAPs) 
were recorded proximal and distal to the site of ablation both before and after ablation 
(Powerlab 16/30 with LabChart 7 software, ADInstruments). The characteristic 
parameters of the nerve CAPs that were analyzed are shown in Figure 43. This figure also 
demonstrates changes that occur as CAPs travel down the nerve, specifically: a 
broadening of the CAP waveform and the peak of the CAP magnitude shifted later in 
time as it takes longer for the signal to travel through the nerve with greater distance. 
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Figure 43: An example of a CAP recorded proximal (top) and distal to ablation (bottom). 
The dotted line (A) indicates time at which stimulus was applied. The magnitude (B) and 
latency to peak (C) were determined and average conduction speed (D) calculated based 
upon the distance the signal traveled. 
 
The cooling power of the cryoprobe (FreezorMAX, Medtronic Inc., Minneapolis, MN) is 
such that, it is generally considered, that the nerve will be permanently injured with every 
application if the probe is placed in direct contact with the nerve. To weaken the amount 
of cooling the nerve receives, and act as a pseudo- atrial wall, a piece of fresh-viable 
skeletal muscle, dissected to 8 by 10 mm with thickness of 3.2±0.4 mm, was placed over 
the nerve between the cryoprobe and nerve (See Figure 2). CAPs were recorded with 
before and after placement of the muscle.  
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Figure 44: Shown left is the cryoprobe relation to the nerve, thermocouple array (*), and 
skeletal muscle segment to reduce cooling power experienced by the nerve. On the right is 
an example of the cooling profile experienced by the nerve. 
 
The thermal profile of the thermocouple that recorded the lowest temperature was further 
analyzed to determine the maximum cooling rate. Temperatures were recorded at a rate 
of 5 hertz and the maximum cooling rate was calculated on a second-by-second basis 
using the average temperature per second. The CAPs were analyzed pre- and post-
ablation to determine changes in latencies, amplitudes, and durations: as defined by 
Figure 4. Nerves were also categorically grouped as to whether or not the CAPs 
recovered distal to the ablation within an hour or failed to be produced. 
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Results 
Phrenic nerves were found to elicit CAPs upon stimulation using this methodology for 
periods up to four hours. Thirty-five nerve preparations were studied using this approach 
and the figures below detail the cooling profile (Figure 45), magnitude (Figure 46), and 
latency (Figure 47) results for these collective studies. A graph of conduction velocities 
would be identical to Figure 47 because the latencies were used to calculate conduction 
rates: i.e., this would be simply a scaling of the latency. The average conduction velocity  
was calculated to be 56.7±14.7 m/S pre-ablation and 49.8±16.6 post- ablation (p=0.17) 
which agrees with values reported in the literature for that of human phrenic nerves173. 
The dwell time of the cooling treatments was 102±93 seconds as defined as the amount 
of time within 5 degrees of the nadir temperature. The dwell time in general was shorter 
for the colder thermal profiles due to higher thermal gradients causing faster rewarming.  
 
Figure 45: Relationship between cooling and recovery of phrenic nerve CAPs. Note that two 
extreme cooling cases are shown bottom left and off the scale of this graph to enable better 
visualization of the data. 
(-60,-1088) 
(-43,-432) 
   95 
  
  
 
Figure 46: Phrenic nerve pre- and post-ablation CAP magnitude and nadir temperature 
relationship. Note that temperature is displayed as 1/10th the actual temperature to fit 
within the scale of the CAP magnitude.  
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Figure 47: Latency to CAP onset pre- and post-ablation. 
5.6 
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Discussion 
The methodology presented here allowed us to reliably record compound nerve action 
potentials for several hours in vitro, but is not without noted limitations. The data suggest 
that cooling to mild subzero temperatures will affect nerve CAPs, but it did not 
necessarily damage them irreversibly. The relative temperatures we observed to cause 
acute termination of CAPs fall in line with longer cooling protocols that have been 
published previously. This suggests that an in vitro experimental approach may be 
employed to accurately predict acute in vivo or in situ therapeutic responses. Importantly, 
we observed that the phrenic nerves that did not recover within the one hour monitoring 
period were those that were cooled at significantly faster rates and to lower temperatures. 
Clinically, although mild subzero cooling may not prove to be a long-term detriment to 
the patient, it may or should alter the course of clinical action, likely causing an ablation 
to be ended earlier than planned. This, in turn, may affect atrial lesion durability and 
long-term outcomes. 
 
Conclusions 
Taking into account data presented here, previous publications, and a conservative stance, 
during cryotherapy applications cooling of the nerve to below 4°C should be avoided 
whenever possible. Data presented here support the notion that cooling to below zero 
Celsius will significantly alter nerve function for a minimum of one hour. In the future, 
ultrasound or magnetic resonance thermography may be utilized by the physician to 
monitor and avoid altering nerve function induced by thermal therapies as described here. 
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II.IV- Concluding remarks 
To summarize the findings of these novel works I have: 
 Developed a method to determine physiologic responses to ablation of vary modalities 
and benchmarked the system using myocardium and skeletal tissues. 
 Further quantified the cryothermal tolerance of the phrenic nerve. 
 Quantified myocardial and lung viability response to cryothermal treatments, which to 
my knowledge has not been performed previously. 
These studies required fabrication of experimental apparatuses and development of novel 
methodologies for viability assessment. The data provided here may be used for 
predictive modeling of viability after an ablation treatment or possibly during 
preoperative planning. Taken in conjunction with data from cell studies performed by our 
collaborators in the Bischof laboratory we have covered a wide range of cooling regimes. 
If future modeling of the procedure is performed and the relative range of cooling the 
target tissue may experience determined, these data may be referred back to in order to 
optimize procedural dosing. This may increase procedural efficacy and reduce procedural 
complications. 
One tissue in which I was unable to characterize the viability response to thermal 
treatments is the esophagus. Using the fore mentioned techniques was not successful, but 
this is not to say it is not possible. A modified TTC staining protocol can be used with 
esophageal tissue. The problem encountered was that esophageal tissue drastically 
changed shape upon ablation. With some fiducial tracking of shape changes and complex 
computer programs to correlate infrared data with viability data and/or strain tracking 
these studies are feasible.  
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III- Section 3 Investigation of Device-Tissue Interactions 
 
One of the great benefits of the Visible Heart®Laboratory is its ability to routinely use 
reanimated human and swine hearts for experimentation. These studies are therefore 
translational in nature through the use of human hearts. The goal of this section of my 
thesis is to better quantify what is happening during a cardiac cryoablation procedure 
using our technically advanced in-vitro models.  
The first chapter of the section details the creation and characterization of a novel, large 
mammalian reanimated heart-lung bloc model for novel device tissue interaction studies. 
This latest in vitro model builds upon previous isolated heart work pioneered by our 
laboratory. Briefly, it was determined that to best study the effects of cryoablation it was 
important to have the native pulmonary veins present. This inspired the creation of heart-
lung bloc reanimation methodologies and its utilization. 
The second chapter utilizes this isolated heart-lung bloc preparation to uniquely quantify 
to what degree  transmural cooling is occurring during a typical cryoballoon ablation 
procedure performed within the ostia of the pulmonary veins. It is believed the transmural 
lesions are required for effective pulmonary vein isolation. To our knowledge this is one 
of the most advanced experimental approaches employed so to obtain the first human 
data on epicardial cryoablation temperatures. This work also compared the resultant 
cooling between the first and second generation balloon cryoablation catheters. 
Interestingly, the identified temperature profiles determined epicardially are more than 
likely in the range of those experienced by collateral tissues (i.e., adjacent tissues such as 
esophagus, lung, etc.). 
The third chapter explains a novel model for imaging ice dynamics to determine what 
extent ice can potentially form within the cardiac and non-cardiac tissues. This approach 
will allow for precise study of the effects of varying cooling regimes and the extent of ice 
formation in collateral tissues. Further, truly opens the door to the study of wide range of 
other parameters effects on ice freeze-thaw dynamics (e.g., catheter contact force, 
distal/inappropriate placement, poor occlusion, varying cardiac output, varying 
myocardial perfusion, novel intraprocedural ice monitoring, etc.).  
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III.I- Chapter 8:The Novel In-vitro Reanimation of Isolated Human 
and Large Mammalian Heart-Lung Blocs  
This chapter is in the submission process to Nature. 
 
Ryan P. Goff, BS 
23,24,25
; Brian Howard MS
23,24
; Steve Quallich BS 
23,24,25
; Julianne 
Spencer PhD
23,24,25
;  
Tinen Iles
24
; Paul A. Iaizzo PhD
23,24
 
Executive Summary 
Introduction: In-vitro isolated heart preparations are an invaluable tool for the study of 
cardiac anatomy, physiology, and device testing. Such preparations afford the 
investigator a high level of control, independent of host or systemic interactions, and high 
throughput if desired. We present here that isolated human and swine preparations with 
the lung(s) attached are particularly valuable for the study of device tissue interaction and 
anatomy. Detailed here is our laboratory’s experience developing these heart/lung bloc in 
vitro methodologies. 
Methods: Four human and 18 swine heart-lung preparations were procured using 
techniques analogous to those of cardiac transplant. Specimens were then rewarmed and 
reperfused using modifications of a previously developed apparatus and methodologies 
by our laboratory: positive pressure mechanical ventilation was also employed. 
Epicardial defibrillation was applied to elicit native sinus rhythm after rewarming. 
Videoscopy, fluoroscopy, ultrasound, and infrared imaging were performed for 
anatomical and experimental study. 
Results: Systolic and diastolic pressures observed for human and swine specimens, 
respectively, were 68/2±11/7 and 74/3±17/5 mmHg, with heart rates of 80±7 and 96±16 
BPM. High resolution imaging within functioning human pulmonary vasculature was 
obtained, among other anatomy of interest.  
                                               
23 Department of Biomedical Engineering, University of Minnesota (Minneapolis, MN) 
24 Department of Surgery, University of Minnesota (Minneapolis, MN) 
25 Medtronic Inc., Mounds View, MN 
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Conclusion: To the authors’ knowledge, this is the first report of dynamic images of the 
pulmonary vasculature during cardiopulmonary function in isolated reanimated 
heart/lung blocs. This experimental approach provides unique in-vitro opportunities for 
the study of novel medical therapeutics applied to both human and large mammalian 
heart-lung specimens. 
Background 
In-vitro, isolated heart preparations have been a cornerstone of cardiac research since 
Langendorff’s original methodology was described in the 1890s 174.  The benefits of 
isolated heart research are numerous and can be remarkable depending on the 
investigator’s goal. Isolated hearts offer a high degree of control over the system 
including, but not limited to: perfusate selection, flow control, and pre- and after-load 
variability. For a thorough historic summary of these aforementioned studies the reader is 
referred to a review by Hill et al.  Furthermore, numerous pharmacological studies using 
such approaches can help elucidate the direct action of agents on the isolated cardiac 
tissues, i.e., while avoiding systemic interactions of other agents or breakdown products 
(e.g., cardiac-nervous system, hepatic metabolism, etc.)
175
. 
Additionally, high-throughput cardiac perfusion systems can be designed, or now even 
purchased off the shelf, in which multiple small mammalian hearts can be experimented 
on simultaneously. Isolated heart preparations have garnered notable insights to 
mechanisms of arrhythmias
176
 and have been reviewed elsewhere
177
. Depending upon the 
system configuration, a wide range of equipment and modalities are available to the 
investigator including: electrophysiologic monitoring and stimulus, ultrasonagraphy, 
ultrasonic stimulation, fluoroscopy, infrared thermography, direct visualization via 
videoscopes, and anatomical mapping systems. Furthermore, the utilization of large 
mammalian isolated hearts allows for critical pre-clinical testing of device-tissue 
interactions in an environment highly similar to human anatomy and physiology, i.e. if 
the proper animal model is selected for the investigation
178
. Comparative imaging of 
normal versus pathologic conditions, or interspecies comparisons, to determine optimal 
approaches, models, and designs are critical to development of novel therapeutics 
115
. To 
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the medical device designer, engineer, or clinician, these insights have proven to be of 
high educational value 
179,180
. 
Despite isolated heart preparations being a valuable tool, proper anatomical relationships 
can be considered lost when the lungs are removed. In particular, the pulmonary veins 
and their native ostia are of interest in the context of pulmonary vein isolation ablation 
treatments for atrial fibrillation. Heart-lung preparations have been utilized previously to 
elucidate the release of atrial natriuretic peptide
181
 and expand the pool of lung 
transplants to non-beating donors
182
; they have also been used in numerous 
pharmacologic studies. Interestingly, the first heart-lung preparations are often attributed 
to Knowlton and Starling
183
, however, their work acknowledges  the methods of 
Martin
184
 which were presented in lecture at Johns Hopkins in 1883. The first publication 
by Martin of his heart-lung bloc preparation was in 1881
185
, therefore predating 
Langendorff’s work by fourteen years. In short, this preparation cannulates in-situ the 
superior vena cava and one of the branches coming off the aortic arch. A closed loop is 
created by which pressure can be monitored, a compliance chamber incorporated, and 
pre- and afterloads varied.  
It is also possible for human hearts from non-viable organ donors to be successfully 
reanimated using an isolated experimental apparatus 
95
. The Visible Heart® 
methodologies have been previously described by our laboratory
96
, but more recently we 
have expanded these novel experimental approaches to incorporate whole large mammal 
heart-lung blocs,  i.e., including both human and swine studies. To the authors’ 
knowledge, this is the first description of such experimental results.  
Method 
The technique developed by our laboratory has been used successfully to reanimate 
human and swine hearts with right, left, or both lungs attached and functioning. Swine 
studies were approved by the Internal Animal Care and Use Committee at the University 
of Minnesota. Human hearts were approved for study by the Human Subject Committee 
Internal Review Board. Consent for use of the hearts for research purposes was received 
from the donors’ family before explantation via LifeSource (St. Paul, MN).  
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The detailed procurement procedure has been described previously
95,96
. Briefly, a median 
sternotomy was performed and an aortic root cannula implanted for delivery of 
cardioplegia. The inferior vena cava (IVC) was ligated and, just prior to cardioplegia 
delivery, the IVC for human preparations was removed with the liver if it was being 
recovered for transplant, and the superior vena cava (SVC) and aorta were cross-clamped. 
Cardioplegia was then delivered under pressure to rapidly cool and arrest the heart. The 
heart and lungs were then dissected and the heart-lung bloc removed by transection of the 
major vessels, trachea, and esophagus. The human specimens were then transported on 
ice to the laboratory within 6 hours of cross-clamp. An analogous procedure was 
performed on swine hearts in our laboratory: mean animal weights of 84 ± 14 Kg (n =18).  
We most commonly have performed these studies with just one lung attached, but the 
method has been adapted to include both lungs.   
Upon arrival of human, or after explantation of swine, specimens, hearts were placed in 
an ice slurry of modified Krebs-Henseleit buffer while cannulation of the great vessels 
was performed (i.e., IVC, SVC, and Aorta). If a one lung preparation was desired, the 
left/right pulmonary veins and artery were dissected from the left/right lung and the lung 
was removed. These vessels were cannulated as well and a hemostasis valve was fitted 
for access. If both lungs were desired in the preparation, the pulmonary trunk was 
cannulated to allow control of the buffer flow, either directing all flow through the lungs 
or allowing some flow to the reservoir (i.e., a parallel path through the lungs and to the 
reservoir). An intubation tube was placed in the trachea and connected to a ventilator to 
control flow through the airway. Preparations were ventilated at a respiration rate of 11-
15 per minute and a volume of 150-250 milliliters per lung.  
The heart-lung blocs were then connected to the apparatus described in detail 
previously
96
 that has been adapted for such use. A schematic of this system can be found 
in Figure 48. The system was altered to vary the aforementioned parameters of other 
isolated heart research systems and functions in either partial or four-chamber working 
mode. Partial working mode is similar to a Langendorff apparatus function, but fluid flow 
continues through an isolated lung. The system utilized a cardiovascular bypass 
oxygenator and heated water jacketed fluid reservoirs to maintain the proper physiologic 
environment. Seven to eight liters of modified Krebs-Henseleit buffer were contained in 
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the system and buffer changes of approximately four liters were performed regularly to 
wash out metabolites and maintain visualization as desired.  
 
 
Figure 48: An external view of human heart 277 in systole and attached to the system is 
shown inset top right. Displayed center is a flow diagram for a functional heart and lung 
reanimation consisting of: (1) a respirator connected to the cannulated trachea and thus 
attached to the lung(s), (2) a pre-load chamber for the right side of the heart, (3) an aortic 
after-load chamber which mimics the resistance that the left ventricle works against, (4) a 
left pre-load chamber employed when only one lung is present, and (5) an oxygenator 
reservoir for pooling fluid expelled by any cannulated branch of the pulmonary artery.  (6 
& 7) fluid pumps to maintain the pre-load pressures, (8) hemostasis valves that allow access 
for delivery of cameras, instruments, and assorted devices, (9) valves that may also be used 
to redirect flow as physiologically appropriate, while (10) cannulation of the pulmonary 
vein(s) are shown here for a right lung preparation, but are absent or translated when 
either both lungs or the left alone respectively are used. 
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Once the specimen was re-warmed to 37°C, dobutamine was added to the system and the 
heart was defibrillated with 34 joules of energy supplied by a programmer-analyzer unit 
(#88345 Medtronic, Inc., Minneapolis, MN) via a pair of external patches (#6721, 
Medtronic, Inc.) placed epicardially above and below the ventricles. These hearts 
generally began beating in native sinus rhythm after a single defibrillation. It should be 
noted that one human heart developed heart block at two hours post-reanimation, and was 
then paced by a temporary pacing lead at 60 beats per minute; all specimens can be paced 
as desired. Hemodynamics of the left and right ventricle were recorded by Utah Medical 
pressure transducers (Model DPT-200, lot#1101991, Midvale, UT) via water columns 
from venogram balloon tipped catheters (Attain 6215, Medtronic, Inc.).  
High-resolution Olympus commercial endoscopes (Model 1V8200T, Model 1V8420, 
Center Valley, PA) were then placed within these heart and/or lungs to capture functional 
anatomy. To our knowledge, these are the first images of the pulmonary veins and 
arteries within the lung of functioning human heart-lung blocs.  
Results 
Using this novel experimental approach, to date, all attempts to reanimate hearts have 
been successful; eighteen swine and four human heart-lung blocs have been reanimated. 
Hemodynamic functioning of these in vitro reanimated specimens can be augmented by 
the delivery of inotropic agents and/or by increased dosing with extracellular calcium.  
Prior to heart recovery, the mean heart rates and blood pressures for the swine were: 91 
±13 beats per minute and 105/56±13/9 mmHg, respectively. Table 1 provides partial 
cardiac medical histories for the organ donors from which the human hearts were 
recovered. Table 2 provides the relative hemodynamic performance data for these 
reanimated heart-lung preparations.  
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Table 1: Summary of donor information and their hemodynamic status prior to organ 
recovery. 
Human Specimens 
Specimen Gender 
Age 
(yrs) 
Weight 
(kg) 
Cause of 
Death 
HR 
(bpm) 
BP 
(mmHg) 
CVP 
(mmHg) 
HH 277 M 60.0 113.4 
Head 
Trauma 71.0 105/61 15.0 
HH 284 F 78.0 54.4 CVA 103.0 118/70 11.0 
HH 291 F 58.0 114.7 Stroke 70.0 100/50 12.0 
HH 295 M 34 68 
Cardiac 
Arrest 92 130/75 - 
Average   69 83.9   87   13 
Standard 
Dev.   12.7 41.7   22.6   2.8 
BP=blood pressure; HR=heart rate; CVP=central venous pressure 
 
Table 2: Hemodynamic performances of each reanimated swine and human heart/lung bloc 
specimen.  
Swine Specimens 
Specimen 
HR 
(bpm) 
LVSP 
(mm Hg) 
LVEDP 
(mm Hg) 
+dLVP/dt 
(mm Hg/s) 
-dLVP/dt 
(mm Hg/s) Tau Lung 
1 95.8 91.2 12.4 982.8 -903.0 31.2 Right 
2 91.0 25.0 -2.0 430.8 -343.8 36.2 Right 
3 100.0 77.0 -4.0 961.0 -462.0 30.0 Right 
4 81.7 73.5 2.3 772.3 -354.5 37.7 Right 
5 91.8 85.7 1.3 927.0 -509.8 33.2 Right 
6 99.5 62.8 11.3 574.0 -435.0 30.2 Right 
7 55.8 82.0 5.7 600.2 -358.2 63.0 Right 
8 90.3 79.3 -4.3 842.5 -618.0 33.5 Left 
9 92.7 75.7 12.0 623.3 -771.7 32.5 Left 
10 102.5 67.5 1.2 637.8 -513.2 29.7 Right 
11 76.7 101.7 10.7 786.5 -501.5 39.7 Right 
12 123.3 76.3 1.3 729.0 -624.5 26.0 Right 
13 124.8 58.7 2.7 762.5 -532.7 24.0 Right 
14 84.5 87.2 0.7 888.8 -646.0 54.0 Right 
15 114.0 91.7 -2.7 922.3 -808.0 27.5 Right 
16 105.0 70.8 0.0 607.7 -446.3 28.8 Right 
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17 101.3 56.5 3.8 529.8 -317.7 29.8 Right 
18 91.2 75.7 7.0 618.3 -810.2 33.0 Right 
Average 95.7 74.3 3.3 733.2 -553.1 34.4   
Standard 
Dev. 16.3 17 5.4 163.6 177.6 9.7   
Human Specimens 
HH 277 85.8 65.7 -7.3 624.5 -475.5 37.2 Right 
HH 284 81.2 79.5 1.7 848.2 -377.7 37.5 Right 
HH 291 70.3 53.3 8.0 341.3 -273.7 45.3 Both 
HH 295 81.3 72.5 4.2 415.7 -343.0 37.7 Right 
Average 79.7 67.8 1.6 557.4 -367.5 39.4   
Standard 
Dev. 6.6 11.1 6.5 227.9 84 3.9   
 
HR=heart rate; LVSP=left ventricular systolic pressure; LVEDP=left ventricular end-
diastolic pressure; +dLVP/dt= maximal positive derivative of left ventricular pressure with 
respect to time; -dLVP/dt= maximal negative derivative of left ventricular pressure with 
respect to time 
 
It should be noted that one of the early reanimated swine heart-lung specimens (#2) 
elicited poor hemodynamic performance from the beginning of reanimation. We suspect 
that injury occurred during isolation and/or that emboli caused poor coronary perfusion.  
It should be noted that recorded data from several hearts elicited negative values for end-
diastolic pressures; we suspect that this is due to drift in the sensors or a vacuum or 
syphoning effect, potentially occurring in the current system modification to incorporate 
the lungs.  
Interestingly, compared to our long-term experience with lone heart reanimation using 
endscopes, a large degree of remaining particulate and blood within the lung has 
complicated our initial imaging during certain studies. Therefore, more frequent buffer 
changes have been required to obtain clear, high-fidelity images and video. 
As previously mentioned the main benefit of this model is the maintenance of proper 
pulmonary ostia and vessel anatomy. A selected anatomical image series of a videoscope 
being retracted from either the pulmonary arteries or veins is shown in Figure 49; a 
corresponding video can be accessed via supplemental materials or online 
(http://www.vhlab.umn.edu/atlas/). The study of cryoballoon ablation procedures 
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motivated much of the development of this model, and a series of cryoballoon procedures 
have been performed, e.g., as viewed from within the vein as displayed in Figure 50, 
panel C. The supplemental video of the pulmonary arteries and veins functioning gives 
the reader an appreciation of the truly dynamic nature of these vessels which are usually 
thought to be relatively passive structures.  
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Figure 49: An image series obtained from reanimated human heart-lung bloc 284 (A,B) and 
277 (C,D) showing the path through the distal pulmonary arteries and veins, respectively. 
The corresponding fluoroscopic images (B,D) in each case show the relative locations of the 
videoscopes (A,C). A supplemental video of the journey through the vasculature can be 
viewed as well. 
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Figure 50: Provided here is a time series of images from human heart 277 showing tricuspid 
valve closure from the right ventricle (A) and right atria (B). Images are displayed 1/15th 
per second apart in time. Panel C displays ice formation on the distal portion of a 
cryoballoon ablation catheter (Artic Front, Medtronic, Inc., Minneapolis, MN) as seen from 
within the pulmonary vein. The images are spaced post-ablation 30 seconds, 1, 2, and 3 
minutes apart. 
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Discussion 
To the authors’ knowledge, this report has provided first time dynamic images of the 
pulmonary vasculature during normal cardiac function in both reanimated human and 
swine heart-lung blocs. This model provides a unique in-vitro approach for the study of 
novel medical therapeutics from both human and large mammalian heart-lung specimens.  
In a similar embodiment (i.e., without the lungs), this reanimated heart model has been 
utilized in numerous cardiac studies. In the electrophysiologic area, these studies have 
included the use of endocardial noncontact mapping, pacemakers, defibrillators, leads, 
and catheters 
186
. The Visible Heart® model has also been employed to study the 
dynamic nature of valves and transcatheter valve deployment
94
. Importantly these 
methodological approaches also allow for use of echocardiography and fluoroscopy to 
guide procedures, i.e., comparative imaging 
187
. Most recently, this approach has proven 
to be quite valuable for the study of novel cardiac treatments, such as leadless pacing 
devices
188
. Nevertheless, the novel addition of a lung(s) to this paradigm still allows for 
any of the prior studies to be conducted, but may in turn reduce the number of hemostasis 
valve access points that were previously available.  
Our continued use and enhancement of Visible Heart® methodology has also facilitated 
the creation of an open-access educational website, The Atlas of Human Cardiac 
Anatomy (http://www.vhlab.umn.edu/atlas)
189
. The anatomical images and videos on the 
website are free to download and use for presentations and teaching; we request that 
proper citations be used. In other words, the novel images and/or comparative imaging of 
functional cardiac anatomy are of high value in teaching the nuances of cardiac anatomy, 
especially of active, complex structures, such as valves. It should be noted that this 
website also provides instructional tutorials on cardiac anatomy and physiology and full 
cadaveric thoracic cavity dissections. Finally, a cardiac device tutorial is available as 
well, which has been well noted as being beneficial in the explanation of therapies to 
patients.  
The model described here is not without limitations, as is true with all in-vitro systems. 
Despite supersaturating the buffer with oxygen, there remains a significant difference in 
the oxygen content of the buffer compared to blood. For this reason, the function of the 
heart slowly declines over time from the initial reanimation. Yet reasonable physiologic 
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function to perform such aforementioned investigations is generally elicited for up to 4 to 
8 hours, in our previous experiences. It is possible that the addition of the lungs may 
extend the functionality, which we tend to believe at this point but need more data to 
substantiate such.  Most recently, we are employing a full anesthesia suite ventilator to 
more closely control the ventilation parameters (e.g., provide positive end expiratory 
pressure, PEEP). In such experimentation, one also needs to consider that although it is 
also known that hypothermal transport of organs protects them, global ischemic injury 
still occurs to some degree. Further, our current system is designed to replicate 
physiologic pre- and after-loads, but there potentially are important physiological effects 
that are not completely replicated, such as vessel compliance. Likewise, in our studies the 
heart-lung blocs are cradled on soft foam sponges, which may focally alter perfusion 
compared to the natural state. Finally, due to the nature of acquiring non-viable donor 
human heart-lung specimens, there are numerous differences between their inherent 
cardiac statuses that cannot be controlled. Such differences in status include, but are not 
limited to: method of cardiac arrest, transport time before arriving in the laboratory, 
inotropic support, potential air or other emboli in the coronary vasculature, and prior 
pathologies. Despite being unable to control for these parameters, the described system 
produced comparable pressures to other isolated human heart alone preparations 
95,190
. As 
reviewed in Table 2, despite these variances the hemodynamic data are fairly comparable 
from specimen to specimen. It should be specifically noted that we are extremely grateful 
and privileged to obtain these donated human heart-lung preparations as gifts for 
research. 
To conclude, this extension of Visible Heart® methodologies has garnished novel, 
functional anatomical heart-lung anatomical visualization. Further, unique abilities to 
image the device-tissue interactions using this approach are unparalleled. Therefore, we 
consider that these obtained images are of high value to the medical device designer, 
educators, and clinicians for both training and educational purposes. The lab will 
continue to reanimate hearts and heart-lung blocs using these methodologies and thereby 
enable: the study of dynamic anatomy, insights into the device-tissue interface, and 
creation of new materials for the free-access Atlas of Human Cardiac Anatomy website.  
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III.II- Chapter 9:Infrared imaging of cryoballoon ablation therapy 
applied to reanimated swine and human heart-lung blocs 
This section is in the submission process to Heart Rhythm. 
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Introduction 
Cardiac balloon cryoablation for the treatment of atrial fibrillation has been gaining 
attention as an approach for isolation of the pulmonary veins (PV): i.e., since its first 
reported use in 2003
15
 and in the current clinical form in 2005
116
. Yet, it should be noted 
that focal cryoablation has been used surgically for many more years
117
 with transcatheter 
devices becoming available in more recent decades. An advantage of cryoballoon 
ablation of a pulmonary vein ostium, is that it is a ‘single-shot’ approach, which aids in 
accelerating the slow nature of freezing compared to RF energy (i.e., not point-by-point 
ablation). Further, the currently available ArticFront (Medtronic, Minneapolis, MN) 
cryoballoon has been shown to have comparable success rates to RF ablation with lower 
adverse events
34,118
. The recent STOP-AF trial concluded similar findings to the 
observational European studies: that being an acceptable safety profile and superiority to 
antiarrhythmic drugs in those who have failed to respond to them
17
.  
Despite widespread and growing clinical use there are still questions regarding dosing 
and treatment times for optimal cryoablation therapy, which in turn may affect both 
efficacy and collateral tissue injury
119,120
.  Conversely, parameters affecting RF ablation 
lesions have been investigated in numerous preclinical and clinical studies, and 
temperatures of 50°C or higher are required for the creation of necessary myocardial 
scars
121
. Additionally, although many open scientific questions remain, the effects of 
power, ablation durations, catheter orientations, catheter sizes, usage of irrigation, and 
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contact forces on lesion size have been investigated for RF
122–125
. Furthermore, the 
release of a second generation cryoablation device with a different cooling profile merits 
additional research to compare to both the previous versions of theses devices and also to 
ablation using RF energy
126
. It should be noted, to date, the highest regularly detected 
clinical complication for ablation with the cryoballoon is phrenic nerve palsy with rates 
of 4-8% 
17,118
. Yet, it remains unknown, the impact on esophageal cooling may also differ 
for the second generation balloon: importantly, esophageal injury is not normally 
detectable unless specifically searched for using endoscopy
44,127
. Reports of hemoptysis 
are also reported in patient series of cryoballoon ablation, indicating the lung may be 
injured during these treatments as well
41,161,191
. It is currently recommended by the 
manufacturer that two separate four minute ablations are applied per PV: yet, several 
clinicians have recently suggested that only one may be adequate.  In other words, given 
that the phrenic nerve and esophagus are in intimate contact with the right PVs and 
posterior wall of the LA, respectively, optimization of dosing is important to both ensure 
permanent isolation of the pulmonary vein tissue while minimizing the impact to these 
structures.  
It is well accepted that in order for cardiac ablation lesions to be effective long-term, it is 
necessary that they are transmural. In the present study through the use of infrared (IR) 
imaging, the epicardial surface temperatures were monitored as well as the relative times 
to reach those temperatures. Due to the anatomical relation of the aforementioned 
collateral tissues that might be impacted during treatment, these epicardial thermal 
profiles should be in the range of those experienced collaterally. That is to say that since 
the tissues that have been reported to be injured collaterally are in intimate contact with 
the epicardial surfaces, that the epicardial temperature profiles measured here are in the 
range of the most extreme temperatures the collateral tissues may encounter. This novel 
infrared imaging data, with additional information regarding the thermal thresholds of 
injury of the tissues of interest, may help guide decisions on dosing.  Uniquely, we were 
able to collect these data from reanimated human and swine heart/lung blocs.  
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Methods 
Isolated Heart-Lung Preparation 
The technique developed by our laboratory has successfully reanimated human and swine 
hearts with right, left, or both lungs attached and functioning. Swine studies were 
approved by the Internal Animal Care and Use Committee at the University of 
Minnesota. The use of human specimens for research were approved for study by Human 
Subjects Institutional Review Board:  consent for use of the hearts for research purposes 
was received from the donor’s closest relative(s) via LifeSource (St. Paul, MN). Note, the 
detailed procurement procedures have been described previously
95
.  The human 
specimens were then transported on ice to the laboratory within 8 hours of cardiac arrest. 
For isolation of the swine specimens, a median sternotomy was performed and an aortic 
root cannula implanted for delivery of cardioplegia. The inferior vena cava (IVC) was 
ligated and just prior to cardioplegia delivery the IVC was removed with the liver and the 
superior vena cava (SVC) and aorta were cross-clamped. Cardioplegia was then delivered 
under pressure to cool and arrest the heart/lung blocs. The heart and one or both lungs 
were then dissected and the bloc then removed by transection of the major vessels, 
trachea, and esophagus. Note, we most commonly have performed these studies with just 
one lung attached, but the method has been easily adapted to have both lungs attached.   
The heart-lung blocs were then connected to an apparatus described in detail previously
96
 
that has been modified to accommodate the lung. The system can vary standard 
parameters of other isolated heart research systems (i.e., pre-load, after-load, perfusates, 
see Hill et al.
95
) and functions in either partial or four-chamber working mode. Partial 
working right-side mode allows fluid flow to continue through the isolated lung(s), but 
without added flow directed into the left atrium. Four-chamber working mode is 
analogous to the native function of the heart and was used during all ablation procedures 
and throughout the thawing phase. Hemodynamic performance of these hearts is 
summarized in Table 9. Note, that as best as possible, the reanimated lung(s) were 
ventilated at a respiration rate of 11-15 per minute and a volume of 150-250 milliliters 
per lung. To do so, the remaining airway (the distal main trachea) was intubated by 
placement of an endotracheal tube (if only one lung was isolated the other primary branch 
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bronchus was tied off) and subsequently attached to the ventilator. Video endoscopes 
(IPLEX FX series, Olympus Corp., Tokyo, Japan) were employed so to observe the 
proper placements of the cryoballoons within the pulmonary vein ostia as previously 
described.  A supplemental video provided here, shows an anterior view of a specimen 
and then the simultaneous multimodal imaging performed during the experiments.  
Infrared Imaging and Data Analysis 
A FLIR SC620 (FLIR Systems, Inc., Boston, MA) infrared (IR) camera was used to 
capture thermographic data at a minimum rate of one hertz. The emissivity and 
appropriate environmental parameters were input to the infrared software (ThermaCAM 
Researcher Pro 2.9, FLIR Systems, Inc., Boston, MA). Emissivity was determined by 
comparison of IR temperatures to a 0.040” T-type thermocouple (Omega Engineering) 
being read by a digital thermometer (Fluke 51II, Everett, WA). It should be noted that 
this IR system is only capable of measuring temperatures as low as -30 Celsius, below 
this level the accuracy of the measurements are reduced.  
Measured parameters using FLIR software include: lowest epicardial temperature 
reached, epicardial area cooled to 10, 5, 0, and -5 °C, and time from start of an ablation 
until epicardial temperatures of 10, 5, 0, -5, and -10 °C were achieved. If required, the 
heart was held in a more lateral position to best view with the IR camera, the area being 
treated/cooled.  
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Figure 51: Shown above (A) the heart-lung bloc, with overlaid thermograph, attached to the 
Visible Heart ® apparatus with heart held laterally to best image area of therapy. Panel B 
shows a close up view of the resultant thermograph with the temperature scale ranging 
from -18 to 37 °C in this example. 
Ablation Procedure 
A steerable outer catheter (FlexCath, Medtronic, Inc.) was placed into the left atria (LA) 
by either a transseptal puncture via the inferior vena cava or directly via the contralateral 
PV cannulated with a fixture containing a hemostasis valve. Using direct endoscopic 
visualization and a 0.035” guidewire (PV tracker, Medtronic, Inc.) the ablation catheter 
was then inserted over the wire into the LA. Once the preparation and catheter delivery 
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sheath were in place the IR camera was setup and not moved throughout that given 
experimental procedure. The cryo-catheters investigated here were 28 mm ArticFront and 
ArticFront Advance (Medtronic, Inc.). The catheters were marked along the length of the 
balloon with colored fiducial markers, so to ensure that the clocking of the catheters in 
between exchanges or ablations were consistent (see Figure 2 and supplemental video). 
 
 
  
Figure 52: ArticFront 28 mm balloon cryoablation catheter with colored markings for 
optimizing the alignments of catheter position between ablations. The blue band 
corresponds to the top of the catheter handle and the red band corresponds to the left side 
of the handle (i.e., the operator’s perspective).  
 
Data were presented as the means ± standard deviations. These results were compared on 
a day-by-day basis using a paired T-test (=0.05) to determine if there were statistical 
differences between the various parameters of interest and between the catheters 
employed. 
Results 
Swine data 
Using these methods a total of 8 heart-lung blocs were reanimated and studied. In most 
cases, two or three ablations per catheter (ArticFront and ArticFront Advance) were 
performed per day; note in one instance only one ablation was performed due to technical 
difficulties.  The daily results of the cooling measurements were averaged by catheter 
type.  This approach was chosen to compare the differences between catheters without 
the influence of daily variabilities such as: camera position, atmospheric conditions, 
cardiac outputs, and differing anatomy. The relative hemodynamic performances of these 
specimens during these applied thermal therapies were provided below in Table 9. 
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Table 9: Hemodynamic performance of reanimated swine heart-lung blocs. 
Specimen 
HR 
(bpm) 
LVSP 
(mm Hg) 
LVEDP 
(mm Hg) 
+dLVP/dt 
(mm Hg/s) 
-dLVP/dt 
(mm Hg/s) Tau Lung 
1 94.0 77.8 -2.3 857.5 -553.5 32.0 Right 
2 106.5 85.5 1.8 838.2 -664.2 28.3 Right 
3 76.8 89.3 -1.0 893.3 -640.7 40.0 Left 
4 105.2 70.7 12.0 715.8 -682.2 30.2 Left 
5 108.0 79.2 1.5 683.3 -564.0 28.5 Right 
6 119.7 74.0 9.0 716.5 -622.3 25.0 Right 
7 90.8 96.3 5.0 853.8 -681.0 37.7 Right 
8 105.0 82.0 -3.5 809.2 -662.2 31.3 Right 
Average 100.8 81.9 2.8 796.0 -633.8 31.6   
Standard 
Dev. 13.1 8.4 5.5 79.3 50.4 5.0   
Human Specimens 
HH 277 63.7 71.8 -3.0 485.3 -428.2 50.7 Right 
HH 284 104.5 83.0 0.8 836.0 -641.0 28.8 Right 
 
The temperature area measurements were made using the time point at which the most 
extreme cooling had occurred. A total of 24 and 26 ablations for ArticFront and the 
ArticFront Advance were measured, respectively. When all the data were examined, 
including cases in which the ablation had not reached the indicated temperatures (i.e., an 
area value of zero),  Figure 53 demonstrates that ArticFront Advance cooled greater areas 
and in most cases achieved lower temperatures. However, when the subset of data in 
which only ablations which reached the measured temperature were plotted in Figure 54, 
one can see that the differences were less pronounced. 
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Figure 53: Relative area cooled by employing ArticFront (blue)  and ArticFront Advance 
(red) catheters. Above each bar is the number of ablations in which the indicated level of 
cooling was achieved. For each the ArticFront and ArticFront Advance catheters, 24 and 25 
ablations were analyzed, respectively. Ablations which did not achieve cooling to the 
measured temperature were averaged with the other ablations performed that day as zero 
area cooled.  (*= p<.05) 
 
Figure 54: Relative area cooled during therapy application by ArticFront (blue)  and 
ArticFront Advance (red) catheters excluding cases in which the measured temperature was 
not achieved (e.g., if -5°C was not achieved, that ablation was not analyzed in the-5°C 
group). The number of ablations measured is displayed above the error bars. (*= p<.05)   
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The cooling time to epicardial temperatures of 10, 5, 0, -5, and -10°C were measured in 
16 ablations delivered using ArticFront and 20 ablations for ArticFront Advance 
catheters. Note, that these Ns differ from the area measurements, due to subsequent 
technical problems during which the digital video recording system was damaged, thus 
making the syncing of multiple timed systems not possible (e.g., IR computer and 
CryoConsole).  
 
 
Figure 55: Time to reach indicated epicardial temperatures from beginning of ablation. 
Note that differences between treatments delivered with ArticFront (blue, n=16) versus 
ArticFront Advance (red, n=20) catheters were not found to be significant.  
The lowest temperature achieved during these series of ablations were measured for each 
application. Again, it should be noted that the limitations of IR imaging somewhat 
complicated this analysis, because of the considered reduced accuracy of this specific 
camera for temperatures less than -30°C: therefore ablations that demonstrated very low 
temperatures (i.e., reading less than -40°C) were considered to be not lower than -40°C 
for the results shown in Figure 57 to take a conservative measurement approach. This 
occurred once for an ArticFront ablation and four times during ArticFront Advance 
treatments, suggesting that the ArticFront Advance catheters allow for greater cooling 
potential. The histogram shown in Figure 56 displays the distribution of nadir 
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temperatures: temperatures less than -30°C are denoted by an * to indicate that they may 
not be reliable. 
 
Figure 56: Distribution of nadir temperatures achieved following treatments with either 
catheter system: ArticFront (blue)  and ArticFront Advance (red). Note, accuracy of 
temperatures less than -30°C may be decreased as denoted by an *. No temperatures fell 
within the 50°C bin and therefore it was omitted. 
 
Figure 57: Minimum temperature achieved by treatment applications with ArticFront 
(blue)  and ArticFront Advance (red) catheters (p=0.036). 
 
* 
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Human data 
Two human specimens became available to our lab during the course of these 
experiments. In each specimen two ablations with the ArticFront Advanced 23 mm 
catheter were performed. To compare the results of the 23 mm catheter in human versus 
swine, one swine experiment with six ablations using the 23 mm catheter was performed. 
The data is included due to the unique opportunity to study human versus swine 
specimens, thus making these studies of high translational value.  
Since it is not feasible to compare different human samples or human to swine samples 
on the same day, with the same setup, anatomy, etc. a ruler was included in the recording 
to scale the images. However, the ruler was not held perfectly planar to the lens by an 
apparatus, but was approximated. The results suggest that a smaller area is cooled in 
human samples as indicated by Figure 58. However, as can be seen there are very large 
standard deviations. Data on cooling speeds were not able to be calculated due to syncing 
technical difficulties mentioned previously. Comparing the data on the lowest 
temperature achieved the differences are minimal, with swine achieving -17.9±18.9°C 
and human samples reaching 14.2±16.6°C. 
 
Figure 58: Area cooled by ArticFront 23 mm catheter in human (blue) and swine (red). The 
number of ablations measured is displayed above the error bars. (*= p<.05)   
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Discussion 
Here we present a novel, technically challenging study utilizing external infrared imaging 
data obtained during cryoablation treatments applied employing ArticFront (blue) and 
ArticFront Advance (red) catheters.  We uniquely performed these studies employing 
both reanimated human and swine heart/lung blocs and believe this to be the first report 
of thermal ablation studies using such a method.  Yet, one must also consider that the 
translational experimental methodology presented here, may be considered as possible 
worst case scenarios or extreme cases, in the sense that the measured temperatures are 
expected to be colder than what would be measured in-vivo. This is due to the fact that 
the reanimated heart and lung(s) were surrounded by air.  Note that this experimental 
design was required so to be able to obtain these real time infrared measurements of the 
resultant tissue temperatures. Therefore, the metabolic heat generated by surrounding 
organs is not being transferred to the isolated block. Additionally, air is a superior 
insulator compared to tissues by orders of magnitude and will in effect keep the cooling 
within in the tissue, having very little warming effects from the air. It should be noted, 
attempts by our laboratory to utilize IR imaging in-situ open chest models proved 
difficult to obtain direct visualization of the zone of ablation. The use of isolated hearts is 
already well established in cardiac research 
95,96
and this methodology incorporates native 
sinus rhythm with physiologically relevant hemodynamics. 
The results of the cooling area measurements suggest that AFA will cool a larger area 
and more frequently to colder temperatures. However, there may be other influencing 
parameters that will dictate how large an area is cooled, such as, anatomical variance and 
catheter pressure. This is suggested by the differences between Figure 53 and Figure 54. 
The time to cool the epicardium to a particular temperature did not vary much between 
catheters. This is expected because rate of heat transfer transmurally is most likely 
governed by the thermal conductivity of tissue, which should remain relatively constant 
between samples. The fact that it varies little between catheters may speak to the 
robustness of this methodology. The depth of cooling appears to be greater for AFA than 
AF based upon the distribution of nadir temperatures. This technique is not limited to the 
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use of cryoablation catheters. Any thermally based ablation targeting the pulmonary 
veins, or even other structures, may be studied using these approaches. The authors 
believe that this is one of the most translational methodologies available for study, 
especially when human heart specimens are available.   
The data presented here suggests that differences exist between human and swine 
cryoballoon ablation cooling profiles. The differences may be due to tissue thickness, 
age, disease state, fibrosis, and relative mass. It should be noted that we have observed 
that the pulmonary veins in aged human samples that our laboratory has received are 
thicker than the relatively young swine. The lungs of the human samples were also larger 
than those of the swine. The fact that only some of the area measurements were 
statistically different, and the end temperatures not significantly different, suggests that 
the translational aspect of the swine data is valid. The human data translates to the 
clinical case, but as mentioned previously the temperatures are most likely colder, and/or 
the rate of cooling faster, than those experienced in-vivo.  
Reviews of cryosurgical injury are readily available in the literature
142
 and it is accepted 
that differing tissues and cells have varying thermal tolerance. Unfortunately, the thermal 
tolerance of myocardium, esophagus, and lung is not fully understood. In our lab efforts 
are underway to further characterize some of these tissues. However, it is accepted in the 
cancer field that if the vascular supply is damaged a lesion will eventually result. The 
vascular susceptibility to cooling also differs by tissue, but has been generally reported to 
be in the range of -20 to -30°C 
142
. Whether or not this applies to tissues that are in 
contact with blood (i.e., myocardium and PV) is unclear, but may guide the community 
until better data is published. However, taking this into account with the aforementioned 
data suggests that shorter treatments may be necessary to avoid collateral injury. As a 
precaution, shorter treatment times are already being proposed in the literature
192
. 
Work done on the swine phrenic nerve in our lab suggests that cooling to mild subzero 
temperatures will acutely, irreversibly cease conduction
193
 in most cases. This data is in 
agreement with previous studies
151,152
. Taken into account with the findings presented 
here, an operator should be particularly careful to avoid placing a cryoballoon deep 
within the pulmonary veins and phrenic nerve monitoring should be used, as is standard 
now. However, certain patients may possess atypical phrenic anatomy that is less 
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compatible with cryoballoon and/or RF ablation of the pulmonary veins, such as: close 
right superior PV and superior vena cava relationship
38
 or the right upper PV ostium to 
the right pericardiacophrenic artery
194
.   
To the author’s knowledge this is the first publication of such an experimental 
methodology to investigate the effects of cardiac thermal ablation. The data from these 
experiments may aid in the guidance of dosing. Future experiments using these 
methodologies could be performed to determine the characteristics of novel ablation 
devices and how they may impact the myocardium and surrounding tissues. 
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III.III- Chapter 10: Magnetic Resonance Imaging of Ice Dynamics 
During Cryoballoon Ablation 
Ryan P. Goff, BS 
29,30,31 
; Devashish Shrivastava PhD
32
;  Jean-Pierre Lalonde
3
; Paul A. 
Iaizzo PhD
1,2 
Introduction: 
As has been stressed many times throughout this thesis the full extent of collateral injury 
occurring to tissues due to cardiac ablations remains largely unknown. Ice formation may 
serve somewhat as a surrogate for the extent of collateral injury. Although, it has been 
established in many tissues and supported in this thesis that temperatures below phase 
change (i.e., ~-0.5°C for most tissues) are necessary for complete destruction of tissue. 
However, this data is still useful through either computer modeling to back calculate 
thermal profiles, estimation based upon thermal injury thresholds, or even just as a quasi-
quantitative examination of the extent of collateral injury. 
In order to better understand the extent to which ice from cryoballoon ablations is 
entering collateral tissues a technique utilizing high-resolution MR (magnetic resonance) 
imaging during cryoballoon ablation was developed. This methodology allows the 
quantification of where ice is forming and on what timescales it is entering other tissues. 
To the author’s knowledge this is the first report of a cardiac cryoablation system being 
used in MR environment and that we are the first collaboration to accomplish such in the 
summer of 2012. 
Methods: 
For isolation of the swine specimens, a median sternotomy was performed and an aortic 
root cannula implanted for delivery of cardioplegia. The inferior vena cava (IVC) was 
ligated and just prior to cardiolpegia delivery the IVC was removed with the liver and the 
superior vena cava (SVC) and aorta were cross-clamped. Cardioplegia was then delivered 
                                               
29  Department of Biomedical Engineering, University of Minnesota (Minneapolis, MN) 
30 Department of Surgery, University of Minnesota (Minneapolis, MN) 
31 Medtronic Inc., Mounds View, MN 
32 4Center for Magnetic Resonance Research, University of Minnesota (Minneapolis, MN) 
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under pressure to cool and arrest the heart/lung blocs. The heart and one or both lungs 
were then dissected and the bloc then removed by transection of the major vessels, 
trachea, and esophagus. Human specimens may be utilized by acquisition using the same 
methods or dissection from fresh cadavers.  
The IVC and the brachiocephalic artery off of the arch of the aorta was then cannulated. 
The descending aorta and SVC were tied off. The pulmonary artery was cannulated with 
Y connector that allows buffer to flow into the lung or bypass the lung. The distal left 
pulmonary vein was cannulated with a Y connector in which one end is connected to a 
hemostasis valve for catheter placement and the other connected to the pulmonary artery 
(i.e., to perfuse the left side while bypassing the lung if the lung were to become 
edematous).  
The specimens were then imbedded in approximately 10-15 liters of ultrasound gel. 
Ultrasound gel was chosen because the thermal properties have been found to be highly 
similar to that of myocardium 
136
. This serves to act as a pseudo thoracic cavity and has 
benefits over liquid buffers (e.g., lungs will float in liquids and liquid in the MRI bore are 
undesirable). A ~20-30 mmHg static pressure head was applied and then the 
brachiocephalic, followed by the IVC, clamped shut to maintain static dilation of the 
chambers. The experiment was performed at room temperature.  
Cryoballoon catheters (ArticFront product line, Medtronic, Inc., Minneapolis, MN) were 
modified by removal of electronics and other ferrous materials from the catheter to make 
them suitable for use in the MRI suite. The patient safety systems on the Cryo Console 
were turned off to allow ablations to be performed. A ten meter refrigerant delivery 
umbilical was fabricated such that the Cryo Console could be outside of the MRI suite 
and fed through a pass through for connection to the catheter. A 2.4 mm endoscope 
(IPLEX TX series, Olympus Corp., Tokyo, Japan) was used to place a .030” carbon fiber 
rod as a guidewire or to place the ArcticFront catheter directly in the right pulmonary 
vein ostia. 
After dilation of the cardiac chambers and placement of the catheter, the first scan was 
started as the ablation began and the balloon inflated. A four minute ablation was 
performed and sequential scans were taken until the ablation was complete and for 
several minutes after. A gradient T2 weight scan with in plane resolution of 1 mm and 2 
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mm between slices was performed. The scan sequence was one minute long resulting in 
four scans during refrigerant injection. 
Datasets were analyzed using Mimics (Materialise, Leuven Belgium) to derive 
anatomical measurements.  To do so, each cardiac image set was imported using the 
native DICOM data files generated from the MRI scan and then converted into 3 
dimensional renditions (i.e., each 2D DICOM image was layered together to create a 3D 
model). A baseline (i.e., no ice present) scan was performed immediately after balloon 
inflation. This is performed due to the fact that the ice and balloon both show up as black 
on the MRI scans due to the fact that the balloon is filled with gas, which has very little 
water content, and that once phase change in a material occurs there is also very little 
detectable MR signature.   
Results: 
Three ablations using the ArticFront 28mm catheter were performed and imaged. The 
balloon/ice were reconstructed and compared over time. The difference between the first 
and second ablation were negligible, but it appears that ablation three may have delayed 
beginning by approximately one minute (Figure 61). Ablation three also appears to have 
delayed fully inflating the balloon or had a lower degree of ice formation.  
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Figure 59: Time progression of ablation at MRI slice number 24. The top four images are 
during the active ablation period. The bottom three images are after the balloon has 
deflated and coolant injection has stopped. Measurements are displayed because the images 
are not the same magnification. 
 
Upon reconstruction of the sequential scan sequences it is apparent when the ablation 
ends and the balloon deflates (see Figure 59 and Figure 60). This is also clearly seen in 
Figure 61 and Figure 62 as the volume peaks at the fourth scan for ablations one and two 
and then drops sharply. Ablation three does not behave the same as ablation one and two, 
and appears to be delayed in time. 
         
Figure 60: Three dimensional reconstruction of the first scan at the beginning of ablation 
and following deflation of the balloon. These reconstructions are from scan one and scan 
five from Figure 59. 
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Figure 61: Volume of balloon and ice reconstruction over time. Ablation 3 was slightly 
delayed in time. Each scan is one minute. 
 
 
Figure 62: Volume of ice versus time. The balloon volume was subtracted from the 
balloon/ice reconstruction for the time points at which the balloon was inflated. Scan 
sequence time of 1 minute 
 
The central slice of the balloon along the axis running from the distal tip to the shaft was 
located and an ellipse was fit to the ice/balloon area (see Figure 59). The major and minor 
axes were measured and the results are displayed as mean ± standard deviation in Figure 
63. 
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Figure 63: Results from fitted ellipse measurements from a cross section slice in center of 
balloon running from distal tip to the shaft. Examples of the measurements can be seen in 
Figure 59. 
Discussion: 
Presented here is the first cardiac cryoablation performed in an MR environment to 
author’s knowledge. This technical feat has yielded novel insights to the temporal and 
spatial progression of ice dynamics caused by cryoballoon ablation. This opens up a new 
avenue of research regarding collateral injury, ice dynamics, and the device tissue 
interaction of balloon cryoablation. 
As noted, ablation three did not behave the same as ablations one and two. The 
discrepancy in volume, from ablation three, apparent in Figure 61 may be due to 
refrigerant delivery line clogging. However, Figure 62 shows that the amount of ice 
formation between ablations was relatively the same. A clog would explain the delayed 
effect and smaller volume of ice formation overall. This may also explain that when peak 
volume occurred later if there was a clog in the refrigerant line, pressure in the line may 
have still been significant even though the ablation had ended on the console. This could 
lead to an extended cooling time beyond four minutes. 
Interestingly, the differences in volumes between ablation one and two were minimal. 
This is somewhat expected when one looks to the literature on changes in thermal 
properties pre- and post-freeze. For many tissues similar to myocardium (e.g., skeletal 
muscles) the properties change little pre- and post-freeze
195
, but the lung properties may 
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change significantly 
196
. This is due to the fact that freezing of the lung is suspected to 
allow fluid into the alveolar spaces, thereby significantly changing the fluid density of the 
lung tissues. This seems to have had little effect between the first and second ablations. 
The novel method presented here is quite technically demanding, but can yield insights 
that are not possible using other methods. In the future, using modified scan sequences 
MR thermography may be performed using this methodology. The incorporation of 
constant flow is technically feasible as well.  This is the ultimate method to help 
determine tissue tolerances of thermal treatments and for possible thermal model 
validations. The results to date are quite impressive and improvements to the 
methodology will be continued in our laboratory. 
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III.IV- Concluding Remarks 
To summarize the results of this section of my thesis, by designing and employing 
several unique experimental approaches to quantify the device-tissue interactions I have: 
 Aided in developing and characterizing a novel in vitro model incorporating reanimated 
human and swine heart-lung blocs. This approach and model system which allows for 
multimodal imaging within both the heart and lung may be used in the Visible Heart 
Laboratory for many years to come. 
 Further elucidated the thermal and cellular effects of cryoballoon ablation procedures 
on function human and swine heart-lung blocs and quantified differences in catheter 
generations. Many of the multimodal images collected during these investigations have 
strong educational benefits for clinicians, design engineers and patients themselves. 
 Developed a novel methodology for the three-dimensional imaging of ice dynamics 
employing MRI, thereby opening the door for complex future studies of parameters 
effecting cryoballoon ablation. 
In summary, these three studies are novel, creative, and require a high degree of technical 
understanding. I believe that the studies I presented here pave the way for future 
experimentation, which can further expand the field of cardiac cryoablation. 
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Thesis Summary 
A translational research approach was utilize for my thesis project, hence at first review 
of the contents it may seem that the works of this thesis are somewhat fragmented, but I 
believe upon further consideration one will determine that the experimental work was 
performed at multiple levels of complexity as required to obtain the desired knowledge 
and also which ultimately complemented each other. In organization of this work I chose 
to group it into three study categories: anatomy, thermal injury, and device-tissue 
interactions. Throughout these three categories there are the common, interwoven themes 
of the phrenic nerve, myocardium, lung, thermal imaging, and three dimensional data sets 
(i.e., MRI, CT). 
The studies on anatomy relate to the investigations on thermal injury because anatomy is 
the basis of understanding of device-tissue interaction and is necessary for simulation. I 
believe that the three-dimensional computer models made of the phrenic nerve and 
coronary sinus associated anatomy can in the future be used for computer 
simulations/computational modeling. For example, simulations of an ablative procedure 
could incorporate the determined thermal injury thresholds of the lung, phrenic nerve, 
and myocardium, in a better attempt to predict and optimize: lesion size, collateral injury, 
and/or lesion transmurality.  
The investigations on device-tissue interaction brings together the work within the other 
two chapters and were performed to answer research questions on a more complex 
system approach. If a simulation were made as mentioned previously, it could be 
validated using the MRI ice imaging studies. Using the anatomy of those studies 
computer simulated cryoballoon ablations could be performed and the degree of ice 
formation compared between the model and the actual data for validation. The MRI ice 
study and the IR Visible Heart studies are also complementary to the aforementioned 
injury work. I believe that it was until this point unknown what temperatures the external 
surface of the heart reach (i.e., the surface contacting surround tissues) and to what extent 
ice travels outside of the heart. In order for collateral injury to occur ice must be traveling 
outside of the heart and as I have described here, this is now better understood and 
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quantified. The IR Visible Heart ablations may also be used to help validate a thermal 
model of the heart by confirming similar epicardial temperatures are reached by a model 
and the actual isolated heart situation. 
To conclude, the works included in my thesis were highly collaborative and novel 
pursuits that were designed and executed to answer numerous basic and applied research 
questions surrounding cardiac cryoablation. These translational studies included herein 
have yielded several publications to date and more are in the submission process, thereby 
disseminating the findings to both the scientific and clinical communities. I believe that 
the knowledge attained through this work should aid in development and optimization of 
ablation technologies and the methods adapted to the study of modalities, if so desired. 
Additional studies using the methodologies developed within may also be used to better 
understand all facets of cryoablation (e.g., multiple freeze-thaw cycles, distinct anatomic 
variances, etc). Also, as mentioned previously, future work in this area may include the 
creation of thermal models of the procedures and would thus complement this thesis well 
because the data presented within may be vital for their validations.  
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Appendices 
Appendix A: Published or Accepted Conference Abstracts 
Listed in chronological order beginning with most recent 
In-Vitro Assessment of Phrenic Nerve Cryothermal Injury 
Selected for poster presentation at American Heart Association 2013 Scientific Sessions, 
Dallas, TX 
Authors: Ryan P. Goff, Paul A. Iaizzo 
 
Background: Phrenic nerve (PN) injury may result from transcatheter ablations for the 
treatment of arrhythmias. Cryoballoon ablation has been reported to cause phrenic nerve 
(PN) injury: occasionally resulting in diaphragmatic hemi-paralysis. To date, the 
tolerance of the phrenic nerve to cold energy on short timescales is largely unstudied.  
 
Methods: Swine phrenic nerves (n=12) were harvested and the fatty sheath dissected 
from the nerve. The PNs were then placed in a nerve recording chamber (ADInstruments, 
Colorado Springs, CO) with a custom built thermocouple array. Stimulus of 1 V and 0.1 
mS were applied to the proximal end of the nerve. Propagated compound action 
potentials (CAPs) were recorded pre- and one hour post-ablation. A 3-5 mm thick section 
of striated muscle was placed on top of the nerve/thermocouple array to reduce the 
cooling power of the catheter. A Freezor Max (Medtronic, Minneapolis, MN) catheter 
was placed in contact with the muscle and a one minute ablation applied while nerve 
temperatures being recorded.  
 
Results: The figure below displays cooling profile and recovery relationship. The table 
summarizes characteristics of the CAPs pre- and post-ablation for nerves that recovered. 
The p-valued were calculated using a paired t-test. 
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Phrenic Nerve CAP Parameter Analysis +/- Standard Deviation 
Parameter 
Pre-Ablation 
Average 
Post-Ablation 
Average 
Average 
Paired 
Percent 
Change 
P 
Value 
Latency to Onset (ms) 0.115 +/- 0.015 0.13+/-0.020 15.0% 0.15 
Amplitude (mV) 1.54375+/-0.940 0.866+/-0.920 -50.0% 0.02 
Duration (ms) 0.065+/-0.013 0.063 +/- 0.011 10.3% 0.77 
Conduction Speed (m/s) 57.25+/-7.80 51.07+/-8.35 -10.7% 0.12 
 
Conclusion: The data suggests that cooling to subzero temperatures will often cause PN 
CAPs to cease, indicating injury/death. For nerves that elicited post-ablation CAPs, 
reduction in amplitude was the recorded parameter with the greatest change. These data 
support the notion that cooling a PN to low, suprazero temperatures, may cause clinically 
relevant changes in diaphragmatic function.  
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In-Vitro Characterization of Myocardial Cryothermal Injury 
Selected for oral presentation at Cryobiology Conference 2013, Washington D.C. 
 
Ryan P. Goff [1,2], Stephen G. Quallich [1,2], Robert A. Buechler [1,3], Jeunghwan Choi 
PhD[4], John C. Bischof PhD [1,4], Paul A. Iaizzo PhD [1,2] 
1) Department of Biomedical Engineering, University of Minnesota 
2) Department of Surgery, University of Minnesota 
3) Medtronic, Inc., Minneapolis, MN 
4) Mechanical Engineering, University of Minnesota 
 
Background: Cardiac balloon and catheter cryoablations for the treatment of atrial 
fibrillation have been gaining attention as approaches for treating arrhythmias, in 
particular for isolation of the pulmonary veins (PV).  Despite widespread clinical use of 
cardiac cryoablation, there are still questions regarding dosing and treatment time, which 
may affect both efficacy and collateral injury. To date injury thresholds for therapy of 
cardiac tissues are largely unreported in the literature.  
 
Methods: Slices of ventricular myocardium (n=11) and left atrial tissue (n=6) from 
female Yorkshire Cross swine hearts were dissected including the native endocardial 
surface. Samples were placed in an infrared imaging apparatus consisting of a plastic 
petri dish with central ablation probe (1.5 mm IceSeed, Galil Medical, Arden Hills, MN) 
and 2 millimeters of Sylgard polymer formed to the bottom. The tissue slices were 
impaled on the central cryoprobe and infrared thermography was captured using a Flir 
A20 looking from the top down.  Subsequently, samples were cultured for 24 hours in a 
cell culture incubator (myocardium) at 37°C or 4 hours at room temperature (PV) for 
optimal lesion identification with 1% TTC in Trizma buffer for 1 hour at 37°C.  
Photographs of the resultant TTC staining of each sample were captured and a custom 
Matlab program was used to normalize staining intensity and correlate the average 
staining intensity with the average thermal profile at any radial distance from the 
cryoprobe. The relationship between the staining intensity and end temperature was fit 
with a sigmoidal curve. Samples with a fit of greater than R
2
 > 0.99 were analyzed. The 
transition from dead to injured tissue was defined as the point on the curve fit where the 
staining ratio was 10% of the range between the lower and upper asymptotes of the 
sigmoid (i.e., 10% of the grayscale value change at the lesion margin closest to the 
lesion).  The maximum cooling rate correlated to this ratio and end temperature was then 
calculated from the thermal profiles. Eight thermal profiles at different radii were 
averaged to obtain a characteristic thermal profile for each sample. This approach has led 
to the creation of a database of thermal profiles that results in either completely or 
partially injured tissues. 
 
Results: Initial results suggest that cooling rates of -103±49 and -72±9 °C/min and end 
temperatures of approximately -21±6 and -17.2±3.2 °C are necessary for complete 
necrosis of ventricular and left atrial tissue, respectively. Using a two-tailed t-test 
assuming equal variance the difference in end temperature and cooling rate between 
ventricular and left atrial tissue were non-significant (p=.21, p=.20 respectively). 
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Conclusions: Experiments are ongoing to determine cryothermal injury thresholds of 
tissues associated with cardiac ablation, such as: lung and esophagus. The TTC staining 
protocol is in the process of being validated by comparison to H&E stain. Cellular 
viability assays are being performed to compare to these findings. 
 
Acknowledgment/Funding: The author’s sincerely thank Dr. Jim Coad for advising on 
staining protocols. This work was supported by the GAANN program, the Institute for 
Engineering in Medicine, and a contract with Medtronic, Inc.  
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Direct Visualization of Pulmonary Vein Ablations within Reanimated 
Swine Hearts to Investigate Recent Advances in Cryo-balloon 
Technologies 
Selected for poster presentation at Transcathteter Therapuetics Conference 2013, San 
Francisco, CA. 
Authors: Ryan Goff B.S., D. Wyn Davies M.D., Stephen Howard B.S., Mark Benscoter 
M.S., Paul A. Iaizzo PhD 
 
Background: The use of cryo-balloon ablation for pulmonary vein (PV) isolation has led 
to questions as to how best to optimize single procedure success. Specifically, what new 
indicators can be identified to better determine ideal ablation durations as well as the best 
catheter orientations and catheter placements in the PV antra. Here we present unique 
data obtained by observing PV antral cryo-balloon ablation under direct vision. 
Methods: Swine hearts were reanimated using Visible Heart ® methodologies as 
described previously via direct visualization capabilities. The device-tissue interface was 
viewed with videoscopes within the left atria. These images were obtained 
simultaneously with fluoroscopy of the PV occlusions. The effects of different cooling 
profiles, catheter orientations, and impact of ablation durations on ice propagation were 
compared.  
Results: Images shown in the figure demonstrate an ablation with an Arctic Front 
Advance
TM
 (Medtronic, Minneapolis, MN) catheter (C,D) versus a previous generation 
(A,B). Note, the advance catheter elicited a more circumferential, ice formation. Ice 
appears to be more evenly distributed for the newer generation catheter shown by a 
visible ring of ice at the balloon/tissue interface (D). 
Conclusion: This method provides unique insights into the rates and sites of ice 
propagation/formation in ways that fluoro and temperature feedback cannot. This 
information can be utilized to show several features of balloon cryo-therapy and serve as 
a foundation for advances in balloon catheter technologies. 
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External Infrared Visualization of an Endocardial Cryoablation: 
Performed on a Reanimated Swine Heart 
Selected for oral presentation at the 2013 International Mechanical Engineering 
Conference and Expo, Houston, TX. 
Ryan P. Goff BS, University of Minnesota, Minneapolis, Minnesota, U.S.A. 
Stephen G. Quallich BS, University of Minnesota, Minneapolis, Minnesota, U.S.A. 
Paul A. Iaizzo PhD, University of Minnesota, Minneapolis, Minnesota, U.S.A. 
Today, clinical electrophysiologists still considered cryoablation a relatively new 
treatment modality for cardiac arrhythmias. Interestingly, the bioheat transfer in this 
environment has been largely unstudied. Furthermore, during the clinical applications of 
cyrotherapy, adjacent tissues may become injured from the induced cooling. These facts, 
along with the desire to validate models of cryotherapy, to potentially increase efficacy 
and safety, warrants the study in reanimated large mammalian hearts where visualization 
of heat transfer is feasible. Specifically, cryoballoon catheters (ArticFront, Medtronic 
Inc.) were positioned in the superior vena cava and the clinically recommended ablation 
duration of four minutes was applied. Similarly, focal cryo-catheters (FreezorMax, 
Medtronic Inc.) were placed in the right atrial appendages and spot ablations were 
performed for four minutes. We believe that this novel model allows for both high spatial 
and temporal resolutions for the study of these treatments. More specifically, multi-modal 
imaging can be performed, with: intracardiac videoscopes, externally with IR and video 
cameras, with fluoroscopy and/or echocardiography and all while hemodynamic 
monitoring of the heart (Fig. 1). Time from beginning of ablation is displayed in the top 
left corner and temperature scale to the right. 
 
 
     Figure 1: Quad-split of simultaneous video.           Cryoballoon ablation 
 
                    Cryoballoon ablation                   Focal ablation 
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Novel visualization of iatrogenic atrial septal defects and ablation 
lesions in a reanimated human heart  
Selected for poster presentation at Experimental Biology 2013, San Diego, CA. 
Published in The Journal of the Federation of American Societies for Experimental 
Biology,April 1, 2012 
 
Ryan P. Goff
1,2
, Stephen A. Howard
1,2
, Paul A. Iaizzo
1,2,3 
Departments of Biomedical Engineering
1
, Surgery
2
, and Integrated Physiology and 
Biology
3 
 
Using methods previously published, we reanimated a donated human heart from a 72 
year old female that was deemed not viable for transplantation. The patient’s cardiac 
history indicated that several months prior, she had undergone a cardiac ablation 
procedure. Photographs were taken of the lesions as well as internal functional images of 
the ablation and transseptal punctures sites.  
This heart contained two iatrogenic atrial septal defects (iASD) presumably from two 
transseptal punctures (through the fossa ovalis) for application of ablation therapy within 
the left atrium. Using an endoscope, video of the ablation lesions was captured and tissue 
around the pulmonary veins appeared pale: indicating fibrous scar.  It was of interest to 
note, that although the procedure was performed months prior, the iASDs (> 7F) were 
still prominent within the anatomy.   
Example images of the ablation procedure effects on the cardiac anatomy are shown 
below. (A) External image of the left atrium where the pulmonary vein lesions are 
noticeably lighter than the other musculature. iASDs are seen through the fossa ovalis 
from the left (B) and right (C) atrium. A pulmonary vein is seen in B with an ablation 
lesion between the fossa ovalis and the right pulmonary veins and the left atrium is 
backlit to show the iASDs in C.   
This work has been supported by the NIH training grant 5T32AR007612-10 
and the Medtronic Professorship for Visible Heart Research. 
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MRI Reconstruction of Human Hearts and Their Relationship to Direct 
Measurements taken from Hypertensive Specimens 
Selected for poster presentation at Experimental Biology 2013, San Diego, CA. 
Published in The Journal of the Federation of American Societies for Experimental 
Biology,April 1, 2012 
Stephen A Howard
1,2
, Ryan Goff
1,2
 and, Paul A. Iaizzo
1,2,3 
Departments of Biomedical Engineering
1
, Surgery
2
, and Integrated Physiology and 
Biology
3 
 
MRI is a very useful tool to examine the blood volume in patients. However one 
downside is that generally it is as an approximation based on an assumed volume shape 
using 3 to 10 individual measurements of the chamber of interest. In this study we are 
examining the blood volume of perfusion fixed human hearts via direct measurements 
and 3D reconstruction of the heart’s chambers.  
The perfusion fixed hearts were suspended in agar gel and imaged with 1.5T or 3T MRI. 
From the images were we are able to analyze the blood volume in the chambers of the 
hearts using 3D reconstructions produced with image processing software. This tool 
allows us to obtain very precise volumes of the chambers of the heart and compare them 
to direct, physical measurements of the blood volume by filling and assessing the fluid 
capacity of each chamber of the heart. This allows us to compare the usefulness of the 3D 
reconstructions and its ability to quantify variables within clinically diagnosed 
hypertensive patients compared to control hearts.  
Funded by NIH training grant 5T32AR007612-10  and Medtronic professorship 
funding.  
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Left-sided Epicardial Pacing Via A Transvenous Lead Delivery 
Selected for poster presentation Design of Medical Devices Conference 2013, 
Minneapolis, MN. 
Published in the ASME Journal of Medical Devices. 
 
Julianne H. Eggum 
Ryan P. Goff 
David G. Benditt 
Paul A. Iaizzo 
Departments of Surgery, Biomedical Engineering, and Medicine 
University of Minnesota 
1 Background 
Cardiac Resynchronization Therapy (CRT) is considered a useful therapy for heart 
failure patients with electromechanical dyssynchrony. To date, it has been reported that 
approximately 10-20% of heart failure patients (570,000-1.14 million people) will benefit 
from the placement of CRT [1]. The current approach of CRT is to pace the site of latest 
left ventricular activation [2-3]. The LV lead is typically implanted in a cardiac vein. 
However, approximately 30% of CRT patients do not clinically respond to the treatment 
[4-5]. In many cases, this is considered to be a result of suboptimal lead placement due to 
limitations of the cardiac venous anatomy. We propose here that it may be possible to 
overcome such limitations by perforating through the wall of the coronary sinus or great 
cardiac vein to gain access to the epicardial surface for optimal lead placement. 
2 Methods 
In order to test our proposed method, we employed the Visible Heart ® 
methodologies, which allows for a four chamber working swine heart preparation as 
described previously [6]. The University of Minnesota’s Animal Care and Use 
Committee approved all experimental protocols involved in this study. 
First, we cannulated a given coronary sinus (CS) with a CS catheter (Attain, 
Medtronic Inc., Mounds View, MN). We then advanced a steerable inner catheter 
(Prevail, Medtronic Inc., Mounds View, MN) through the CS catheter and identified a 
target perforation site. The target perforation site will be the location within the CS or 
great cardiac vein that is close to the site of latest activation. Next, we advanced a stylet 
(Medtronic Inc., Mounds View, MN) through the lumen of the inner steerable catheter 
until it perforated the target venous perforation site. Then we advanced the inner steerable 
catheter over the stylet through the perforated vein and steered the catheter to the target 
pacing site.  
3 Results 
Figure 1 exhibits our proposed method. Figure 1(a) demonstrates perforation of the 
great cardiac vein with a stylet followed by the advancement of the inner catheter 1(b). 
Figure 1(c) displays access to the target pacing site with a steerable inner catheter. Figure 
1(d) demonstrates a subsequent lead placement. 
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(a)   (b)  
 
(c)   (d)  
Figure 1 
 
4 Interpretation 
We believe that these preliminary tests provide evidence that this epicardial lead 
placement technique is a feasible method to obtain access to optimal CRT pacing sites. 
There are a few factors that must be considered as we continue to develop this method. 
It is important to ensure that the stylet will perforate outwardly into the pericardial fluid 
and not into any nearby arteries. The use of fluoroscopy should reduce this risk. There is 
also a risk for pericardial perforation; however, our preliminary in situ studies indicate 
that this risk is low. The risk of cardiac tamponade is minimized due to the low pressures 
in the veins and right atrium, but we plan to investigate this risk further. 
We will continue to perform further testing in an in situ swine model, with the 
pericardium intact. We will also look into various epicardial lead anchoring techniques 
once the optimal pacing position has been obtained. 
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Functional In-Vitro Cardiac Tissue Model For The Evaluation of Ablation 
Parameters and/or The Use of Adjuvant Therapies.  
Selected for poster presentation at European Cardiac Arrhythmia Society 2011, Paris, 
France. 
Published in the Journal of Interventional Cardiac Electrophysiology, March 2011. 
 
Ryan P. Goff, Mark Benscoter, Paul A. Iaizzo 
 
Cardiac cryoablation is expanding with novel uses of minimally invasive procedures and 
endocardial tools. This in-vitro model allows one to uniquely investigate, four parameters that will 
alter contractility, to describe the thermal history of a treatment: cooling rates, end temperatures, 
hold times, and/or thaw rates. Multiple tissue baths provide for a higher throughput analysis of 
novel ablative products and adjuvant therapies (versus in situ or in vivo animal models). 
Methods: 
Swine trabeculae muscle bundles were hung from a force transducer and bathed in oxygenated 
Kreb’s buffer at 37 degrees C. Care was taken during dissection to keep constant cross sections 
of approximately 3 mm by 3 mm. Field stimulation was applied every 10 seconds and maximum 
twitch force generated was measured. After a control period, ablative treatments of varying time 
were applied to the segments and decline in contractility was measured. To visualize lesion size a 
TTC assay was performed. As shown in the figure, the test method is able to accurately 
characterize the decrease in contractility when using ablation therapy. The photo inset in the 
graph shows the muscle bath, catheter (blue), and iceball formation on muscle bundle.  
Conclusion: 
The model simulates an environment similar to that found endocardially, with convective 
movement of constant temperature fluid in which ablative parameters can be varied their effect on 
contractility measured. The model is able to vary lesions as evidenced by the TTC assay and 
reduced contractility. An active fixation pacing/sensing system can be applied to examine local 
versus field stimulation and conduction block with relation to the therapy applied. Using this 
system new treatment regimens can be evaluated in a highly controlled environment without 
varying anatomy or physiology. Future work involves evaluation adjuvant treatment (such as local 
delivery of high NaCl or glycine solutions) effect on human muscle and lesion formation. 
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ABSTRACT 
This paper presents the preliminary development of a novel cryoablation catheter 
for the delivery of cryo energy and complimentary pharmacological agents selected to 
improve lesion formation.  The described prototype uses a commercially available 
cryoablation catheter with a deployable needle injection catheter grafted onto it.  The 
device would be used in endocardial ablation of thick structures and would inject an 
adjuvant at the desired depth prior to cryo-therapy delivery.  Adjuvants have been 
investigated previously to increase the “kill zone” of an ablation lesion and can minimize 
the zone of incomplete death near the iceball edge.  This makes visualization of the 
iceball via ultrasound a better predictor for lesion size and progression. Transmurality of 
a lesion can be  essential for a clinical ablation procedure to have long-term effectiveness. 
The secondary goal of such a device may be to increase energy transfer via the metal 
needle in the myocardium, so to further aid in the creation of transmural lesions in thick 
tissues (e.g., the ventricles).  
Added embodiments of such therapeutic devices would be to also have electrical 
pacing/sensing capabilities and/or temperature monitoring capabilities at the tip of the 
needle. Such features would likely provide a physician with more precise information 
regarding lesion progressions and efficacies. One potential device design could therefore 
have two temperature sensors, one at the ablative tip and one at the needle tip. This will 
allow the user to monitor how far and how fast the lesion has advanced into the 
myocardium at the preset depth of the needle.  After the lesion is formed, entrance and 
exit block tests could then be used to evaluate the ability of the lesion to block electrical 
propagation. 
A unique feature of this catheter design approach is the method of active 
deployment. The physician will pre-set a desired needle deployment depth and then 
navigate the catheter to the location of treatment.  Next, the cryocatheter would be 
positioned and frozen to the desired location of the endocardium, when appropriate, the 
needle would then be deployed, perhaps by first applying a RF energy to warm the 
system within the created iceball so to allow needle to be actively plunged into the 
myocardium. Subsequently, the contact of the needle to the cryo-catheter system will 
rapidly cool the needle within the engaged myocardium. This approach could potentially 
reduce the risks of perforations and ensure consistent deployment depths.   
As found in the literature, and during preliminary testing, lesion size can be 
readily increased using the focal delivery of a high NaCl infusion, prior to energy 
application. We consider here that it should be possible to create the final embodiments 
of such devices with additional pacing/sensing, temperature monitoring, and active 
deployment: this should be technologically feasible using commercially available 
products and SLA rapid prototyping. 
 
INTRODUCTION 
 The field of cryo therapy is rapidly expanding with many novel devices and 
associated procedures currently under development or in clinical trials [1] [2] [3] [4].  For 
example, recent search of the clinical trials database for cryoablation yielded over sixty 
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results.  The most common application of cryoablation is the destruction of tumors in the 
lung, liver, breast, kidney, and prostate. Use of cryoablation in the cardiovascular system 
is gaining popularity due to the inherent advantages over conventional ablation energy 
sources and novel therapies, such as peripheral vasculature cryoplasty.  Nevertheless, one 
of the unique problems associated with ablation of the myocardium, it that fact that the 
heart is moving, it has very non-homogeneous wall thicknesses and it is associated with 
the potentials for causing stroke.  This paper will discuss the development of a novel 
catheter for endocardial ablative procedures that allows for the targeted delivery of 
adjuvant drugs selected to increase efficacy of cryoablation lesions. 
 Recently, there are several touted benefits that cryoablation has been found to 
have over conventional RF energy ablation.  In the eyes of most, relative to inducing 
lesions with the heart, the highest importance is patient safety.  Cryoablation for the 
treatment of cardiac arrhythmias has been found to have a 5.6 fold lower risk of thrombus 
formation versus RF energy [5]. This is of great concern when performing procedures in 
the left side of the heart.  In the right side of the heart emboli are essentially filtered out 
by the lungs, causing blockage of blood flow to a portion of the lung and eventually 
necrosis of the part of the lung being supplied by the blocked artery. This is usually 
asymptomatic because the majority of the lung is still functioning.  In the left side of the 
heart emboli can have much graver consequences by traveling to the brain or coronary 
vasculature causing strokes and/or myocardial infarctions, respectively. Interestingly, the 
use of cryoablation  has also been associated with lower immune responses, even being 
described as immunosuppressive [7].  
 Most current systems used to deliver cryoenergy also have the ability to perform 
cryomapping.  Generally, a short period of -30°C energy, versus -70°C for permanent 
ablation, is used to “stun” the myocardium temporarily (Jensen-Urstad). This can be 
beneficially exploited during procedures requiring ablation near the conduction system of 
the heart, such as the AV node [8]. This allows the physician to test the location of a 
lesion before making it permanent and also to observe the electrophysiological effects of 
placing a lesion in that exact position.  It is important to note that, to date, the other 
energy modalities (e.g., RF) cannot offer this assurance to the physician. 
 The iceball formation associated with cryoablation also offers the benefit of 
stabilizing the catheter.  The natural motion of a beating heart can cause catheters to 
move around substantially within it. To maintain the desired position, physicians must 
apply pressure against the endocardial surface with the catheter, which in some anatomic 
locations may be difficult to achieve.  Furthermore with using such energy sources, the 
pressure must be maintained by the physician and it has been found that higher pressures 
on the wall can lead to charring, crater formation, and perforation [9]. One can imagine a 
physician wanting to be absolutely sure that their catheter will not move during the 
application of energy and applying more force than necessary.  This can lead to the 
negative effects of emboli, as discussed earlier, or perforation which can cause cardiac 
tamponade, which will lead to death if not remedied. .  In contrast, when using a 
cryogenic based catheter, after a few seconds the catheter is anchored to the desired 
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location of endocardium by the iceball and added pressure during localizing the catheter 
can be released.   
 Of upmost importance to the success of cardiac ablative procedures is the creation 
of transmural lesions. A lesion that is not transmural is some patients will not completely 
block conduction and may therefore immediately or over time be clinically ineffective. 
Thus it is important to note, that near the edge of a formed iceball there is an intermediate 
zone where incomplete destruction exists, leading to ineffective lesions [10]. Often such 
an iceball boundary can be visualized using ultrasound. However, the value of this 
imaging is limited because it is known that a zone close to the outside of the iceball is 
often not completely ablated and these zone can be difficult to visualize clinically in a 
beating heart. Hence, to aid in the effectiveness of placed lesions, adjuvant therapies have 
been investigated by several authors [12] [7] [11]. Importantly, these therapies have been 
shown to reduce the size of the incomplete kill zone and beneficially make the 
visualization of iceballs better predictors of lesion sizes, while simultaneously creating 
more complete lesions.   
 Adjuvant therapies can also lead to enhanced destructions of tissues at warmer 
temperatures.  This can even lead to the ablative region being outside of the iceball.  It is 
considered that with some tuning of concentration and delivery dosage, cryoablation with 
adjuvant therapy should make the lesion size match the iceball size.  This could be of 
great benefit with the growing use of 3D echocardiography (reducing fluoroscopy times 
during such procedures), allowing for real-time visualization of lesion formation. This 
could also allow for effective ablation lesions to be created at higher temperatures and 
reduction in damage to adjacent anatomy. 
 It has been reported that adjuvant therapies can work via substantially different 
pathway and can be generally classified into four groups: thermophysical, 
chemotherapeutic, cytokine/vascular agents, and immunomodulators [7].  More 
specifically, TNF-α has been investigated to increase the immune and inflammatory 
response after a cryoablation [11].  Yet, this type of treatment will probably meet some 
opposition from clinicians in the cardiac arena, due to concern over of the actions of 
TNF- α on “healthy” tissue; but may be of great use in the field of oncology.  Thus we 
propose here that the initial focus of novel ablation devices, like the one described here, 
will be on the delivery of thermophyscial adjuvants: due to their relatively benign 
methods of action.  Nevertheless, we believe that the proposed device designs could be 
used to deliver any class of adjuvant.   
 In general, thermophysical adjuvants work primarily by modulating physical ice 
formation.  Examples of these agents include salt solutions (NaCl, KCl, etc.) [11], amino 
acids [11], and proteins.  The salt and amino acid adjuvants can cause secondary, or 
eutectic ice formation which has been shown to enhance cell death in the warmer 
temperature range of -21 to    -5°C [7].  More specifically, NaCl eutectic ice formation 
has also been shown to cause a decrease from 64 to 18 percent cell viability at - 25 °C 
with all other parameters being constant (the only difference was formation of eutectic 
ice) [11].  
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 Another interesting thermophysical adjuvant is a class of proteins called 
antifreeze proteins (AFP).  In high concentration they have been shown to modulate ice 
formation into a sharper, needle-like shape.  This causes greater damage to cell 
membranes and tissue structures. In lower concentration they actually have cryo 
protective action which could be particularly useful when ablating near areas such as the 
AV node. 
 The device approach described here is primarily intended to increase lesion 
creation efficacy and/or intraprocedural evaluation.  It is proposed that such an injectable 
catheter will have greatest utility in situations with larger tissue mass, like the ventricles, 
versus thin walled structures, like the atria.  Therefore, ventricular or septal ablative 
procedures are envisioned as the primary application for this device.  
 So to increase intraprocedural evaluation and monitoring of lesions the next 
generation versions of such catheters could also employ sensing/pacing capabilities and 
temperature monitoring at the catheter tip and/or at the adjuvant delivery needle.  Such 
capabilities have been incorporated in many types of thermal specific ablation catheter so 
to provide the physician with additional information and capabilities.  For example, one 
can imagine a situation where an adjuvant was delivered into the middle of the 
myocardium. After delivery, the energy application begins and the controller can then 
monitor the catheter tip (endocardial) temperatures as well as the mid myocardial 
temperatures (needle tip), hence to better assess lesion progression.  As such it is 
predicted that the user will be then better informed as to the length of time that the energy 
should be applied.  After the lesion is assumed complete, entrance and exit block testing 
could be performed using the pacing and sensing capabilities of the delivery needle. 
Entrance and exit block testing is standard electrophysiological testing to evaluate lesion 
sets and their electrical isolation abilities.  In other words, this will provide more accurate 
evaluations of transmurality of formed lesions, if the pacing and sensing are performed 
within the tissue. The needle/catheter approach will also provide higher thermal transfer 
within the tissue and that alone should aid in the creation of transmural lesions. 
 
Methods 
A prototype catheter was created by grafting an injectable catheter onto a 
CryoCath Freezor Xtra 5mm catheter as seen in Fig. 1.  The grafting allowed the 
prototype to perform ablation and articulation uninhibited. The needle catheter had the 
capability to allow the user to define the final needle depths. 
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Figure 1: A functional catheter prototype with injection needle pre-deployed at 5 mm. 
 To test the ability of the catheter to create lesions, ablations were performed on 
freshly isolated swine skeletal muscle: which was selected as a test tissue because of its 
homogeneity and the fact that the heart itself has similar composition.  This skeletal 
muscle biopsy was submerged in 37°C Kreb’s buffer to help simulate a physiologic 
environment. Ablations were performed for a three minute period with a one minute 
infusion of 14.6% NaCl at 1 mL/min by syringe pump started 30 seconds prior to 
ablation, similar to what is described by Bhowmick et al. A photo of the setup appears in 
Fig. 2. In this protocol, the optimal time to display a detectable lesion was found to be a 
three minute ablation treatment. Therefore, three minute cryoablation periods were used 
for subsequent testing. The injection catheter was set for a depth of 5 mm for all tests. For 
the control group, the procedures and needle punctures were performed exactly as in the 
treatment group but without NaCl infusions. It should be noted that this concentration of 
NaCl alone, was found to not cause a significant level of direct tissue damage by itself 
[13]. 
 
 
Figure 2: Experimental setup with Cryo Console, syringe pump, and test sample in 37°C 
Krebs buffer. 
 To macroscopically examine lesion size a standardized triphenyltetrazolium 
chloride (TTC) assay was [14] [12].  TTC stains for intracellular dehydrogenase activity; 
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therefore, viable tissue stains red and nonviable tissue remains gray or white.  Fig. 3 
shows the sample with high concentration NaCl before stain and Fig. 4 shows the same 
sample after staining and sectioning.  For analysis, tissue was sliced parallel to the 
injection to yield lesion cross sections and immersed in 1% TTC in phosphate buffer 
solution for 45 minutes at 37°C.  Slices were then photographed with a caliper set to 20 
mm included for reference and placed in formalin for storage. Images were analyzed for 
area and depth using ImageJ (NIH) software. If an area was questionably part of a lesion 
it was included regardless, therefore results more accurately represent the area at risk 
rather than the “kill zone”. One tailed paired T-tests were performed with statistical 
significance set at p < 0.05. 
 
Results 
As seen when comparing Fig. 4 to Fig.5, the sample with the adjuvant therapy 
showed a much larger lesion. Both Fig. 4 and Fig. 5 are tissue slices at a depth of 
approximately 5 mm perpendicular to the needle, which is also the injection depth of the 
infusion needle. Although these are preliminary results, it is clear that the adjuvant did 
induce a significant increase in lesion dimensions. In Fig. 5 the lesions are barely evident 
versus Fig. 4 it is clear that there are large lesion areas. Effectiveness of adjuvants is 
already supported in the literature, but a small sample of lesions were created to support 
the proof concept (N=3). 
 
 
Figure 3: High NaCl treatment clearly shows large lesions even prior to staining with 
TTC. 
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Figure 4: TTC stained three minute ablation sample with 1 ml high NaCl infusion. 
Lesions are outlined in blue to delineate for the reader. The black scale bar between the 
calipers is 20 mm. 
 
 
Figure 5: Control sample with three minute ablation and no infusion. Lesions are 
outlined in blue to delineate for the reader. The black scale bar between the calipers is 20 
mm. 
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Figure 6: Cross sections of ablation lesions perpendicular to injection needle. Calipers 
are set to 20 mm and needles are indicating where injection catheter was positioned.  The 
control group is on top labeled A and the 1 minute NaCl infusion is on bottom labeled B. 
 
 In Fig. 6 it is clear that even prior to staining the high NaCl infusion group created 
much larger lesions, whereas the non-infusion group appeared almost unchanged. To 
quantify the difference, TTC staining of cross sectional area perpendicular to the depth of 
the needle was performed and analyzed using image J. The high NaCl infusion group 
showed statistically significant deeper and larger lesions than the control as seen in Fig. 7 
and Fig. 8.   
 
 
 
Figure 7: Graph of lesion depth between experimental groups. The high NaCl infusion 
had significant impact on both pre- and post stained analysis. 
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Figure 8: Graph of lesion perpendicular area between experimental groups. The high 
NaCl infusion had significant impact on both pre- and post stained analysis. 
                
 
Figure 9: An envisioned future prototype consisting of a retractable, concentric needle. 
The gold tip is the main ablative segment of the catheter. The gold rings are pacing 
electrodes.  The small red area within the needle represents a resistive style heating 
element designed to melt through the iceball prior to injection of needle.  Pacing/sensing 
from the needle could be achieved by insulating the entire needle except for the very 
distal surface (beveled surface) . 
 
Discussion/Future work 
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 As the results of this preliminary study and support of previously publications 
show, adjuvants can have significant impact on the modulation of lesion size and depth. 
The reason for the large variation in the control group lesion depth is because only one of 
the lesions actually showed virtually any depth.  The other two were hardly visible.  The 
same is true for the TTC stained area of lesion for the control group. In that case, two 
samples showed virtually no destruction of tissue and one sample showed large 
destruction. It is the author’s opinion that this is actually due to connective tissue not 
being stained well in that sample by the TTC assay. The author believes this because the 
lesion, as shown by lack of red staining, was not evident at the surface, but at depth of 
approximately 5 mm. Indicating that the lack of stain was not due to the ablation, but 
another factor. Nevertheless, it was included because the protocol called for including 
any regions of possible damage. 
Although the underlying concepts discussed herein have been proven at the 
bench, until now there has been no discussion of leveraging the concept of adjuvants in 
the cardiovascular area. The results show that it is feasible to deliver agents via catheter 
and with the proper tuning of adjuvant concentration and volume ice formation can be 
modulated however the user desires. 
As described here, we envision that the design and use of such adjuvant/ablation 
catheter could be of high utility for electrophysiologist performing cardiac cryo-ablation 
procedures.  Ideally, the user would initially map the area and determine exacty where 
lesions are needed. Such a catheter design may have its maximal utility if focal lesions 
are needed in the ventricular or septal myocardial areas.  In such a procedure, the catheter 
would be navigated under fluoroscopy to the desired position and then the needle would 
be deployed to the desired depth.  This deployment could also be aided by prior iceball 
formation: i.e., an initial cryo treatment could be turned on for a short period to anchor 
the catheter to the endocardial surface and then the needle plunged into the myocardium: 
the needle may need to be distally heated to allow for advancement (see Fig. 9).  This in 
turn may help prevent transmural perforations, because the physician is not pushing on 
the entire catheter to insert the needle; only the needle portion is being extended.  This is 
also envisioned being deployed actively, meaning the physician would set the desired 
depth, push a button, a small iceball would form to anchor the tip to the endocardial 
surface, and the needle would extend through the ice ball deeper within the myocardial 
tissue.  Provided the depth was set correctly, and the catheter anchored to the 
myocardium by an iceball, there would be virtually no chance of perforation.   
 Once the needle was deployed the adjuvant could be delivered and again cryo 
therapy applied, but this time for a therapeutic duration.  During such, the temperatures 
could then be monitored at both the cryo and needle tips (endocardial surface and within 
the myocardium, respectively). This should provide the physician a better idea of how far 
and how fast the lesion is progressing within the myocardium.  After the lesion is made, it 
would then be evaluated for completeness by performing entrance and exit block testing 
using this same catheter system. This could also be facilitated by pacing and sensing from 
the tip of the needle to determine electrical isolation.  Performing such test at known 
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depths within the myocardium should provide for better transmural lesion evaluation, 
versus testing at the endocardial surface alone. 
 For complete utilization of such a described device, a computer controlled 
temperature sensing, electrical sensing, and pacing system should be specifically 
designed or an application program developed for existing systems.  This would require 
electrical isolation of the needle tip from the main cryocatheter, which should be 
technologically feasible using electrically insulated coatings to control electrical routing 
and small thermocouples available commercially.  A system for active deployment of the 
needle also needs to be developed. 
 To ideally test early prototypes of such a device, animal models with histologic 
assays would be required.  The author also proposes to use the Visible Heart preparation 
for evaluation.  The Visible Heart preparation uses an isolated swine heart on a modified 
double pump system which circulates a clear buffer perfusate.  Advantages of this setup 
include a thermodynamic environment very similar to that found physiologically, ease of 
endocardial access, and the ability to visualize tissue/device interaction using endoscopes.  
The lesion size can then be evaluated macroscopically using methods similar to those 
described above and subsequent histological studies can also be performed. 
 The primary goal of this novel design of a cryoablation catheter system is to 
create a more well defined lesion and also to provide physicians more intraprocedural 
information and hence more treatment options.  Hopefully, this will lead to fewer follow 
up treatments, as stated by multiple professional bodies in the document titled 
EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias, 
“Inability to create a sufficiently deep lesion to ablate VT is an important cause of 
ablation failure…”. We consider that such a system should provide for better realtime 
assessments and more procedural options, so to allow the electrophysiologist more 
confidence in their treatment, hence in turn minimize secondary procedures, and lowering 
risks of damaging adjacent cardiac structure also leading to fewer complications.  
 
NOMENCLATURE 
RF- Radiofrequency 
AFP-Antifreeze Proteins  
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